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Most new human immunodeficiency virus (HIV) infections are acquired through vaginal 
or rectal mucosa, and gut mucosal tissue is a primary target of HIV infection.  To generate 
mucosal immunity against HIV or its simian counterpart simian immunodeficiency virus (SIV), 
the Gram positive bacterium Clostridium perfringens was used to develop a vaccine that delivers 
SIV p27 to the gut and induces local T cell immunity.   
Under in vitro conditions, Clostridium perfringens expressing SIV p27 (Cp-p27) was 
found to induce dendrite cell (DC) maturation and stimulate p27-specific T cell responses.  To 
improve intracellular delivery of p27 to DCs and thereby enhance immune priming, Cp-p27 
variants expressing p27 conjugated with protein transduction domains (PTDs) at the 5’ end were 
constructed.  While internalization of p27 by DCs and gut epithelial cells was improved 
following exposure to the PTD-Cp-p27 variants, cellular p27-specific immune stimulation was 
not significantly improved compared with wild-type Cp-p27.  
The Cp-p27 vaccine was then tested in vivo in mice for its ability to prime gut mucosal T 
cell responses.  First, an adjuvant optimization study with three mucosal adjuvants,  cholera toxin 
(CT), mutant E. coli heat-labile enterotoxin (LT(R192G)), and unmethylated cytosine-phosphate-
guanine oligodinucleotides (CpG ODNs) was performed to determine the best T cell immune 
response in the gut. While the combination of CpG ODNs and (LT(R192G)) induced the highest 
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T cell immune response, (LT(R192G)) alone provided the best multifunctional CD8+ T cell 
response in the gut. 
Oral Cp-p27 vaccination was then tested for induction of T cell immunity in vivo in a 
prime-boost model by combining Cp-p27 with systemic immunization with an adenovirus 
expressing p27 (Ad-p27).  Cp-p27 vaccination primed a strong multifunctional T cell immune 
response in gut lamina propria, although it could not stimulate a systemic immune response.  In 
contrast, Ad-p27 vaccination stimulated strong systemic immunity but limited gut mucosal 
immunity.  By sequentially delivering Cp-p27 and Ad-p27, immunity in both the gut and 
systemic tissues was achieved.   
Altogether, this study demonstrates that Cp-p27 can deliver p27 to gut T cells through 
dendritic cells to prime a strong, multifunctional immune response in the gut effector tissue. 
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1.0  INTRODUCTION 
1.1 INFECTION AND CONTROL OF HIV 
1.1.1 Global HIV Infection 
Since its description in 1981 [1-4], the acquired immune deficiency syndrome (AIDS) 
has been responsible for the death of 20 million people around the world [5].  In December 2007, 
33.2 million people were estimated to be infected with the causative agent of AIDS, human 
immunodeficiency virus (HIV), with 2.5 million new infections of HIV estimated to have 
occurred in 2007 alone [5].  Highly active antiretroviral therapy drugs can extend the lives of 
many infected individuals.  However, much of the HIV epidemic is due to infections in countries 
where access to health care and medicines is limited [5].  In some rural areas of Zimbabwe, life 
expectancy has been reduced by 19 to 22 years since the onset of the HIV epidemic [6]. 
The HIV epidemic has severe public health and economic consequences.  In South 
Africa, an estimated $1342 is spent per person per year by the public sector for HIV 
antiretroviral therapy and health-care treatment, resulting in an economic burden of the 
equivalent of several billion US dollars each year [7].  Infection with HIV enhances 
susceptibility to other infectious diseases such as tuberculosis, Kaposi’s sarcoma, 
cryptosporidiosis, and Pneumocystis carinii pneumonia, further enhancing the cost of health care 
per capita [8].  The morbidity and mortality associated with HIV infection also lowers the 
economic productivity of regions affected by HIV.  This scenario is most severe in areas where 
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HIV is widely prevalent, which are usually areas where access to treatment is limited.  The 
World Bank estimates that the annual national income in a country with an HIV infection 
prevalence of 10% would decrease by up to one-third [9].  In 2005, 8 of 26 sub-Saharan African 
countries reported prevalence rates of at least 10% [5]. 
Controlling the HIV virus through vaccination is thus a major goal of international 
organizations; however, it has proven to be an incredibly difficult goal to achieve.  To aid in the 
development of such a vaccine and the construction of novel vaccine vectors, the monkey 
counterpart of the virus, simian immunodeficiency virus (SIV), is used as a model.  Studies of 
SIV infection in susceptible animal species such as rhesus macaques have helped to guide human 
studies, drive vaccine development, and shed light on the tissues and immune responses 
important in HIV infection. 
1.1.2 HIV Life Cycle 
HIV infection of a susceptible cell begins with binding of the virus’s envelope protein 
gp120 to CD4, a surface protein predominantly expressed on immune cells such as macrophages 
and the CD4+ subset of T cells [10, 11].  This initial binding to CD4 is followed by a 
conformational change of gp120 and its associated transmembrane glycoprotein gp41, enabling 
binding of the envelope protein to a co-receptor protein [12-14].  The two major co-receptors for 
gp120 are CCR5 and CXCR4 [15-17].  Following entry of the viral core through fusion of the 
viral membrane with the host cell membrane, the HIV RNA genome is reverse transcribed into 
DNA through the action of the reverse transcriptase enzyme carried in the virion [18].  This 
DNA is then integrated into the host cell genome [19, 20].  New viruses can be produced from 
infected cells by induction of the HIV long terminal repeat promoter, which drives transcription 
of the HIV genes and genome, resulting in production of HIV proteins and new full-length 
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copies of the HIV RNA genome [21, 22].  Generally, the structural polyproteins gag-pol and env 
accumulate at the host cell plasma membrane and interact with the viral genetic information to 
package the genome into virions [23, 24].  Complete virions then bud from the plasma 
membrane [25, 26].  Final maturation of the virion occurs after budding from the cell and 
involves cleavage of the remaining gag polyprotein into a proline-rich protein (p6), a nucleic 
acid binding protein (p7), matrix (p17), and capsid (HIV p24, SIV p27) [23]. 
1.1.3 Natural History of HIV Infection 
The natural history of HIV disease can be divided into three major phases:  i) acute 
infection (3 to 6 weeks in humans); ii) chronic, asymptomatic infection (1 to 10 years); and iii) 
symptomatic infection and the onset of AIDS (12 to 18 months).  Immediately following 
infection of cells with the virus, a rapid decline in CD4+ T cells is observed in multiple tissues as 
infected cells are eliminated from the host by a number of mechanisms including super-antigen-
induced death and direct effects of the virus on the cell membrane and genetic material [27-29].  
HIV or SIV DNA/RNA becomes detectable in the blood within the first month after viral 
exposure, and viremia peaks around 4 to 8 weeks [30-34].  Individuals are often unaware of their 
infection status at this stage since the typical manifestations of acute HIV infection include only 
mild symptoms such as fever, rash, and swollen lymph nodes.  However, the results of this initial 
phase of infection likely determine the remainder of HIV/SIV disease progression [35].  It is 
during the acute stage that viral reservoirs are established, ensuring chronic infection of the host 
[35, 36]. 
Viremia in the acute phase is limited by the action of viral-specific CD8+ T cells which 
control viral replication through cytolytic and non-cytolytic actions [37-49].  However, by this 
time the infecting strain(s) of virus has completed several replication cycles and accrued 
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mutations that allow some viruses to escape immune control and persist.  The controlled but not 
ablated infection establishes a viral load setpoint that is maintained throughout the chronic phase 
of infection with only a gradual increase.  Virus replication is limited by the continued action of 
CD8+ T cells as well as HIV-specific neutralizing antibodies that arise around the time of chronic 
infection establishment [50-52].  The severity of the setpoint viral burden is inversely associated 
with development of disease and the duration of the chronic phase [53-56]. 
The CD4+ T cell level in the blood progressively declines during the chronic phase.  It is 
the loss of CD4+ T cells that ultimately drives the collapse of the host’s immune system, for they 
are required for the formation and maintenance of CD8+ T cell and antibody immune responses 
[57, 58].  When CD4+ T cell levels fall below a critical level (approximately 200 cells/mL 
blood), the host loses the ability to control HIV viral replication and AIDS disease is imminent.  
Since CD4+ T cells are necessary for formation of immunity against new threats to the body, as 
CD4+ T cell levels decline the ability to fight other infections is also weakened.  Therefore, 
AIDS patients are susceptible to and often succumb to opportunistic infections.  Because HIV 
infection immediately diminishes the capacity for immune response formation, a vaccine that 
provides immunity before HIV exposure and infection is desirable.   
1.2 HIV AND THE MUCOSA 
Much of the research on immunity regarding HIV and SIV has been examined by 
analyzing the systemic immune response in lymphatics, organs such as the spleen and liver, and 
the easily-monitored blood.   However, it appears that immunodeficiency virus infection is 
primarily a disease of mucosal immune tissue [59, 60].  The mucosal immune system protects 
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the tissues lining environment-exposed body cavities, including nasal, bronchial, gastrointestinal, 
rectal, and urogenital tracts.  The major routes of HIV transmission are rectal and urogenital 
tissue (i.e. vaginal, cervical, and potentially foreskin tissues) [61].  Mucosal tissue is well-suited 
for infection by HIV because it contains a large population of activated CD4+ T cells that express 
high levels of CCR5, the major co-receptor for viral entry [62, 63].  Infection and replication of 
virus has been observed in both urogenital and intestinal mucosa in humans and macaques [64-
67].  Thus, to control the virus infection and replication, protective immune responses must be 
induced at mucosal sites. 
The intestine is a primary target for HIV and SIV infection.  The reason for this is not 
fully defined, but likely the nature of gut resident cells and the ability for virus or virally-infected 
cells to enter the gut mucosa contribute to infection of gut tissue.  Intestinal gut lamina propria 
tissue contains a majority of the body’s CD4+ T cells, and about 70% of these express CCR5 [68-
70].  Arthos et al. recently demonstrated that lymphocytes, including natural killer (NK) cells 
and CD4+ and CD8+ T cells, can bind to HIV gp120 via the α4β7 gut homing molecule, 
suggesting a method by which virus is preferentially delivered to the gut following transmission 
[71].  Since envelope proteins remain associated with the host cell membrane following fusion 
[72], infected cells as well as free virus may bind to α4β7 and thus be transported to the gut. 
In both monkeys and humans, SIV or HIV infection leads to a profound loss of lymphoid 
tissue in the gut, primarily through the depletion of CD4+ T cells via direct effects of the virus on 
infected cells and activation-induced cell death of bystander cells [29, 36, 37, 73].  Lymphocyte 
repopulation of the gut is decidedly absent throughout infection [29, 74-77].  The long-term 
effects of such a disruption to the major mucosal surface of the body include malabsorption of 
nutrients, increased gut inflammation, weight loss, diarrhea, increased permeability of the 
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epithelium, and enhanced susceptibility to enteric pathogens [73].  In addition, infected cells that 
are not eliminated are maintained as viral reservoirs throughout infection [39, 78, 79]. 
Destruction of gut CD4+ T cells occurs within days of infection, before an adaptive 
immune response can form [36].  HIV patients known as long-term non-progressors (LTNPs) 
who exhibit low levels of HIV RNA and sustain healthy levels of CD4+ T cells in the blood also 
maintain gut CD4+ T cells and show low levels of HIV replication in the gut [80].  These 
observations suggest that CD4+ T cell depletion is due to the direct effects of replicating virus on 
cells, killing them either through lysis or bystander effects.  If CD8+ T cells able to selectively 
destroy infected CD4+ T cells through cytolytic and non-cytolytic mechanisms were to exist in 
the gut mucosa, ablation of this uncontrolled gut viral replication may be achieved.  Therefore, 
because of its significance in HIV and SIV infection, the formation of such an immune response 
in the intestine should be a major function of an HIV vaccine. 
1.3 PROTECTIVE IMMUNITY AND CORRELATES OF PROTECTION AGAINST 
HIV/SIV 
Knowing the characteristics of an immune response that is effective against a given 
pathogen creates a framework for rational vaccine design against the pathogen and guides the 
evaluation of vaccine trials during vaccine development.  Despite years of research and many 
advances in the field, the type of immunity required for protection against and/or control HIV or 
SIV infection has not been fully defined.  Undoubtedly the correlates of immune protection are 
multiple and complex.  A majority of the current understanding about the type of immunity that 
is most effective against HIV or SIV has come from LTNP HIV patients, individual animals who 
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control SIV infection, and animals or humans who have been exposed to virus but remain 
uninfected. 
Both antibody-producing B cells and antiviral CD8+ T cells have been implemented in 
control of HIV or SIV.  While these two types of immune responses are not mutually exclusive, 
there is often a tendency to form one or the other type.  The direction in which the immune 
response is swayed depends upon the cytokine environment in which it is formed.  A Th1-type 
environment, dominated by interferon gamma (IFN-γ) and interleukin (IL)-12, promotes the 
generation of mature CD8+ T cell responses.  A Th2-type environment, dominated by IL-4, 
promotes B cell response maturation.  Much of the cytokine production driving Th1- or Th-2 
responses occurs in activated CD4+ T cells, although other cells also play vital roles. 
1.3.1 Neutralizing Antibodies:  Immune Correlate of Protection from Infection 
B cells are referred to as plasma cells when they are activated to produce antigen-specific 
antibody.  Antibodies are able to bind to free virus to prevent viral attachment and infection of 
target cells.  Virus opsonized by antibody can be internalized by phagocytes and destroyed 
intracellularly.  Unfortunately, such internalization of virus has also been implemented in viral 
spread to new target cells [81, 82].  Opsonization can also target virus for direct lysis through the 
complement cascade, which has also been correlated with viral dissemination [82, 83].  The most 
effective antibody function against HIV is neutralization of free virus.  Antibodies that bind to 
virus and block the interaction of gp120 with the CD4 receptor or a coreceptor are able to 
prevent infection of host cells [52].  Antibodies against gp41 can also be neutralizing by 
inhibiting fusion of the viral and host membranes [84].  Since these actions prevent entry of virus 
into cells, effective neutralizing antibodies form the immune correlate of protection from SIV or 
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HIV infection.  Neutralizing antibodies have been found in LTNP but have proven to be 
extraordinarily difficult to induce in humans or animals [85-88]. 
The specificity and quality of antibody responses against HIV and SIV change 
throughout the course of infection.  During the first 6 to 8 months after infection, both SIV 
infected macaques and HIV infected patients demonstrate a gradual maturation of the antibody 
response that includes changes in the antibody titer, antibody avidity, and dependence upon the 
natural conformation of envelope glycoprotein for antibody recognition of envelope [89].  
Regardless of whether individuals show control of viral infection or rapid progression to AIDS, 
antibodies change during this maturation phase from being of low titer to being of high titer, 
having low avidity to having high avidity, and being dependent upon natural envelope 
conformation to possessing conformational independence [89-91].  When mature, these qualities 
of antibody responses are maintained throughout infection, and mature antibody responses 
appear to help control SIV and HIV viral titers during chronic infection [92-98]. 
The extent to which antibodies can continue to control virus and thus promote long-term 
nonprogression to AIDS is dependent upon the specificity of antibody to the viral envelope 
glycoprotein.  Structural properties of HIV envelope glycoproteins ensure that a large portion of 
gp120 and gp41 can evade antibody responses.  Antibodies that are specific to the many variable 
loops, buried residues, and glycan-shielded regions of the envelope proteins are much less 
effective at neutralizing than are antibodies specific for the few vulnerable regions that tend to be 
conserved among diverse viral isolates [99-102].  Envelope proteins that cannot successfully 
bind and fuse with CD4 serve as decoy antigens against which antibodies are formed [103, 104].  
These antibodies can bind to the non-functional protein but fail to prevent viral entry into cells.  
Indeed, one of the requirements of an effective neutralizing antibody is its ability to recognize 
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the functional trimeric form of envelope protein [105, 106].  Despite these challenges to the 
immune system, when an effective neutralizing antibody response is formed, antibodies alone 
can prevent infection of cells and thus block HIV infection at the site of transmission [107-109]. 
1.3.2 Cytotoxic T Lymphocytes:  Immune Correlate of Protection from Disease 
SIV- or HIV-specific cytotoxic T lymphocytes (CTLs) recognize cells displaying viral 
antigen on MHC class I, which generally denotes viral infection of that cell.  Upon recognition, 
CTLs induce apoptosis of the infected cell by one of two mechanisms.  First, signal transduction 
initiated by the binding of FasL on CTLs to Fas on target cells engages the caspase cascade, 
leading to apoptosis [110, 111].  Second, and most commonly, CTLs degranulate, releasing 
perforin and granzyme proteins from intracellular lytic granules into the space between the CTL 
and its target [112].  Monomeric perforin inserts into the target cell plasma membrane and can 
polymerize to form pores through which granzymes can enter.  Granzymes are serine proteases 
which can cleave cellular proteins to initiate the caspase cascade.  Most CTLs are CD8+ T cells, 
although CD4+ CTLs have also been described [111, 113]. 
The CD8+ CTL response to HIV or SIV appears to play a major role in controlling viral 
infection.  Since CTLs are effective only after virus has infected cells, this cellular response is 
the immune correlate of protection from disease.  However, recent evidence suggests that CTLs 
directed against capsid protein could feasibly also serve to prevent productive infection of CD4+ 
T cells.  This was demonstrated by Sacha et al. using an in vitro infection system.  Gag-specific 
CTLs were able to detect and eliminate SIV-infected cells within 2 hours after infection, before 
viral integration and de novo viral protein expression [114].  While the full implications of this 
remain to be defined, a large body of other research makes it clear that CTLs directed against 
HIV/SIV are important in controlling infection. 
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Evidence for a CTL correlation of protection from disease comes from both monkeys and 
humans.  Primary SIV infection is controlled by CTLs in rhesus macaques [43], and depletion of 
CD8+ T cells eliminates the ability of these monkeys to control viral load [44, 45].  Macaques 
with strong vaccine-induced CTL responses can control viral load and maintain CD4+ T cells 
following challenge with SIV [47].  Resistance to HIV infection has been correlated with 
enhanced levels of HIV-specific CD8+ T cells in mucosal tissue of exposed, seronegative 
individuals [46].  Protection from establishment of a productive infection has been also been 
correlated with local mucosal CTLs [48, 49].  Clearly, CTLs are important in systemic and 
mucosal immune responses to HIV/SIV. 
A mucosal CTL response may be effective at limiting early infection and thus preventing 
a sustained infection [36].  In the first 3 to 4 days after exposure to SIV, the number of virally 
infected cells in vaginal and rectal mucosa is low [115-118].  This is the first site at which CTLs 
may be able to prevent the establishment of infection.  If not checked and given a large enough 
and sufficiently concentrated target population, this small level of infection can seed a larger 
infection in draining lymph nodes and other lymphoid tissue, including the gut [115, 116, 118].  
An effective CTL immune response in such lymphoid tissue may be able to effectively limit the 
infection [119].  Such an effect has been observed in monkey models of infection.  Monkeys who 
demonstrated the presence of antigen-specific CD8+ T cells in the colon displayed lower levels 
of virus in the blood [120].  A separate study observed a delay in detectable serum SIV when 
immunization of monkeys generated colonic high avidity SIV-specific CD8+ T cells, which was 
interpreted to mean that the mucosal SIV-specific CTL response controlled dissemination and 
establishment of viral infection [121].  When vaccine-induced anti-SIV CTLs were present in the 
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small intestine of monkeys, establishment of a productive mucosally transmitted infection was 
abrogated or was significantly less severe [79, 122]. 
 
1.3.3 Role of Multifunctional T cells in Immune Control of HIV Infection 
The quantitation of T cell responses is usually evaluated using an IFN-γ ELISpot assay, 
with the assumption that IFN-γ production signifies an effective T cell capable of having positive 
effects on HIV control [123].  Indeed, IFN-γ has been shown to interfere with viral replication of 
other viruses, promotes an antiviral environment in the infected cell, and promotes Th-1 type 
immune response formation [124-127].  However, the correlation between IFN-γ production and 
health of HIV-infected individuals is weak and in many cases inverse, and IFN-γ levels in 
vaccinated individuals do not correlate with protection [128-130].  The production of IFN-γ is 
only one of several features of activated, effective antigen-specific anti-viral T cells.  IL-2 and 
tumor necrosis factor alpha (TNF-α) production are also key determinants of T cell survival and 
anti-viral effectiveness, respectively.  IL-2 drives T cell proliferation and differentiation [131, 
132].  TNF-α enhances the production of IFN-γ, supports Th1-type response formation, and can 
trigger apoptosis of virally infected cells through death domain signaling [133, 134].  As 
mentioned above, the cytotoxic capacity of CD8+ T cells is imperative in HIV virus control.  
Cytotoxicity can be assayed by the detection of CD107a and b on the surface of T cells after they 
have released the granzyme and perforin molecules from their lytic granules [130, 135].  
Growing evidence supports the concept that evaluation of the multifunctionality of T cells more 
accurately reflects effective anti-viral immunity in HIV or SIV infection than IFN-γ production 
alone.  In other words, cells that display more than one of the “functions” of IFN-γ production, 
TNF-α production, IL-2 production, and degranulation via CD107a/b surface expression are 
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more often detectable in individuals with low viral loads and healthy levels of CD4+ T cells [40, 
42, 136-141]. 
The reasons for the superiority of multifunctional CD8+ T cells in HIV infection are 
being delineated.  Investigation of the functionality of human CD8+ T cells at various stages of 
infection with viruses that persist for varying lengths of time indicate that the initial CD8+ T cell 
response to viral infection is dominated by IFN-γ production, with most CD8+ T cells 
exclusively producing IFN-γ but not IL-2 [132, 142].  These cells are unable to proliferate in the 
absence of antigen-specific CD4+ T cells [138, 143].  The same type of response persists in 
infections with uncontrolled viral replication [142].  However, chronic infection in which virus is 
maintained at a low level is associated with CD8+ T cells that produce both IL-2 and IFN-γ 
[142].  These dual-producing CD8+ T cells show proliferative capacity after antigen-specific 
stimulation independent of CD4+ T cells [131, 144-146].  CD8+ cells producing IL-2 and IFN-γ 
simultaneously have been observed in HIV LTNPs and 30-40% of patients who maintain low 
HIV viral loads while receiving anti-retroviral therapy [40, 142].  In addition to IL-2 and IFN-γ 
co-production, the CD8+ T cells from these patients also display populations of CD8+ T cells 
with additional functions such as cytotoxicity and TNF-α production, which are at lower levels 
or absent in uncontrollers [40, 138].  Such a multifunctional response is thought to be desirable 
to achieve through vaccination.   
The quality of response is important not only in CD8+ T cells but also in CD4+ T cells.  In 
these cells, the co-production of IL-2 and IFN-γ is also correlated with control of viral infection, 
whereas IFN-γ-only producing cells are associated with high viral loads [137, 144, 147-149].  
The importance of multi-function CD4+ cells is highlighted by the fact that only when HIV-
infected patients have detectable levels of IFN-γ+IL-2+ CD4+ T cells do they also have IFN-γ+IL-
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2+ CD8+ T cells [142].  Like CD8+ T cells, the capacity to secrete TNF-α in addition to IL-2 and 
IFN-γ has been associated with control of HIV infection [136].  Notwithstanding, the 
significance of vaccine-induced multifunctional CD4+ T cells is less defined than for CD8+ T 
cells.  It is not clear whether vaccine-induced activation of CD4+ T cells would aid in limiting 
infection or would aid in establishment of infection by supplying ideal targets (i.e. activated 
CD4+ T cells) for HIV infection. 
1.3.4 Other Functions of the Immune System Controlling HIV Infection 
1.3.4.1 Physical Barriers 
An important aspect of the immune system often neglected is the fact that many 
infections are fended off simply because infectious agents cannot overcome the body’s anatomic 
barriers (skin, keratinous layers, sebum, cilia, mucus) and physiologic barriers (temperature, 
enzymes, pH).  Letvin et al. observed that a cohort of mucosally exposed, uninfected rhesus 
macaques displayed no detectable systemic or mucosal anti-SIV immunity using the most 
sensitive standard techniques to assess cellular immunity [150].  Furthermore, the presence of 
local mucosal IgA did not correlate with protection.  Despite their resistance to repeated mucosal 
infection, these animals were readily infected intravenously.  These findings, along with others 
[151-153], suggest that factors other than the adaptive immune response provide resistance to 
primate lentivirus infection.  Intact tissue that is impenetrable by virus at the site of exposure 
may be sufficient to prevent infection.  How to maintain intact mucosal tissue in the face of 
human physical interactions that spread HIV and inherently disrupt the mucosa is the challenge 
of this approach to preventing HIV infection. 
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1.3.4.2 Innate Immunity 
HIV and SIV can counteract the efforts of cellular and humoral adaptive immune 
responses by mutating.  The error-prone nature of reverse transcriptase allows for inaccurate 
insertion of nucleotide base-pairs at a rate of 3 x 10-5 per cycle of replication, errors are 
maintained because reverse transcriptase lacks proof-reading ability, and recombination between 
different viral quasispecies is promoted by reverse transcriptase at a rate of over two 
recombination events per replication cycle [154-160].  Given the fact that HIV can produce on 
the order of 109 to 1010 new virions every day [161, 162], the mutation rate of virus in an 
infected individual is extremely high.  These activities, as well as direct effects of HIV/SIV 
accessory proteins, contribute to immune escape from both humoral and CTL viral-specific 
immune responses [163-165].  However, other types of immune responses are not dependent 
upon antigen specificity and can provide immune control of HIV/SIV either before adaptive 
immunity forms or after virus has escaped established adaptive immune responses.  
Inflammatory responses that occur immediately after viral exposure encourage the action of cells 
comprising the innate immune system, including phagocytes and natural killer cells.  
Innate immune responses have been suggested to inhibit HIV/SIV infection and disease 
upon initial exposure to virus, and yet they remain largely uncharacterized.  Of particular interest 
to HIV/SIV infection is the natural killer (NK) cell.  NK cells cytotoxically eliminate non-self 
cells similar to CD8+ T cells and express activating and inhibitory killer immunoglobulin-like 
receptors (KIRs) on their surface, which recognize specific MHC class I molecules.  Recognition 
of non-self cells occurs through activating KIRs, with ensuing signal transduction leading to the 
release of cytolytic granules.  Inhibitory KIRs counteract this action by preventing the cytotoxic 
activity of NK cells and ensure that cytotoxicity is directed only against cells with abnormal 
expression of MHC class I molecules.  However, many virally infected cells display 
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downregulation of MHC class I, and thus these cells become targets for NK cells.  Mounting 
evidence suggests a role for NK cells in control of HIV viral load and disease progression.  This 
includes the observation that certain HIV-control-associated genotypes encode Bw4-80I, the 
ligand of a particularly strong inhibitory KIR [166-170].  Lack of inhibitory KIR binding by 
downregulation of Bw4-80I upon HIV infection may escalate NK cell killing of infected cells.  
The activating KIR KIR3DS1 is also able to bind Bw4-80I [166, 170-172], possibly promoting 
NK cell activation against these cells in the absence of an effective inhibitory KIR signal.  A 
broader understanding of the function and regulation of NK cell killing in the face of HIV 
infection may provide new avenues for HIV prophylaxis research. 
In addition to cytolytic activity, CD8+ cells exhibit non-cytolytic control of HIV 
replication.  This phenomenon does not require MHC antigen presentation or even expression of 
HIV protein by target cells and is active against cells infected with diverse viral isolates [173-
178].  Indeed, CD8+ T cells demonstrating HIV suppressive activity but lacking T cell receptors 
specific for HIV have been identified [179, 180].  Non-cytolytic control occurs through the 
repression of HIV replication by inhibiting transcription from the long terminal repeat promoter 
through action at a location immediately downstream of the transcription initiation site [175, 
177, 181].  The identity of this CD8+ cell antiviral factor (CAF) remains unknown, but it is has 
been observed to exist in both a secreted form and a cell membrane-associated form.  CAF 
activity is a correlate of protection from disease progression insomuch as CAF activity in 
untreated HIV-positive patients inversely correlates with viral load, and CAF activity in 
lymphoid tissue positively correlates with control of viral replication [182, 183].  Whether CAF 
activity can be primed through prophylactic intervention will also be a question that future 
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research should address.  Some studies have suggested that this may be the case, but how this 
occurs has not been delineated [184-188]. 
1.4 HIV VACCINE DEVELOPMENT 
Thus far, the understanding of CAF activity and innate immunity suggests that these 
types of responses cannot be achieved through traditional vaccination since antigen-specificity 
and lasting memory for these activities do not appear to be inducible.  However, vaccines that 
generate antibody and CTL adaptive immune responses against HIV/SIV are both being pursued. 
1.4.1 Challenges of a Neutralizing Antibody-Inducing Vaccine 
Effective prevention of SIV infection via a vaccine-induced antibody response has been 
demonstrated in the rhesus macaque model [189-194].  Since antibodies can limit viral infection 
before SIV or HIV enters host cells, this sort of sterilizing immunity is a primary goal for HIV 
vaccine development [189, 195].  However, protective antibody responses have been difficult to 
achieve through vaccination, with killed or attenuated strains of SIV being the most consistently 
successful strategies [194]. 
There are many concerns about employing killed or attenuated HIV for vaccination 
purposes.  The potential for recombination of the attenuated strain with circulating strains has 
limited the development of this approach [196, 197].  In addition, long-term studies of monkeys 
and patients infected with attenuated strains have displayed eventual progression to disease, 
possibly via mutations acquired through the natural error-prone replication of the viruses [194, 
196, 198].  Using killed HIV as a vaccine strategy has also been met with both safety and 
technical concerns.  Currently there exist no approved culture methods for generating HIV 
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virions for vaccine use.  There are also technical challenges in the ability to achieve purified 
virus with intact envelope glycoprotein, and traditional chemical and heat-based methods of viral 
inactivation tend to denature the trimeric conformation of HIV envelope proteins that is 
imperative for successful protective antibody response formation [196].  Novel strategies for 
virus inactivation are helping to overcome this problem [192, 199, 200].  However, to date the 
killed SIV vaccinations that elicit protective immunity in animal models have required the use of 
strong adjuvants not appropriate for human use [190-193, 201]. 
Alternative vaccination strategies for producing the envelope trimer and inducing 
neutralizing antibodies include DNA vaccines and non-replicating virus-like particles [196, 202-
205].  These approaches show much promise and are safe for use in humans but thus far cannot 
fully protect against viral infection in animal models [196].  Thus, while a vaccine-induced 
neutralizing antibody response would undoubtedly provide the ideal situation of sterilizing 
immunity against HIV, current technical and knowledge limitations have prevented the 
successful formation of this type of response.  The potential for an antibody vaccine certainly 
exists, and as technology and further understanding of the structure of the HIV envelope protein 
advance a neutralizing antibody-inducing vaccine is likely to be developed. 
1.4.2 Rationale for a Cellular Immunity-Inducing Vaccine 
Since an effective CD8+ CTL response can control HIV and SIV infection and possibly 
prevent productive infection, a vaccine that induces appropriate T cell responses against 
HIV/SIV may be adequate to control infection at both the individual and population levels.  
Based on experiments in the monkey model and the observation that control of HIV replication 
in acute infection occurs through CTL immune responses, a vaccine-induced T cell immune 
response should be able to control early infection and prevent the establishment of a productive, 
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persistent infection [36, 73, 206].  However, even if this sterilizing immunity does not result, a 
cellular response that can limit the infection, similar to the level of infection observed in LTNPs, 
may significantly alter the course of the HIV epidemic [206-212].  Presumably, the resultant 
lower viral load in a T cell-limited infection would not only provide longer, healthier lives for 
those who contracted HIV, but also less virus would be transmitted to new individuals [207, 213, 
214]. 
1.4.3 Systemic Vaccine Development 
The overwhelming majority of currently licensed vaccines against infectious diseases are 
delivered systemically, generally intramuscularly or subcutaneously.  It thus comes as no 
surprise that most of the HIV vaccines in completed or current human trials are also systemic 
vaccines.  Early HIV vaccines focused on eliciting antibody responses against the HIV envelope 
proteins included vaccination strategies such as recombinant whole protein administered with 
adjuvant and recombinant vaccinia virus expressing HIV protein.  By 1993, new strategies began 
to be tested as novel vectors and antigens (e.g. gag, pol) showed more promise than conventional 
vaccination approaches.  Vectors derived from pox viruses (i.e. canary pox, modified vaccinia 
Ankara), plasmid DNA, and non-replicative HIV virus-like particles were introduced into 
clinical trials, and cellular immunity in addition to humoral responses grew to be standard in 
vaccine evaluation.  The possibility of utilizing two separate vaccines in a prime-boost regimen 
to create better immune responses than a single vaccine began to be explored in clinical trials in 
the late 1990s, with encouraging results.  To date, over 60 clinical trials have been completed 
worldwide.  As of January 2008, the AIDS Vaccine Advocacy Coalition reports 29 ongoing 
human trials, which include vaccines using pox-based vectors, adeno-associated virus, DNA, 
adenovirus, lipoprotein, protein, and peptide. 
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Adenovirus (Ad) has been employed by many researchers as a vaccine vector for 
efficient delivery of HIV or SIV proteins through intramuscular inoculation.  The resultant 
systemic cellular and humoral immunity tends to be quite strong and multifunctional, even with 
only a single dose [215, 216].  This is due partly to the broad tropism of adenovirus, which is 
able to enter a number of cell types from a multitude of lineages [217].  Naturally, more than 50 
serotypes of these DNA viruses cause generally mild disease in respiratory, gastrointestinal, 
urogenital, and ocular tissues.  Of these serotypes, Ad serotypes 5 and 35 have been widely 
explored for their use as vaccine vectors.  By deleting genes essential for Ad replication (e.g. E1 
and/or E3) and replacing them with a vaccine antigen gene, Ad can be manipulated to carry 
vaccine antigen genes, which are expressed in the cells which Ad infects. 
Many reports argue for the notion that pre-existing immunity to Ad lowers the 
effectiveness of Ad-vectored vaccination [218-222].  Preliminary results from a recent proof-of-
concept clinical trial also suggest that pre-existing immunity may be a factor in Ad-vectored 
vaccine-inducible immunity [207]; however, the overarching result of this trial was that systemic 
immunization using the Ad-vectored vaccine did not afford protection from HIV or lower the 
viral setpoint after infection.  Nevertheless, Ad remains one of the most well-defined vector 
strategies currently being used for HIV vaccine development, and future improvements may 
overcome the limitations of current Ad vectors.  In addition, priming the immune system using a 
rare Ad serotype vector, a separate vector, or an alternative route of administration before 
boosting with a systemic Ad-based vaccine have been noted to aid in overcoming the limitation 
of pre-existing immunity that would otherwise compromise immune response formation 
stimulated by Ad-vectored vaccination [222-228]. 
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1.4.4 Mucosal Vaccine Development 
Mucosal vaccines have the potential advantages of being painless, easy to administer on a 
large scale and also generally less expensive to produce, store, and deliver than current systemic 
vaccine technologies [229].  In light of the fact that most HIV infections are transmitted through 
rectal and vaginal mucosal contact, it is imperative for a vaccine to provide mucosal immunity.  
Vaccination at a mucosal tissue stimulates local immunity in that tissue and usually also induces 
systemic immune responses detectable in the blood, spleen, and peripheral lymph nodes.  This is 
in contrast to systemically delivered vaccines, which are generally incapable of or limited in the 
ability to stimulate an immune response in mucosal tissues.  Thus, mucosal immunity is thought 
to best be induced by antigen delivery directly to the mucosa [229]. 
Some systemically delivered viral vectors appear to enable mucosal immune response 
formation against HIV or SIV, most notably in the gut, rectal, and genital mucosa [216, 230].  
However, the strength of these responses is generally poor.  For example, some level of mucosal 
immunity can be detected after systemic inoculation with Ad-vectored vaccines, but at levels 
approximately 10-times less than in systemic samples [216, 230].  Individuals inoculated 
intramuscularly with a pox-based vector have also demonstrated some mucosal immune 
responses [231, 232].  It is generally accepted that direct mucosal stimulation achieves more 
effective mucosal immunity [229], although again this is dependent upon the vaccine strategy 
utilized.  Ad-vectored vaccines delivered mucosally have been explored; however, although Ad 
typically causes mucosal disease, mucosal immunity has not been detected following oral 
inoculation [227].  Alternative vectors that are more adept at antigen delivery to mucosal tissues 
are necessary for successful mucosal vaccination. 
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The development of a mucosal SIV or HIV vaccine has been pursued for many years.  
Vaccines targeted to the nasal, oral, rectal, and urogenital mucosa and to mucosal draining lymph 
nodes are under investigation [233, 234].  Antigen delivery has been tested using attenuated live 
virus, killed virus, recombinant virus, DNA, dendritic cells and peptides.  Recently the potential 
for recombinant microorganisms to be used as vectors has been investigated.  HIV vaccine 
vectors have been designed using organisms such as Salmonella enterica, the Bacillus of 
Calmette and Guerin, Shigella flexneri, and Listeria monocytogenes [235-238].  Many of these 
novel vaccine strategies have been shown to induce strong humoral or cellular immunity in 
mucosal compartments, including the gut, more effectively than systemically delivered vaccines. 
Most mucosally administered HIV vaccines are in pre-clinical stages of development.  In 
the vaccine pipeline are vaccines vectored by Venezuelan equine encephalitis, attenuated 
vesicular stomatitis, herpes simplex, and Sindbis viruses, which may be effective when 
administered mucosally [229, 239, 240].  One ongoing clinical trial (C86P1 through St. George’s 
University of London, Richmond Pharmacology, and Novartis Vaccines) uses a protein-plus-
adjuvant vaccine administered intranasally as a prime to an intramuscular boost.  This mucosal-
systemic prime-boost strategy is a popular strategy being characterized in pre-clinical trials 
utilizing a multitude of vaccine vectors [228, 241-246].  The only other mucosa-targeted vaccine 
to have reached clinical trials utilizes Salmonella enterica serovars typhimurium and typhi that 
include a Type-III secretion system to deliver gag proteins to the cytoplasm following invasion 
of gut macrophages upon oral ingestion.  Phase I clinical trials have shown a single dose of the S. 
typhimurium vaccine to induce mild gastrointestinal symptoms and nearly no systemic immunity 
to HIV gag [247].  In the SIV model, monkeys primed with S. typhimurium and boosted with a 
systemic vaccine demonstrated SIV-specific CD8+ T cells in the colon and blood, as well as 
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somewhat lower severity of infection than a systemic-only vaccinated animal following 
intrarectal SIV challenge [248]. 
Mucosal vaccines against any infectious disease have historically been difficult to 
generate.  Of the over 55 licensed vaccines in the United States, only 7 are delivered mucosally, 
6 through the oral route and one intranasally.  By and large, the effectiveness of these mucosal 
vaccines is wholly dependent upon the production of humoral, not cellular, responses.  This 
underscores the difficulty the scientific community has experienced in developing mucosally 
delivered vaccines that induce antigen-specific CD8+ T cell responses.  Ongoing studies of novel 
vaccine vectors may prove to overcome this challenge. 
1.5 MUCOSAL IMMUNOLOGY 
The major obstacle in mucosal vaccine development is the challenge of induction of 
immunity in the mucosa.  Whereas the systemic immune system readily responds to most foreign 
molecules with responses that eliminate the foreign particle, the mucosal immune system is more 
selective in the molecules to which it produces responses that destroy foreign particles.  The 
necessity of the mucosa to co-exist with environmentally acquired non-pathogenic molecules 
(i.e. food) and organisms (i.e. beneficial commensal bacteria) indicates that an intricate system 
exists to discern between safe and toxic antigens acquired at mucosal surfaces. 
1.5.1 Anatomy of Mucosal Immune Tissue 
The various immune inductive sites of the mucosal immune system show similarity in 
overall structure.  A single layer of epithelial cells separates interstitial tissue from the external 
environment.  As shown in Figure 1, the underlying tissue just beneath the barrier consists of  
 23 
M
SED
B B4
8 4
8 8
84
8
GCIFR
IFR
FAE
?
lamina propria
Peyer’s patch
system
ic
distal mucosa
trafficking of activated B & T cells
migration of LPDCs
migration of PPDCsafferent MLN lymphatic
efferent MLN lymphatic
M microfold cell
PPDC
LPDC
antigen
8 CD8+ T cell
4 CD4+ T cell
8B B cell
epithelial cell
intestinal lumen
MLN
4
8B
8
portal
vein
circulation  
Figure 1.  Gut associated lymphoid tissue (GALT) anatomy and immune priming 
The primary inductive tissue structure of the GALT in the terminal ileum of the small intestine is the Peyer’s patch 
(PP).  Antigen is transcytosed by microfold (M) cells of the follicle associated epithelia (FAE) and is delivered to 
dendritic cells (DCs) in the sub-epithelial dome (SED).  DCs can migrate to intrafollicular regions (IFRs) or 
germinal centers (GCs) to prime cells in the PP; some evidence also suggests that PPDCs can migrate via afferent 
lymphatics to prime cells in the mesenteric lymph node (MLN).  DCs from the lamina propria also acquire antigen 
(see text for details) and can migrate to PPs or MLN to prime immunity.  Primed B and T cells travel via lymphatics 
to enter circulation via the portal vein and are then delivered to the gut effector tissue (lamina propria), distal 
mucosal sites or systemic sites. 
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large numbers of antigen presenting cells (APCs), particularly dendritic cells (DCs).  As 
mentioned above, generation of a protective immune response in one mucosal area is able to 
afford protection at other mucosal sites [249-251].  For example, an oral vaccine against typhoid 
has been shown to induce mucosal immune responses in saliva and vaginal secretions in human 
volunteers [250].   Mucosal tissue therefore does not rely on systemic immune responses to 
populate its effector sites with B and T cells.  Interactions between the two immune systems do 
occur, however.  This is believed to be mediated by lymph nodes of the mucosal immune system 
serving as crossover points and may also involve lymphocytes trafficking through the liver [252, 
253]. 
The gut associated lymphoid tissue (GALT) comprises inductive immune tissue that 
collect antigen from the mucosal surface and lack afferent lymphatics.  Peyer’s patches (PPs), 
isolated lymphoid follicles, and the appendix make up the GALT, and it is in these tissues that 
most gut mucosal B and T cell immune responses are primed.  PPs are the major GALT structure 
in the small intestine, where they are concentrated in the terminal ileum in humans. 
1.5.2 Generation of Mucosal Immune Response in GALT 
Generation of a protective immune response in the GALT is able to afford protection at 
other mucosal sites (see Figure 1).  Microfold (M) cells in the follicle-associated epithelium 
(FAE) transport antigen from the lumen to the sub-epithelial dome (SED) where DCs serve as 
the major antigen presenting cell [254].  Peyer’s patch DCs (PPDCs) have also been observed to 
acquire antigen from apoptotic epithelial cells [255].  Following antigen uptake, DCs mature and 
can migrate to present antigen to naïve B and T cells in the intrafollicular region (IFR) and B-cell 
rich germinal center (GC) areas of the PP.  Activated B and T cells primed in the PP can be 
imprinted with the α4β7 mucosal homing marker, and thus the cells localize to effector sites such 
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as the lamina propria.  Also, DCs from the PP may travel to the mesenteric lymph node (MLN), 
the regional lymph node draining the gut.  Intra- and subepithelial DCs in the small intestinal 
lamina propria can also acquire antigen from the lumen directly by extending dendrites across 
the FAE barrier, and then migrate to PPs or MLN to prime B and T cells [256].  T cells primed in 
the MLN can travel to local mucosal effector sites, e.g. lamina propria.  In addition, efferent 
lymphatics may serve as conduits for activated T cells to travel from the gut to distal mucosal 
effector sites as well as the systemic immune system after entering the bloodstream through the 
thoracic duct.  Lymphocytes from the gut can also drain via portal blood to the liver, where 
regulation of immunity may occur [253]. 
The normal reaction to oral antigen presented by gut DCs is tolerance via the generation 
of secretory IgA and either Th3 or T-regulatory cells.  The major cytokines present during 
tolerance induction include IL-10 and transforming growth factor beta (TGF-β), and low levels 
of co-stimulation occur between DCs and CD4+ T cells [252].  An immune response is generated 
only under inflammatory conditions, such as those generated by pathogenic organisms.  Under 
these circumstances, completely mature DCs provide high levels of co-stimulation and produce 
IL-12 [257].  Both Th1 and Th2 responses can result.  The natural tendency for oral antigen to 
produce tolerance complicates the formation of mucosal immune responses with vaccines. 
1.5.3 Mucosal Adjuvants 
Adjuvants are used in mucosal vaccines to overcome tolerance and direct the immune 
response towards either Th1 or Th2 immune responses.  To date, no mucosal adjuvants have 
been licensed for use in prophylactic vaccines in the United States.  The major mucosal 
adjuvants in various development stages fall into two categories, bacterial toxin-based and Toll-
like receptor (TLR)-stimulating. 
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The heat-labile enterotoxin (LT) produced by certain species of enterotoxigenic E. coli 
has been known for years to be a potent mucosal adjuvant.  The A subunit of LT is the catalytic 
subunit responsible for LT toxicity as well as immune enhancement.  Dickinson and Clements 
created a mutant form of LT by substituting alanine at residue 192 of the A subunit with glycine 
[258].  The resultant LT(R192G) is capable of inducing both Th1 and Th2 responses and in SIV 
vaccines enhances SIV-specific CTL levels [259, 260].  Furthermore, the safety of LT(R192G) 
has been demonstrated in mice, non-human primates, and humans [259-261].  Incorporating 
LT(R192G) into an oral vaccine is expected to prevent tolerance and encourage a Th1 response. 
Cholera toxin (CT) is a related bacterial toxin that serves as a mucosal adjuvant.  It is 
produced by Vibrio cholerae and, like LT(R192G), is known to help overcome mucosal 
tolerance when administered orally with protein [262-264].  Although the CT B subunit (CTB) is 
not approved for use as an adjuvant, CTB is delivered with inactivated whole cell V. cholera in a 
safe and widely-used oral vaccine against cholera [265].  Safety mutation versions of CT and 
recombinant CTB have been created and tested for decreased toxicity and sustained 
immunogenicity with somewhat less success than LT(R192G) [266, 267].  Nevertheless, this 
potent mucosal adjuvant may be applicable for human use in the near future, and it serves as the 
classical oral adjuvant.  Orally delivered CT is known to be transcytosed by M cells and is 
thought to promote maturation of DCs in the SED, driving their migration to T and B cell 
priming areas in PPs [266, 268].  Both CT and LT have also been shown to induce the rapid 
migration of murine DCs to the PP FAE and subepithelial connective tissue of villi where they 
are thus situated to acquire antigen from the lumen [266, 269]. 
A leading TLR-stimulating mucosal vaccine is a mimic of bacterial DNA.  TLR9 helps 
the mucosa to differentiate between the presence of safe host DNA and pathogenic bacterial 
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DNA by recognizing differences in the methylation patterns of cytosine-phosphate-guanine 
(CpG) dinucleotides.  Accurate identification of foreign DNA depends upon the fact that 
bacterial DNA contains far fewer methylated CpG motifs than host DNA and that host DNA is 
not normally found in endosomes, the location of TLR9 molecules [270, 271].  Three different 
classes of CpG oligodinucleotides (ODNs) have been described based on their different primary 
sequence motifs, secondary and tertiary structures, backbone, and stimulatory effects on B cells 
and DCs [272].  All three classes result in the induction of Th1-promoting cytokines by DCs and 
promote Th1 cellular responses [273].  In the gut, TLR9 expression has been observed in villus 
enterocytes and Paneth cells typically found in villus crypts, as well as PPDCs, which can mature 
in response to CpG ODNs [274, 275].  The administration of CpG ODNs with a systemic 
vaccine has been tested in human clinical trials [272, 276, 277].  In mice, CpG ODNs delivered 
with oral vaccines have helped stimulate Th1-type mucosal immune responses against a variety 
of antigens using numerous vector systems [278-283]. 
1.5.4 Encouraging Mucosal Immune Response Formation 
Many factors influence the immunostimulatory nature of antigen that interacts with the 
GALT.  Proteins tend to be poorly immunogenic, but the nature, dose, and frequency of their 
delivery can dramatically influence the propensity for immune activation to result following their 
ingestion.  Particulate or denatured protein is less likely to induce tolerance than soluble or intact 
protein, probably because particulates and unfolded proteins are more readily engulfed by M 
cells and better delivered to DCs [229, 284-287].  Low levels of antigen administered repeatedly 
do not encourage immune responses, whereas low doses can prime immunity if not administered 
frequently [229].  A single high dose of antigen encourages tolerance, whereas medium to high 
doses of antigen administered repeatedly can result in immunity [229].  Of course, the 
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administration of adjuvant with the antigen also drives immune response formation and 
overcomes tolerance.  In summary, mid- to high-level doses of particulate or denatured protein 
that can be delivered to DCs repeatedly are most likely to induce strong mucosal immunity. 
Protein transduction domains (PTDs) are cationic peptides that enable the proteins on 
which they are located to efficiently enter target cells through a receptor-independent mechanism 
[288-290].  It is hypothesized that PTDs function by preferentially adhering to negatively 
charged molecules on the outer membrane of cell, thus enhancing the number of PTD-containing 
proteins in position for internalization.  PTDs have been designed that specifically target proteins 
to certain cell types.  The PTD peptide known as PTD-5 enhances protein uptake by many cell 
types, including epithelial cells and DCs [291].  Another PTD, 8K, is especially proficient at 
directing proteins into DCs (P.D. Robbins, personal communication).  Incorporating either of 
these PTD peptides as a fusion to orally administered antigen should increase delivery of the 
antigen to PPDCs either directly or indirectly via enhanced uptake by M cells.  In addition, PTD-
fused antigen may be better internalized by the lamina propria epithelial cells or DCs that are 
important for immune response formation in the MLN. 
Activation of CD8+ CTL responses requires presentation of antigen on MHC class I 
molecules.  DCs possess the unique ability to present exogenously acquired antigen, which 
normally is loaded onto MHC class II molecules, in the context of MHC class I.  While the 
details of this cross-presentation are not fully understood, it is known that some phagocytosed 
antigen interacts with the proteasome and is thus directed for MHC class I loading [292-295].  In 
this way, increased internalization of protein by DCs through PTD-fusion can encourage 
presentation of epitopes on MHC class I.  PTD sequences may also promote the delivery of 
protein directly to the cytoplasm of cells, which engages the MHC class I pathway, thus 
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enhancing DC cross-presentation and increasing induction of CTLs [296, 297].  Therefore, 
presentation of protein epitope of MHC class I via either pathway can be enhanced through the 
fusion of PTD to the protein. 
1.6 CLOSTRIDIUM PERFRINGENS EXPRESSING SIV P27 AS A VACCINE 
VECTOR 
1.6.1 Exploiting Clostridium perfringens as a Vaccine Vector 
In addition to the microorganisms mentioned above, Clostridium perfringens has also 
been considered as a vehicle for antigen delivery to the GALT.  C. perfringens is a Gram-
positive spore-forming rod-shaped anaerobic bacterium [298].  In adult humans, ingested 
vegetative C. perfringens that survive the upper gastrointestinal (GI) tract conditions enter the 
small intestine where bile salts help to induce sporulation of the bacteria.  Spores and 
cytoplasmic inclusion bodies are protected in the mother cell as sporulation ensues and the 
bacteria travel through the small intestine.  The spore and inclusion bodies are released from the 
mother cell when C. perfringens cells lyse at the terminal ileum of the small intestine, which is 
where PPs are found in high frequency in humans.  The ability for C. perfringens to naturally 
travel through the intestine, deliver protein to the vicinity of PPs, and exit the host without 
colonizing or causing infection makes it an attractive vector for further exploration. 
Rare isolates of C. perfringens cause food poisoning and nonfoodborne GI disease 
because they carry C. perfringens enterotoxin (CPE) encoded by the cpe gene [299].  Knocking 
out the cpe gene renders such isolates non-pathogenic for GI disease and thus provides a 
bacterial vehicle safe for human consumption [300].  The cpe gene can be carried 
chromosomally or episomally and is under control of the unique cpe promoter.  The cpe 
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promoter is activated only during sporulation [301, 302].  The strength of the cpe promoter is 
demonstrated in the fact that CPE production in the human intestine accounts for up to 15% of 
total bacterial protein, which accumulates in cytoplasmic inclusion bodies inside the mother cell.  
This ensures that the protein expressed from the cpe promoter remains untouched by proteases 
and bile salts of the intestinal lumen which would degrade extracellular or secreted protein.  
These properties make the cpe promoter and its natural regulation in C. perfringens an exquisite 
tool for expressing large amounts of protein that can be delivered intact in particulate form to the 
site of many PPs in the small intestine terminal ileum.  Both the large dose and particulate nature 
of protein delivered in this manner are believed to be associated with the induction of an antigen-
specific mucosal immune response and resistance to mucosal tolerance. 
Oral ingestion of C. perfringens not carrying the cpe gene may be considered safe for 
humans [300].  Nevertheless, C. perfringens encodes several other toxins that may damage the 
host if orally ingested bacteria surpass the mucosal barrier and enter the underlying tissue.  For 
example, gas gangrene can result if type A C. perfringens carrying the perfringolysin O (pfoA) 
and phospholipase C (plc) genes enters an open wound [303].  The actions of these two 
exotoxins collectively lead to the creation of pores in cell membranes and necrotization of tissue.  
Phospholipase C, also known as α-toxin, has never been shown to cause gangrene following oral 
delivery of type A C. perfringens, and inoculation of rabbit ileal loops with the toxin does not 
result in cytopathic effects [300].  Perfringolysin O, also known as θ-toxin, is also unlikely to 
cause disease when acquired orally.  Of the hundreds of thousands of cases of C. perfringens 
type A-related gastrointestinal disease, none have included gangrene.  The only possible 
examples of α- and/or θ-toxin-induced disease resulting from gut C. perfringens infecting 
extraintestinal tissue might occur following surgery that involves opening of the intestine or via 
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metastasized cancerous cells.  While literature indicates that there is a very low potential for 
orally acquired type A C. perfringens to exert harmful effects through the actions of α- and/or θ-
toxin, to ensure the safety of C. perfringens for its use as an oral vaccine vector, C. perfringens 
strains with inactivation of both of these toxins have been created [304, 305].  The triple toxin-
depleted C. perfringens is now being developed as a vaccine vector against HIV and SIV. 
In addition to the natural ability to deliver intact protein to the locale of GALT, C. 
perfringens has the benefits of being an inexpensive vaccine vector that can be delivered without 
the requirement of needles.  Both of these qualities are important to possess when a vaccine is 
most needed in resource-poor areas; indeed, the bulk of the burden of HIV is in countries defined 
as low- or middle-income [5].  In summary, the use of C. perfringens as an inexpensive, non-
toxic vaccine vector is appealing because of the inherent ability of C. perfringens to express viral 
protein from cpe promoter in a sporulation-regulated manner that allows for production of a large 
quantity of protein which is naturally delivered intact to a region of concentrated inductive 
GALT.  Non-toxic, cpe-negative C. perfringens has been reengineered to produce HIV and SIV 
proteins under control of the cpe promoter for use in development of vaccines against HIV and 
SIV [306]. 
1.6.2 Initial Characterization of C. perfringens Expressing SIV p27 as a Vaccine 
Delivery System 
Generation of C. perfringens expressing SIV p27 (Cp-p27) has been achieved using the 
pJRC200 plasmid, which contains the C. perfringens cpe gene including its promoter [307].  
Restriction enzyme digestion of the plasmid with BstB I and Bsu36 I removes all cytotoxic 
portions of the cpe gene and retains the initial 36 nucleotides necessary for efficient transcription 
from the cpe promoter and a small number of C-terminal nucleotides required for stabilization of 
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trascribed mRNA.  The SIV p27 gene from the molecular clone SIV-17e [308] was inserted into 
the digested vector to achieve a plasmid that, upon electroporation into cpe-negative type A C. 
perfringens, allows for expression of SIV p27 explicitly as a result of sporulation.  p27 can be 
detected in inclusion bodies of sporulating recombinant Cp-p27 using immunogold stain electron 
microscopy.  Additionally, expression of p27 by sporulating Cp-p27 has been quantitated to be 
20-30μg/mL sporulated culture (108 cfu) or approximately 70μg p27/mg C. perfringens protein 
using semi-quantitative Western blot.  In comparison, reports of other bacteria-based expression 
systems include protein production of 2.5μg Helicobacteri pylori urease/108 cfu Salmonella typhi 
[309].  The expression rate of p27 accounting for about 7% of the total C. perfringens protein is 
one of the highest known to be reported in a bacterial vaccine construct.  Indeed, the expression 
rate is also respectable when compared with bacteria commonly used for protein expression.  In 
one example of an efficient expression system, E. coli expressed human metallothionein 2A as 
10-15% of total protein [310]. 
Murine bone marrow-derived DCs (BMDCs) accumulated p27 when incubated with 
lysates of sporulating C. perfringens expressing p27 [306].  Furthermore, incubation of ligated 
murine intestine with the same C. perfringens preparation enabled DC in PPs to take up p27, and 
oral delivery of this Cp-p27 vaccine resulted in the presence of p27 in the lumen of the terminal 
ileum within 90 minutes of administration [306].  These results suggest that the Cp-p27 vaccine 
can deliver p27 to PPDCs in the terminal ileum of mice.  The resulting gut and systemic immune 
response remained to be fully characterized and is the object of the study described herein. 
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1.7 STATEMENT OF THE PROBLEM AND AIMS OF THE STUDY 
Since most HIV infection is transmitted through vaginal or rectal mucosal tissue and the 
gut mucosa is an immediate target following HIV/SIV infection, vaccine-induced mucosal 
immunity against the virus is important to control HIV infection.  The Cp-p27 oral vaccine is 
designed to stimulate immunity in the gut, and the resulting immunity may be transferred to 
other mucosal sites such as vaginal and rectal tissue.  Previous studies have demonstrated that 
oral inoculation of Cp-p27 can deliver a large quantity of SIV p27 to the terminal ileum, which 
contains a concentration of PPs patches that are rich with antigen presenting cells such as DCs.  
The central hypothesis formed from these previous findings is that Cp-p27 can deliver p27 to 
gut DCs and thereby prime mucosal and systemic humoral and cellular immunity against 
SIV.  To address this hypothesis the present study was undertaken to generate and characterize 
an anti-p27 cellular response upon oral administration of the Cp-p27 vaccine in mice.  The 
Specific Aims and research plans were as follows: 
 
Specific Aim 1:  Characterize the ability of Cp-p27 vaccine to induce DCs to 
stimulate p27-specific T cells in vitro 
Hypothesis:  DCs exposed to Cp-p27 will mature and gain capacity to present 
p27 epitopes on MHC to T cells 
Approach:  Murine bone marrow-derived and purified Peyer’s patch DCs 
were exposed to Cp-p27 and examined for maturation characteristics including co-
stimulatory molecule expression and cytokine production.  The function of DCs was 
assessed through ELISpot to detect IFN-γ produced by p27-specific T cells following 
restimulation by vaccine-exposed DCs. 
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Specific Aim 2:  Improve Cp-p27 vaccine to stimulate stronger DC and T cell 
responses in vitro by using PTDs conjugated to p27 
Hypothesis:  Vaccines containing p27 conjugated to PTD sequences will increase 
internalization of p27 and thus drive production of stronger immune response 
Approach:  C. perfringens strains expressing p27 conjugated to PTD-5 and 
8K PTD sequences were constructed and evaluated for their effects on cellular 
internalization.  Efficiency of uptake of conjugated or unconjugated p27 by DCs and 
intestinal epithelial cells were tested using quantitative protein immunoblotting.  
These PTD-conjugated C. perfringens strains were then compared with wild-type Cp-
p27 for effects on DCs and resulting T cell-stimulating capacity. 
 
Specific Aim 3:  Evaluate Cp-p27 as an oral vaccine in vivo in mice 
A.  Optimize mucosal adjuvants for use with Cp-p27 
Hypothesis:  Combinations of strong mucosal adjuvants will improve immune 
response to Cp-p27 vaccination 
Approach:  The mucosal adjuvants CT, LT(R192G), and CpG ODNs were 
administered to mice orally with Cp-p27.  The resulting cellular immunity in gut 
tissues was assayed with IFN-γ ELISpot.  The functionality of p27-specific T cells 
generated through use of leading adjuvants/adjuvant combinations was also assayed 
using intracellular cytokine staining and surface staining followed by flow cytometry. 
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B.  Determine the priming and/or boosting capacity of Cp-p27 when 
combined with a systemically delivered adenovirus expressing p27 
Hypothesis:  Cp-p27 priming can enhance mucosal and/or systemic immunity 
induced by boosting with adenovirus expressing SIV p27 
Approach:  Cp-p27 was administered to mice orally as a prime or boost to an 
intramuscular adenovirus vaccine expressing SIV p27.  SIV p27-specific cellular 
immune responses in systemic and gut tissues were assayed through IFN-γ production 
via ELISpot, and p27-specific humoral responses were assayed with ELISA.  In 
addition, the functionality of gut T cell responses in inductive and effector tissues was 
characterized with multi-color flow cytometry. 
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2.0  IN VITRO DENDRITIC CELL RESPONSE TO CP-P27 
2.1 PREFACE 
The study described in this chapter is a collaborative effort between Dr. Phalguni Gupta 
and Dr. Jay K. Kolls and constitutes a manuscript currently being revised following peer review.  
Dendritic cell cultures and experiments were performed by Ruth Helmus in Dr. Gupta’s 
laboratory, Bio-Plex assays were performed by Amy Magill in Dr. Kolls’ laboratory, and animals 
were cared for by the University of Pittsburgh Division of Laboratory Animal Resources.  These 
results were presented as poster abstracts at AIDS Vaccine 2003 (Development of a novel 
Clostridium perfringens-based oral vaccine against SIV.  Chen, Y., R. Helmus, B. McClane, J. 
Clemens, R. Hoffman, and P. Gupta.) and the 2005 Conference on Retrovirology and 
Opportunistic Infections (A novel C. perfringens-based SIV vaccine induces maturation of 
dendritic cells and enables dendritic cell priming of T cells.  R. Helmus, Y. Chen, T. Wehrli, and 
P. Gupta.) 
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2.2 ABSTRACT  
The induction of both systemic and mucosal immunity is a high priority in the 
development of an anti-HIV vaccine.  Dendritic cells (DCs) at inductive mucosal sites such as 
gut Peyer’s patches are important mediators of mucosal immune priming.  In this study, the 
interaction of a vaccine using Clostridium perfringens expressing SIV capsid p27 (Cp-p27) with 
murine DCs was investigated.  Both bone marrow-derived DC (BMDCs) and freshly isolated 
Peyer’s patches DCs (PPDCs) responded to exposure to Cp-p27 by upregulating maturation 
markers and producing pro-inflammatory cytokines. Furthermore, the mature dendritic cells 
stimulated p27-specific IFN-γ production by T cells, demonstrating that the p27 antigen was 
efficiently delivered to, processed by, and presented on MHC by BMDCs and PPDCs.  These 
findings suggest that Cp-p27 vaccine-mediated delivery of p27 to DCs could induce immunity 
against SIV. 
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2.3 INTRODUCTION 
The major sites of exposure to and transmission of human immunodeficiency virus (HIV) 
are mucosal surfaces.  An immune response induced by delivery of antigen to one mucosal site 
can stimulate immune responses at other mucosal sites as well as systemic immune responses 
[48, 49, 238, 249, 311]. Thus, an effective vaccine against HIV or its non-human primate 
counterpart simian immunodeficiency virus (SIV) should target a mucosal site.  One important 
mucosal tissue that can be targeted by oral vaccination is the gut.  In addition to its role in 
mucosal immunity, the gut has been shown to be a major site of viral replication and cell 
destruction early in SIV/HIV infection in both non-human primates [64, 312, 313] and humans 
[74, 75, 314] and likely serves as a reservoir for virus throughout infection [78, 79].  It is, 
therefore, important for an HIV or SIV vaccine to provide immunity in the gut by inducing 
immune responses through the gut associated lymphoid tissue (GALT). 
The main inductive immune tissues of the GALT are Peyer’s patches (PPs). Dendritic 
cells (DCs) in terminal ileum PPs are adept at capturing and processing antigens for presentation 
to naïve T cells.  DCs possess the unique ability to present exogenously acquired antigens that 
are normally loaded onto MHC class II molecules in the context of MHC class I, which is 
necessary for inducing a CD8+ cytotoxic T lymphocyte (CTL) response (reviewed in [315, 316]).  
The CD8+ CTL response to HIV or SIV appears essential for limiting viral infection, as 
displayed by numerous studies of both systemic and mucosal immune responses to HIV/SIV [43-
49, 79].  Thus, to generate an effective anti-SIV CD8+ CTL response, a vaccine must cause DCs 
to present SIV antigen to CD8+ T cells and induce priming of anti-SIV CD8+ CTLs. 
 39 
It has previously been shown that Clostridium perfringens expressing SIV p27 (Cp-p27) 
can deliver a large amount of viral antigen to the terminal ileum where PPs are concentrated 
[306].  The bioengineered C. perfringens has the natural ability to generate high levels of 
antigenic protein using the strong CPE gene (cpe) promoter during sporulation and then shield 
this protein in the mother cell until reaching the PPs. To study the effectiveness of the Cp-p27 
vaccine to induce a DC-mediated immune response, the phenotype, cytokine profile, and T-cell 
stimulatory capacity of DCs exposed to the vaccine were investigated.  The effects of the vaccine 
were examined using both systemic (bone marrow-derived DCs) and gut mucosal (freshly 
isolated Peyer’s patch DCs) DCs.  The results demonstrate that the Cp-p27 vaccine can 
efficiently stimulate a DC-mediated p27-specific immune response in vitro, which suggests that 
in vivo immunization would result in p27-specific CD8+ CTL responses.  This is the first analysis 
of the immune response of an extracellular bacteria-based oral vaccine via its target mucosal 
DCs. 
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2.4 MATERIALS AND METHODS 
Animals 
Female Balb/c mice were purchased from Charles Rivers Laboratories, Inc. and housed in 
a pathogen-free facility in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee and federal regulations.  Animals were used between 6 and 8 weeks of age. 
 
Antibodies 
FITC-α-CD40 (clone L3T4), FITC-α-CD40 (HM40-3), FITC-α-CD80 (16-10A1), FITC-
α-CD86 (GL1), FITC-α-I-Ad (39-10-8), R-PE-α-CD8a (53-6.7), R-PE-α-CD11c (HL3), 
unconjugated α-I-Ad (AMS-32.1), and unconjugated α-H-2Dd (34-5-8S) antibodies against 
mouse antigens and α-human CD3 (UCHT1) were purchased from BD Pharmingen.   PE/Cy5-α-
CD3ε (145-2C11), PE/Cy5-α-CD40 (1C10), PE/Cy5-α-CD80 (16-10A1), and PE/Cy7-α-CD86 
(GL1) antibodies against mouse antigens were purchased from BioLegend.  Isotype control 
antibodies were purchased from the same manufacturers according to the fluorescent conjugate 
used. 
 
Vaccine 
Construction of the Clostridium perfringens vaccine expressing SIV p27 has been 
described previously [306].  Sporulating cultures were achieved by overnight culture of modified 
Duncan-Strong medium [299] inoculated with a fresh 8h culture grown in fluid thioglycolate 
broth (Difco), with all growth performed at 37°C and in the presence of 10μg/mL 
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chloramphenicol.  Sporulation of at least 90% of all bacteria in cultures was confirmed by phase-
contrast light microscopy.  Sporulated bacteria were isolated and washed twice with PBS by 
centrifugation at 9700xg at 4°C for 10 minutes per centrifugation.  Isolated sporulating bacteria 
were sonicated, and expression of p27 was confirmed in sporulating cultures of the transformed 
bacteria by Western blot. 
 
BMDCs 
Mouse bone marrow-derived dendritic cells (BMDCs) were prepared as described 
previously [306].  Briefly, bone marrow cells flushed from the femurs and tibias of mice were 
seeded and cultured at 8x106 cells in 6-well plate wells in 4mL RPMI 1640 containing 10% heat-
inactivated fetal bovine serum, 1% L-glutamine, 1% sodium pyruvate, 1% nonessential amino 
acids, 1% penicillin-streptomycin, 0.025M 2-mercaptoethanol, and 4ng/mL of both GM-CSF and 
IL-4.  At day 2, nonadherent cells were removed and 50% of the supernatant was replaced with 
fresh cytokine-containing medium.  Cells (40-60% CD11c-positive) were used on culture day 5 
or 6. 
 
Isolation of PPDCs 
Peyer’s patch dendritic cells (PPDCs) were isolated as described by Iwasaki et al. [317] 
with modifications.  Aside from enzymatic incubations, isolation of cells was performed on ice.  
Peyer’s patches (PPs) were aseptically removed from small intestines and incubated at 37°C with 
stirring for 15-30 minutes in Hank’s balanced salt solution with 10% heat-inactivated FBS, 
145μg/mL 1,4-dithioerythritol, 25mM HEPES, and 5mM EDTA.  After washing with PBS, PPs 
were incubated for 15-30 minutes with stirring at 37°C in RPMI 1640 containing 10% heat 
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inactivated fetal bovine serum, 1% penicillin-streptomycin, and 1mg/mL collagenase D (Roche).  
The medium was passed through a 70μm-pore nylon mesh strainer and a 5mL syringe pestle was 
used to crush PPs through the same strainer.  The cell mixture was then passed through a 40μm-
pore nylon mesh strainer and recovered by centrifugation at 4°C.  Cells were blocked with anti-
CD16/CD32 antibody at 1:100 dilution, washed, and then incubated at 4°C for 15 minutes with 
MACS CD11c MicroBeads (Miltenyi Biotec) using 10μL beads per 107 cells.  Cells were then 
enriched for CD11c+ cells by passing through MS Columns (Miltenyi Biotec) following the 
manufacturer’s protocol.  Cells were then cultured at 1x106 cells/mL in 96-well plate wells in 
RPMI 1640 containing 10% heat-inactivated FBS, 1% penicillin-streptomycin, 3mM L-
glutamine, 1mM sodium pyruvate, and 50μM 2-mercaptoethanol.  Isolated cells were routinely 
65-75% CD11c-positive as detected by flow cytometry. 
 
Treatment of cells with vaccine 
BMDCs that had been grown for 5-6 days (1-2x106 cells per 4mL) or freshly isolated 
PPDCs (2x105 cells per 200µL) were incubated with ~2x105/mL sporulated, sonicated C. 
perfringens expressing p27, empty vector C. perfringens control, purified p27 protein at a 
concentration equivalent to that expressed by the vaccine bacteria.  As a positive control 
0.5μg/mL LPS were added to BMDC, and 10μM unmethylated CpG oligodinucleotides were 
added to PPDCs.  Treatments were removed after 2h via washing and centrifugation, and the 
cells were returned to culture for 22 (BMDCs) or 4 (PPDCs) additional hours.  Supernatant of 
cultures was then collected and stored at -20°C, and cells were harvested and utilized for further 
assays. 
 
 43 
Flow cytometry 
DCs were surface stained for CD11c, CD40, CD80, CD86, and MHC class II (I-Ad).  
BMDCs were also assayed for phagocytosis by incubating cells for 30 minutes in media 
containing 1mg/mL FITC-dextran (40,000 kDa molecular weight; Sigma).  Cells were then 
surface stained at 4°C.  After staining, all cells were fixed, and data were collected on using a 
Coulter Epics XL-MCL flow cytometer.  Cytometry data were analyzed using FlowJo version 
7.2.2. 
 
Bio-Plex 
DC supernatants were analyzed for cytokines using the Bio-Plex Mouse Cytokine 
Th1/Th2 Bio-Plex Panel kit from Bio-Rad.  50μL samples were assayed following the 
manufacturer’s instructions, and beads were analyzed using a Bio-Plex Luminex system. 
  
Western blot 
Cells were lysed and separated on a 15% SDS-PAGE gel.  Protein was transferred to 
nitrocellulose and blotted with monkey anti-SIV serum (a gift from Michael Murphey-Corb), 
washed, and blotted with horseradish peroxidase-conjugated goat anti-monkey antibody (Nordic 
Immunological Laboratories).  Protein bands were detected with SuperSignal West Pico 
Chemiluminescent Solution (Pierce).  Blots were analyzed via densitometry using Quantity One 
software (Bio-Rad). 
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ELISpot assay 
Detection of interferon-gamma (IFN-γ) was performed using mouse IFN-γ ELISpot Kits 
from Mabtech.  Precoated anti-IFN-γ ELISpot plates were activated with 5 washes with PBS and 
blocked at room temperature for ≥30 minutes with RPMI containing 10% FCS.  2x105 SIV p27-
specific splenocytes derived from mice inoculated subcutaneously with SIV p27 in Freund’s 
adjuvant were plated in wells.  These cells were placed at 37°C for 1h, and then BMDCs or 
PPDCs exposed to SIV p27-expressing C. perfringens or vector control C. perfringens were 
added to ELISpot plate wells at a 1:5 or 1:25 DC:splenocyte ratio, respectively, in a final volume 
of 200μL ELISpot media (RPMI-1640 with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, 0.1mM non-essential amino acids, 2mM L-glutamine, 10mM HEPES, 
and 1mM sodium pyruvate) per well.  Control wells included splenocyte or DCs only, and 
media-only control wells were also included for each plate.  In the case of MHC-blocking 
experiments, DCs at a concentration of 4x105 cells/mL were pre-incubated for 2h 1:50 (v/v) with 
the appropriate antibody (α-I-Ad for MHC class I blocking, α-H-2Dd for MHC class II blocking, 
and α-human CD3 as a control) before being added to splenocytes.  The cells were then 
incubated at 37°C for 24 to 36h.  Detection of IFN-γ spot-forming cells (sfc) was performed 
according to the manufacturer’s protocol.  Briefly, cells were removed and plates were washed 5 
times with PBS.  100μL of 1μg/mL R4-6A2-biotin detection antibody in PBS with 0.5% FCS 
was added to each well, and plates were incubated at room temperature for 2h.  Antibody was 
discarded and plates were washed 5 times with PBS, then 100μL of 1:1000 streptavidin-ALP in 
PBS with 0.5% FCS was added to each well, and plates were incubated at room temperature for 
1h.  Plates were washed as before, and 100μL of 0.45μm-filtered BCIP/NBT-plus substrate 
solution was added to each well.  Spots were allowed to develop for about 20 minutes at room 
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temperature, and then plates were washed extensively with tap water.  The underdrain was 
removed and the back of well membranes was also washed.  Excess water was blotted away 
using paper towel, and plates were left to dry in the dark at room temperature.  When dry, sfc 
were counted on an automated ELISpot reader.  Background sfc values from media- and cell-
only control wells were removed as appropriate, and sfc were normalized to 106 cells. 
 
Statistics 
Except where noted, p values were determined using 1-tailed two-sample Student’s t-test 
with unequal variance. 
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2.5 RESULTS 
2.5.1 Maturation of BMDCs Exposed to C. perfringens Expressing SIV p27 
In order to prime an effective immune response against an antigen, a DC exposed to the 
antigen must mature. To test the ability of the C. perfringens SIV vaccine to stimulate maturation 
of DCs, murine bone marrow-derived DCs (BMDCs) were exposed to C. perfringens expressing 
SIV p27 or empty vector C. perfringens or other stimuli.  Following exposure to Cp-p27, 
BMDCs showed an increased surface expression of CD80, CD86, CD40, and MHC class II, 
similar to stimulation with LPS as a positive control (Figure 2).  BMDCs exposed to control  
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Figure 2.  Maturation of bone marrow-derived dendritic cells (BMDCs) in response to C. perfringens SIV p27 
vaccine (Cp-p27) 
BMDCs were cultured without stimulus (filled grey curve/bar), with LPS (dotted curve/bar) as a positive control, 
with empty vector (black filled bar) control C. perfringens, or with Cp-p27 (unfilled solid dark curve/bar).  Unfilled 
solid light curve represents isotype control.  A, Representative flow cytometric histograms from 3 or 6 independent 
experiments showing the level of expression of maturation markers CD80, CD86, CD40, and MHC class II (I-Ad).  
All histograms are pregated on CD11c+ cells.  B, Average mean fluorescence intensity + standard error of the mean 
of maturation marker expression in response to stimuli as determined by flow cytometry.  Values of p were 
determined by Student’s t-test against untreated cells.  *p<0.05; **p<0.10. 
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Figure 3.  Internalization of dextran in BMDCs following exposure to Cp-p27 
BMDCs were cultured without stimulus, with LPS as a positive control, or with Cp-p27.  Following culture, cells 
were assayed for phagocytic ability by culture with FITC-conjugated dextran at 4°C (grey filled curve) or 37°C 
(unfilled curve).  Flow cytometric histograms show FITC-dextran internalization in the CD11c+ cell gate 
representative of 3 independent experiments.  Average difference in mean fluorescence intensity (ΔMFI) ± standard 
error of the mean is shown, with ΔMFI calculated by subtracting the 4°C MFI from the 37°C MFI. 
 
bacteria carrying an empty expression vector also displayed increased expression of the 
maturation markers, as is expected due to the presence of peptidoglycan in the C. perfringens 
cell wall. To confirm maturation, BMDCs exposed to stimuli were incubated with FITC-labeled 
dextran, and phagocytosed FITC signal was detected via flow cytometry.  BMDCs exposed to 
LPS, Cp-p27, or empty-vector C. perfringens displayed lower dextran internalization than 
untreated BMDCs, indicating a loss of phagocytic capacity (Figure 3). 
The matured BMDCs in all treatment groups produced high levels of a number of 
cytokines.  Specifically, proinflammatory cytokines known to play important roles in developing 
Th1 responses (IFN-γ, TNF-α, IL-12 p70) were all produced in quantities at least 3.5-fold higher 
than untreated cells (Table 1).  IL-4 was reduced in vaccine-treated cells compared with 
untreated cells; however, the Th2 and T-regulatory mediator IL-10 was increased, albeit to a 
much lesser degree than in positive-control LPS-treated cells.  BMDCs exposed to empty-vector 
C. perfringens produced less IL-5, IL-10, IL-12 (p70), and TNF-α than Cp-p27-exposed 
BMDCs.  IFN-γ and IL-4 levels were similar. 
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Table 1.  Cytokine profile of culture supernatants from BMDCs exposed to no stimuli, Cp-p27 vaccine, 
empty-vector control Cp vaccine or LPS 
 
 IL-2 IL-4 IL-5 IL-10 
 (pg/mL) fold increase (pg/mL) 
fold 
increase (pg/mL) 
fold 
increase (pg/mL) 
fold 
increase 
none 1.53±0.40  1.85±0.90 0.21±0.06 3.19±1.34 
Cp-p27 20.78±1.80 7.05 0.47±0.10 0.25 2.02±1.59 9.49 137.21±58.94 43.01 
control Cp 35.81±14.32 23.40 0.47±0.06 0.26 0.41±0.11 1.95 69.09±27.02 21.66 
LPS 2.80±0.53 1.83 1.67±0.31 0.90 5.73±1.55 26.98 570.70±168.2 178.90 
         
 
 
 
 
 
 
Changes observed in BMDCs following exposure to the Cp-p27 vaccine are in 
accordance with a mature DC phenotype activity [318].   These results suggest that the BMDCs 
exposed to the vaccine should be able to prime T cells to form a productive immune response. 
2.5.2 Functional Capacity of Cp-p27 Vaccine-Exposed BMDCs 
It has been demonstrated previously that p27 protein is internalized by BMDCs when 
they are exposed to the Cp-p27 vaccine [306].  To track the fate of the internalized p27, a 
polyclonal anti-SIV serum was used in Western blots to probe cell lysates of BMDCs over a time 
course following exposure to the vaccine.  Within 8 hours after exposure, these p27 levels were 
markedly decreased or undetectable in the BMDCs (Figure 4 A). 
 IL-12 (p70) TNF-α IFN-γ 
 (pg/mL) fold increase (pg/mL) 
fold 
increase (pg/mL) 
fold 
increase 
None 0.80±0.27 2.28±0.31 0.08±0.05  
Cp-p27 14.34±5.48 17.89 135.25±83.53 59.19 0.31±0.13 3.73 
control Cp 4.82±1.96 6.02 10.54±3.87 4.61 0.40±0.16 4.75 
LPS 100.50±67.14 125.43 2366.91±964.14 1035.85 0.42±0.18 5.03 
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Figure 4.  SIV p27 delivered by Cp-p27 processing and presentation by BMDCs 
A, Western blot of lysates from Cp-p27 bacteria and BMDCs at multiple times following exposure to Cp-p27.  B, 
IFN-γ ELISpot results representative of 5 independent experiments with vaccine-treated BMDCs cultured with p27-
specific murine splenocytes.  Error bars indicate standard error of the mean of samples assayed in triplicate.  p-value 
determined by Student’s t-test.  C, IFN-γ ELISpot results representative of 3 independent experiments with vaccine-
treated BMDCs cultured with p27-specific murine splenocytes in the presence of antibody against MHC class I or 
MHC class II.  The inset shows the percentage of CD4+ or CD8+ T cells in murine splenocytes (white bars; n=6) 
compared to the percentage of MHC class II- or class I-mediated IFN-γ production in the ELISpot assays (black 
bars). Error bars indicate standard error of the mean.  p-value determined by 2-tail heteroscedastic Student’s t-test. 
 
 
Next the fate of p27 was investigated by using vaccine-exposed BMDCs as antigen 
presenting cells in an ELISpot assay to determine if degraded p27 epitopes could be displayed on 
BMDC MHC molecules.  For this purpose, the vaccine-exposed and matured BMDCs were used 
to restimulate p27-specific mouse splenocytes in an IFN-γ ELISpot assay.  Splenocytes cultured 
with the vaccine-exposed BMDCs displayed p27-specific IFN-γ production, indicating that the 
BMDCs were indeed displaying p27 epitopes on MHC molecules and were capable of 
stimulating an immune response against p27 (Figure 4 B).  The IFN-γ ELISpot response 
stimulated by Cp-p27-exposed BMDCs was about 12.8 times that stimulated by BMDCs 
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exposed to empty vector C. perfringens.  It should be noted that the low background IFN-γ 
response detected by ELISpot in BMDC-only wells was similar regardless of whether BMDCs 
were treated with Cp-p27 or the empty vector control C. perfringens. 
By blocking MHC class I- or II-mediated epitope presentation with antibodies against 
these molecules, p27 epitopes were detected to be presented in the context of both MHC class I 
and class II (Figure 4 C).  More IFN-γ response was detected in assays with MHC class I 
blocking, indicating that the BMDCs presented more antigen in the context of MHC class II.  
However, the percentage of CD4+ or CD8+ T cells used in the assay were similar to the 
percentage of ELISpot sfcs resulting from MHC class II- or MHC class I-mediated expression, 
respectively (Figure 4 C inset).  These findings indicate that presentation of p27 peptides on 
BMDCs after exposure to the vaccine is biased neither towards MHC class I nor towards class II. 
2.5.3 Immune Response to Cp-p27 Vaccine in PPDCs 
BMDCs, representative of systemic myeloid DCs, have many differences from the 
Peyer’s patch DCs (PPDCs) that are the target for the development of mucosal immunity via oral 
vaccination.  The DC subpopulations resident in PPs occur at different frequencies than in 
systemic compartments, including higher proportions of lymphoid and CD4- DCs [319-322].  
DCs native to the PPs differ from other DCs in their reaction to antigen and subsequent cell-
stimulatory ability.  For example, PPDCs produce significantly more IL-10 following antigen-
induced maturation and are more inclined to stimulate a Th2-type T cell response [317, 323, 
324].  In order to better assess the vaccine’s potential to prime a gut immune response and to 
determine if these cells behave differently in response to the vaccine than BMDCs, the BMDC  
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Figure 5.  Maturation of Peyer’s patch dendritic cells (PPDCs) in response to Cp-p27 
PPDCs were cultured without stimulus (filled grey curve/bar), with CpG ODNs (dotted curve/bar) as a positive 
control, or with Cp-p27 (unfilled solid dark curve/bar).  Unfilled solid light curve represents isotype control.  A, 
Representative flow cytometric histograms from 2-5 independent experiments showing the level of expression of 
maturation markers CD80, CD86, CD40, and MHC class II (I-Ad).  All histograms are pregated on CD11c+ cells.  B, 
Average mean fluorescence intensity + standard error of the mean of maturation marker expression in response to 
stimuli as determined by flow cytometry. 
 
 
 
Table 2.  Cytokine profile of culture supernatants from PPDC exposed to no stimuli, Cp-p27 vaccine, empty-
vector control Cp vaccine or CpG ODN 
 
 IL-2 IL-4 IL-5 IL-10 
 (pg/mL) fold increase (pg/mL) 
fold 
increase (pg/mL) 
fold 
increase (pg/mL) 
fold 
increase 
None 0.95±0.04  0.51±0.14  0.10±0.02  1.29±0.16  
Cp-p27 1.61±0.28 1.69 1.79±0.61 3.54 26.48±2.46 268.10 163.82±18.74 126.99 
control Cp 1.05±0.09 1.11 1.23±0.38 2.44 0.20±0.09 2.00 5.74±4.45 4.45 
CpG ODN 2.25±0.60 2.37 0.85±0.43 1.68 0.13±0.03 1.30 11.79±5.01 9.14 
 
 IL-12 (p70) TNF-α IFN-γ 
 (pg/mL) fold increase (pg/mL) fold increase (pg/mL) 
fold 
increase 
none 0.64±0.08  1.89±0.21  0.70±0.13  
Cp-p27 308.57±23.31 485.93 1806.96±150.94 956.69 39.69±13.53 56.80 
control Cp 3.59±2.09 5.66 18.34±12.05 9.71 0.84±0.34 1.20 
CpG ODN 12.93±4.43 20.36 3.41±0.97 1.80 1.61±0.35 2.30 
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experiments were repeated using DCs isolated from the PPs of mice.  Vaccine-treated PPDCs 
showed enhanced surface expression of maturation markers and production of pro-inflammatory 
cytokines, similar to BMDCs (Figure 5 and Table 2).  Interestingly, the percentage of PPDCs 
expressing CD40 in response to the positive control unmethylated cytosine-phosphate-guanine 
oligodinucleotides (CpG ODN) was similar to that of unstimulated cells; however, the mean 
fluorescence intensity of the small percentage of CD40-expressing cells was distinctly higher in 
CpG ODN-stimulated PPDCs than unstimulated PPDCs.  In contrast to BMDC cytokine 
responses, PPDCs treated with Cp-p27 displayed much higher levels of expression of IL-5, IL-
10, IL-12(p70), TNF-α, and IFN-γ in comparison to untreated PPDCs as well as CpG ODN- and 
empty vector C. perfringens-treated PPDCs.  In an ELISpot assay, the Cp-p27-exposed PPDCs 
also displayed the ability to stimulate p27-specific IFN-γ (Figure 6).  In this assay, background  
control wells of just PPDCs showed identical numbers of IFN-γ spot-forming cells (sfc) (which 
was at or near zero) regardless of whether they were treated with Cp-p27 or empty vector C. 
perfringens.  Thus, although PPDCs respond to antigen differently than other DCs, these data 
suggest that the C. perfringens-p27 vaccine would be able to generate an anti-SIV-p27 immune 
response in the gut if successfully delivered to PPDCs. 
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Figure 6.  SIV p27 delivered by Cp-p27 vaccine is presented as epitopes by PPDCs 
Shown are IFN-γ ELISpot results representative of 5 independent experiments with vaccine-treated PPDCs cultured 
with p27-specific murine splenocytes.  Error bars indicate standard error of the mean of samples assayed in 
duplicate.  p-value determined by Student’s t-test. 
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2.6 DISCUSSION 
The present study investigated the phenotype and functionality of murine DCs following 
exposure to C. perfringens-SIV p27 vaccine.  Both bone marrow-derived and freshly isolated PP 
DCs demonstrated characteristics of maturation following exposure to vaccine including 
upregulation of costimulatory and MHC molecules and loss of phagocytic capacity (Figures 1 
and 4).  Once internalized into BMDCs, p27 was degraded, and the antigen became undetectable 
within 8 hours (Figure 3a).  The matured dendritic cells expressed high levels of pro-
inflammatory and Th1- and memory-promoting cytokines (Tables 1 and 2) and stimulated an 
IFN-γ response in p27-specific cells (Figures 3b and 5).  IFN-γ was produced in the presence of 
antibodies against either MHC class I or MHC class II (Figure 3c), indicating that p27 epitopes 
are effectively presented in both contexts, and the DCs can thus stimulate both CD4+ and CD8+ T 
cells.  This study demonstrates the ability of p27 in the context of the Cp-p27 vaccine to induce 
murine DCs to stimulate a p27-specific T cell response. 
The goal of the C. perfringens-p27 vaccine examined in this study is to successfully 
deliver SIV p27 antigen to DCs of the PPs and induce an immune response against the antigen.  
Since the p27 antigen is present in inclusion bodies of the bacterial cell, the p27 is protected from 
destruction by stomach acid and by degrading enzymes of the small intestine as the bacterial 
vector travels through the duodenum and jejunum until it reaches the terminal ileum.  This would 
allow for delivery of high amounts of intact viral antigen to the site of the gut that has been 
shown in humans and monkeys to be rapidly infected and depleted of lymphocytes following 
infection of the individual by HIV or SIV, respectively [64, 74, 75, 312-314].  A vaccine-induced 
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immune response in these tissues is likely to be important in controlling the virus soon after 
infection, and the Cp-p27 is an attractive possible tool for inducing such a response.  DC 
maturation and antigen presentation is the first requirement for the formation of a DC-mediated 
immune response. 
The evaluation of HIV and SIV vaccines by characterizing their interactions with and 
effects upon DCs has been undertaken with leading vaccine vectors.  For example, a study of the 
mechanism of the ALVAC canary-pox vector’s induction of innate immune activation included 
investigation of its effects upon murine BMDCs [325].  ALVAC is used as a vector for many 
HIV vaccines previously and currently in clinical trials.  BMDCs exposed to ALVAC displayed 
enhanced expression of costimulatory molecules CD40, CD80, and CD86.  In the current study, 
BMDCs exposed to Cp-p27 demonstrated upregulation of these same markers as well as MHC 
class I.  Whereas ALVAC treatment was reported to induce less costimulatory molecule 
upregulation as compared to a positive control TLR4 agonist, Cp-p27 treatment in the current 
study displayed equal or enhanced levels of most maturation indicators compared with the TLR4 
agonist LPS.  This may be due in part to the presence of peptidoglycan in C. perfringens, which 
might interact with DCs via TLR2 as has been suggested for another Gram positive organism, 
Staphylococcus aureus [326-329].  Both ALVAC- and Cp-p27-treated BMDCs secreted 
cytokines including TNF-α and IL-12.  Additionally, Cp-p27-treated BMDCs and PPDCs 
secreted IFN-γ, which has been suggested to be essential for PPDCs to mediate optimal 
resistance against oral pathogens [330]. 
The most promising bacteria-based anti-immunodeficiency virus vaccines to date utilize 
Salmonella enterica serovar Typhimurium [247, 331] and Listeria monocytogenes [332, 333].  
Like these vaccines, Cp-p27 is designed to deliver intact protein to gut cells.  However Cp-p27 
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does not involve infection or colonization of the gut mucosa since the protein is delivered in the 
context of a non-replicative bacterial spore.  Human monocyte-derived DCs exposed to HIV gag-
expressing L. monocytogenes stimulated cytotoxicity against target cells [334].  Although the 
evaluation of this Listeria vaccine in mucosal DCs was not reported, the vaccine has been shown 
to stimulate gut mucosal as well as systemic immunity in animal models when delivered orally, 
indicating that the in vitro response to the vaccine in systemic-type DCs (e.g. monocyte-derived 
DCs) corresponded to mucosal in vivo immunostimulatory capacity of the vaccine[332].  In the 
current study, murine systemic DCs exposed to C. perfringens expressing SIV p27 caused IFN-γ 
production by p27-specific cells via both MHC class II and class I, indicating that stimulation of 
CTLs was likely resulting from vaccine-exposed DCs.  Murine gut mucosal DCs exposed to the 
vaccine also stimulated p27-specific IFN-γ production.  In light of the findings with the L. 
monocytogenes vaccine, the current results encourage further exploration into the in vivo 
capacity of the orally-delivered Cp-p27 vaccine to stimulate systemic and mucosal immunity via 
DCs. 
Dendritic cells exposed in vitro to free antigen or vaccine-delivered antigen have also 
been used themselves as vaccines in many non-human primate and human studies (reviewed in 
[335]).  When treated in vitro, these DCs demonstrate upregulation of costimulatory molecules 
and MHC class II, pro-inflammatory cytokine production, and capacity to trigger antigen-
specific IFN-γ production.  These characteristics correspond to immunostimulatory capacity of 
the DC-vaccines when administered in vivo.  The enhancement of DC-mediated IFN-γ observed 
in these types of studies is of the same magnitude as that detected in this study with Cp-p27-
exposed DCs (i.e. approximately 10-fold enhancement of IFN-γ sfc when comparing vaccine-
exposed DCs with DCs exposed to vector control vaccine) [336, 337]. 
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The results of the current study demonstrate that in vitro exposure of both systemic and 
gut mucosal DCs to the Cp-p27 vaccine leads to effective stimulation of a p27-specific immune 
response.  Previously it was shown that oral delivery of the vaccine to mice resulted in high 
levels of p27 in the terminal ileum [306].  Together, these findings suggest that the vaccine 
should be effective at priming an immune response in Peyer’s patches in vivo when orally 
delivered.  Given the importance of the gut in HIV and SIV infection, it is vital to pursue 
development of vaccine vectors such as ours that may induce effective anti-viral immunity in the 
gut.  Experiments are underway to investigate the immune response generated against SIV p27 
when animals are fed the Cp-p27 vaccine. 
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3.0  USE OF PROTEIN TRANSDUCTION DOMAIN CONJUGATION TO SIV P27 
TO ENHANCE IMMUNE RESPONSE AGAINST VIRAL ANTIGEN 
3.1 PREFACE 
The study described in this chapter was performed by Ruth Helmus in Dr. Phalguni 
Gupta’s laboratory.  Dr. Bruce McClane graciously provided the pJRC200 plasmid.  Bio-Plex 
assays were performed by Amy Magill in Dr. Kolls’ laboratory, and animals were cared for by 
the University of Pittsburgh Division of Laboratory Animal Resources.  Dr. Paul D. Robbins 
provided guidance for PTD sequence selection.  These results were presented as a poster abstract 
at the 2005 Keystone Symposia on HIV Vaccines (Protein transduction domain fusion enhances 
dendritic cell SIV p27 internalization and stimulatory function in response to a C. perfringens-
based SIV vaccine.  R. Helmus, Y. Chen, T. Wehrli, and P. Gupta.) 
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3.2 ABSTRACT 
Protein transduction domains (PTDs) are cationic peptides that improve the delivery of 
their attached cargo into the cytoplasm of mammalian cells.  The Cp-p27 vaccine consists of a 
Clostridium perfringens bacterium expressing SIV p27 and is designed to deliver p27 to 
dendritic cells (DCs) of the small intestine.  By conjugating PTD peptide sequences 8K and 
PTD-5 to the N-terminus of p27 in Cp-p27, it was hypothesized that enhanced p27 delivery 
would result, leading to more p27 epitope display on MHC class I, and thereby improving the 
induction of CD8+ T cell immune responses that have been associated with control of SIV.  
Although C. perfringens expressing p27 conjugated to PTD sequences resulted in higher protein 
internalization, no difference was observed between PTD-conjugated and unconjugated strains in 
the ability to induce DCs to stimulate p27-specific IFN-γ by splenocytes.  In addition, no 
improvement in systemic immunity was observed following vaccination with the 8K-conjugated 
strain when compared with the unconjugated Cp-p27 vaccine.  In summary, a higher immune 
response by the PTD-conjugated Cp-p27 strains was not induced despite an increase in protein 
internalization by DCs. 
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3.3 INTRODUCTION 
In order to stimulate an immune response in the gastrointestinal tract, antigen must be 
delivered in sufficient quantity to antigen presenting cells (APCs).  The major APCs of the 
intestine are dendritic cells (DCs), which are found in the subepithelial dome (SED) of Peyer’s 
patches (PPs) and interspersed in lamina propria tissue.  PPDCs acquire antigen when it is 
transcytosed to the SED through specialized epithelial cells known as M cells [254].  Lamina 
propria DCs extend their dendrites across the epithelial layer to directly capture luminal contents 
[256, 338] and can also acquire antigen from intestinal epithelial cells [339, 340].  DCs are 
generally required for the formation of productive mucosal immune responses [341, 342], 
although intestinal epithelial cells may also function as APCs [343]. 
DCs possess the unique ability to present exogenously acquired antigens, which normally 
are loaded onto MHC class II molecules, in the context of MHC class I.  Antigen presentation on 
MHC class I is required for the formation of CD8+ T cell responses, including CD8+ CTL 
responses, which are important in control of HIV and SIV infection [40, 42, 136-140].  
Enhancing the delivery of vaccine antigen to DCs is expected to increase the number of DCs 
presenting antigen and thus the number of resulting antigen-specific effector cells. 
Protein transduction domains (PTDs) are peptides that enable the proteins to which they 
are bound to efficiently enter target cells through a receptor-independent mechanism [288-290].  
PTD-mediated uptake delivers antigen to the cytoplasm, which engages the MHC class I 
pathway, thus enhancing DC cross-presentation and increasing induction of CTLs [296, 297].  
Unique PTDs have been designed with the ability to specifically target proteins to certain cell 
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types.  Among these are the arginine-rich PTD-5 peptide (RRQRRTSKLMKR) and the lysine-
rich 8K peptide (KKKKKKKK).  Both of these positively charged cationic peptides show strong 
binding to glycosaminoglycans such as heparan sulphate [288].  Thus, through electrostatic 
interaction with the plasma membrane, the PTDs with their attached protein cargo are more 
efficiently transduced into cells than unattached protein [288].  PTD-5 and 8K have been 
successfully used to deliver fluorescent proteins and active enzymes to cells and tissues [288, 
291, 344].  PTD-5 enhances protein uptake by many cell types, including epithelial cells and 
DCs [291].  8K also transduces protein into epithelial cells [288] and is especially proficient at 
directing proteins into DCs (Dr. Paul.D. Robbins, personal communication).  Incorporating either 
of these PTD peptides as an N-terminal conjugation to orally administered antigen should 
increase delivery of the antigen directly to gut DCs or to DCs indirectly via enhanced uptake by 
M cells or epithelial cells. 
To evaluate the potential for PTD conjugation to enhance immunity against SIV p27 
through vaccination with Clostridium perfringens expressing SIV p27, PTD-p27 conjugate 
strains of C. perfringens were examined for immune stimulatory capacity under in vitro and in 
vivo conditions.  The responsiveness of DCs to the various C. perfringens vaccine strains 
expressing PTD-conjugated SIV p27 and the resultant ability of DCs to stimulate p27-specific 
cellular responses were determined. 
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3.4 MATERIALS AND METHODS 
Construction and growth of C. perfringens expressing SIV p27 and PTD conjugates 
Construction of C. perfringens expressing SIV p27 (Cp-p27) using the pJRC200 plasmid 
has been described in Chapter 2 and published elsewhere [306].  For PTD conjugate strains in 
which p27 was expressed with the N-terminal fusion of either PTD-5 (RRQRRTSKLMKR) or 
8K (KKKKKKKK), primers encoding the appropriate PTD sequence, BstB I and Bsu36 I 
enzyme cut sites, and a di-glycine (GG) linker were used in the initial p27 amplification step (see 
Table 3) and the resulting PCR product was cloned.  The empty vector C. perfringens used in 
these experiments contained the pJIR418 plasmid, the parent of pJRC200.  Recombinant 
plasmids and C. perfringens strains were confirmed by sequencing to contain the desired genetic 
information.  Sporulating cultures were achieved, isolated, and quantitated for p27 expression as 
described in Chapter 2. 
 
Table 3.  5' primers used for cloning of SIV p27 into C. perfringens 
peptide for 
conjugation to p27 5’ to 3’ primer sequence 
  
PTD-5 TTCGAAATGAGACGCCAGCGTCGCACGAGCAAACTGATGAAACGAGGCGGCCCAGTACAACAAATAGGTGGTAAC 
8K ACTGTACTACTCTTCGAAATGAAGAAGAAGAAGAAGAAGAAGAAGGGCGGCCCAGTACAACAAATAGGTGGTAAC 
none TTCGAACCAGTACAACAAATAGGTGG 
3' primer for all constructs was 5’--CCTAAGGACATTAATCTA GCCTTCTG--3’ 
Italics:  BstB I recognition site 
Underline:  PTD overhang 
Bold:  diglycine linker 
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Animals 
Female Balb/c mice were purchased from Charles Rivers Laboratories, Inc. and housed in 
a pathogen-free facility in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee and federal regulations.  Animals were used at 6 to 8 weeks of age. 
 
Cell culture 
Bone marrow-derived DCs (BMDCs) were generated and grown as described in Chapter 
2.  The DC2.4 cell line was cultured in DMEM containing 10% FBS, 1% penicillin-
streptomycin, and 2mM L-glutamine.  Adherent cells grown in 75cm2 flasks were trypsinized 
and reseeded (1-2x106 cells per flask) every 3-4 days.  For uptake experiments, cells were seeded 
at day 0 at 1x106 cells per 100mm diameter round culture dish and grown in a volume of 10mL 
for use on culture day 4.  CaCo2 cells were cultured in DMEM containing 10% FBS, 1% 
penicillin-streptomycin, 0.76% sodium bicarbonate, 0.1mM non-essential amino acids, and 2mM 
L-glutamine.  Cultures were fed on day 3 or 4 of culture by removing ¾ media and replacing 
with fresh media.  Adherent cells grown in 75cm2 culture flasks were trypsinized and reseeded 
(1.5x106 cells per flask) on day 6-8 of culture.  For uptake experiments, cells were seeded on day 
0 at 1x106 cells per 100mm diameter round culture dish and grown in a volume of 10mL for use 
on culture day 7, with feeding at day 3.  All cells were grown at 37°C in the presence of 5% CO2. 
 
BMDC treatment and assays 
BMDCs were treated with bacteria and surface stained as described in Chapter 2.  
Dextran uptake experiments were also performed as described in Chapter 2.  Cells were 
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examined using a Coulter Epics XL-MCL flow cytometer or FACS Canto flow cytometer.  
Cytometry data were analyzed using FlowJo version 7.2.2.  DC supernatants were analyzed in 
the laboratory of Dr. Jay K. Kolls for cytokines using the Bio-Plex Mouse Cytokine Th1/Th2 
Bio-Plex Panel kit from Bio-Rad.  50μL samples were assayed following the manufacturer’s 
instructions, and beads were analyzed using a Bio-Plex Luminex system. 
 
p27 uptake experiments 
Optimal exposure time and treatment concentration was determined for both DC2.4 and 
CaCo2 cells grown in culture dishes to be 2 hours with 100mg p27 expressed by sonicated C. 
perfringens strains all grown to similar concentrations and with similar sporulation percentages.  
After this incubation period, cells were extensively washed with Hanks’ buffered salt solution 
and trypsinized (1mL per dish) for 1-5 minutes at 37°C.  Trypsin was neutralized by the addition 
of RPMI containing 10% FBS, and all cells were removed from the dish and pelleted at 700rpm.  
Cell samples from each pellet were counted and assessed for viability using trypan blue 
exclusion.  For CaCo2 cells, viability was confirmed with propidium iodide staining and analysis 
via flow cytometry.  Pellets were washed with HBSS and stored at -20°C until Western blot 
analysis.  For Western blots, a minimal volume of loading buffer containing SDS was added to 
each cell pellet, and this mixture was boiled for 10 minutes.  Samples were separated on a 15% 
SDS-PAGE gel which contained low mass p27 standards ranging from 25ng to 250 ng).  Protein 
was transferred to nitrocellulose and blotted with monkey anti-SIV serum (a gift from Michael 
Murphey-Corb), washed, and blotted with horseradish peroxidase-conjugated goat anti-monkey 
antibody (Nordic Immunological Laboratories).  Protein bands were detected with SuperSignal 
West Pico Chemiluminescent Solution (Pierce).  Blots were analyzed via densitometry using 
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Quantity One software (Bio-Rad), with valid measurements falling within the linear portion of a 
standard curve. 
Each uptake experiment contained 5 or 6 culture dishes per C. perfringens strain tested, 
and cells from each dish were loaded into separate lanes on the same SDS-PAGE gel.  The 
average mass of p27 internalized was calculated for each C. perfringens strain in each 
experiment.  For both cell lines used, the experiment was performed at least 3 times with similar 
internalization trends observed each time. 
 
 
Dendritic cells ELISpot assay 
Detection of interferon-gamma (IFN-γ) was performed using mouse IFN-γ ELISpot Kits 
from Mabtech as described in Chapter 2.  To determine the percent of response due to MHC 
class I epitope presentation, MHC-blocking experiments were conducted as described in Chapter 
2.  The number of sfc from α-H-2Dd-treated samples was divided by the sum of sfc from α-H-
2Dd-treated samples and α-I-Ad-treated samples and then multiplied by 100 to determine the 
percentage of response due to MHC class I. 
 
Vaccination 
Mice were inoculated using an infant enteral feeding tube inserted down the esophagus 
into the stomach, where a total volume of 500μL was delivered.  Two mice per group received 
either Cp-8K-p27 or Cp-p27, each expressing similar levels of p27 and each delivered with 25μg 
LT(R192G) adjuvant (provided by J. D. Clements), or PBS as a control.  Vaccine was 
administered 3 times at 2 week intervals.  19 days after the final inoculation mice were sacrificed 
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and spleens were collected.  Spleens were gently crushed with glass stoppers to release 
splenocytes, which were passed through nylon mesh, pelleted with centrifugation at 4°C at 1200 
rpm for 5 minutes, treated with 3-5mL red blood cell lysis buffer (Sigma) for 5 minutes with a 
gentle shake after 3 minutes, and washed with RPMI containing serum.  2x105 splenocytes were 
assayed using mouse IFN-γ ELISpot Kits from Mabtech in a volume of 200μL ELISpot media 
(RPMI-1640 with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 0.1mM non-essential 
amino acids, 2mM L-glutamine, 10mM HEPES, and 1mM sodium pyruvate).  Samples were 
stimulated with two separate pools of SIV mac239 15-mer peptides (NIH AIDS Research and 
Reference Reagent Program) covering the majority of SIV p27 with peptides 5265 through 5298 
of SIV gag with each peptide at a concentration of 5μg/mL.  Each sample also included a 
background control in which a concentration of DMSO equivalent to that in the peptide pools 
was added to the well.  As a positive control, each sample was stimulated with 1mg/mL 
concanavalin A.  All treatments for all samples were plated in triplicate.  Cells were incubated at 
37°C for 24h.  Detection and quantitation of IFN-γ sfc was performed as described in Chapter 2.  
These results were compared with IFN-γ sfc values determined from mice who received 109 pfu 
of Ad-p27 delivered in 50μL into the quadriceps muscle using a 26G needle and were sacrificed 
2 weeks later. 
 
Statistics 
Values of p were determined using 1-tail two-sample Student’s t-test with unequal 
variance. 
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3.5 RESULTS 
3.5.1 Construction of C. perfringens Expressing PTD-conjugated SIV p27 
C. perfringens expressing p27 conjugated to either PTD-5 or 8K were constructed as 
described in Materials and Methods (section 3.4) using the standardized pJRC200 expression 
plasmid cloning method established during the engineering of Cp-p27 [306].  Expression of p27 
with each PTD conjugate was confirmed by Western blotting in sporulated cultures of each 
conjugate strain (Figure 7).  The level of p27 expression was not significantly affected by 
inclusion of either PTD conjugate (Figure 7). 
3.5.2 Maturation of BMDCs Exposed to PTD-Conjugated C. perfringens Strains 
C. perfringens strains expressing each PTD conjugate were then evaluated for their 
abilities to stimulate dendritic cell (DC) maturation.  Like Cp-p27, Cp-PTD-5-p27 and Cp-8K-
p27 conjugate strains enhanced expression of CD80, CD86 and CD40 costimulatory molecules, 
as well as MHC class II (Figure 8 A&B).  Phagocytosis of dextran was decreased in DCs after 
exposure to conjugate strains, similar to wild type Cp-p27 (Figure 8 C). 
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Figure 7.  Expression of PTD-conjugated p27 from C. perfringens 
Samples of sporulated C. perfringens expressing unconjugated p27 (Cp-p27), p27 conjugated to PTD-5 (Cp-PTD-5-
p27), or p27 conjugated to 8K (Cp-8K-p27) were probed via Western blot using SIV-specific antisera.  Control lanes 
contained 12.5ng purified p27 or C. perfringens carrying an empty expression plasmid (empty vector Cp). 
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Figure 8.  Dendritic cell maturation following exposure to C. perfringens expressing PTD-conjugated SIV p27 
Bone marrow-derived dendritic cells were exposed to C. perfringens expressing unconjugated SIV p27 (Cp-p27, 
blue), PTD-5-conjugated p27 (Cp-PTD-5-p27, red), 8K-conjugated p27 (Cp-8K-p27, green), or empty-vector C. 
perfringens (light gray).  As negative controls, cells were left untreated (black) or exposed to purified p27 protein 
(dark gray).  As a positive control, LPS was added to cells (dashed).  Unfilled solid light curve represents isotype 
control.  All histograms are pregated on CD11c+ cells.  A, Representative flow cytometric histograms from 2 to 5 
independent experiments showing the level of expression of maturation markers.  B, Average mean fluorescence 
intensity + standard error of the mean of maturation marker expression.  Values of p were determined by Student’s t-
test against untreated cells.  *p<0.05; #p<0.10.  C, Flow cytometric histograms show FITC-dextran internalization 
at 4°C (grey filled curve) or 37°C (unfilled curve).  Average difference in mean fluorescence intensity (ΔMFI) is 
shown in the upper right hand corner of each histogram, with ΔMFI calculated by subtracting the 4°C MFI from the 
37°C MFI. 
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3.5.3 Uptake of PTD-Conjugated p27 Delivered by C. perfringens 
To determine whether conjugation to either PTD sequence enhanced uptake of p27, two 
cell lines were exposed to bacteria expressing equivalent levels of p27, and internalized protein 
per cell was quantified by Western blot.  To examine the effect of PTD conjugation on 
internalization of p27 by both DCs and epithelial cells, the murine dendritic cell line DC2.4 and 
human colon epithelial cell line CaCo2 were exposed to C. perfringens expressing wild-type or 
PTD-conjugated p27.  In both cell types, more p27 was detected in cells treated with PTD 
conjugate strains than wild type, with p<0.10 (Figure 9).  In 6 of 10 experiments, there was 
consistently more p27 internalization by DC2.4 and CaCo2 cells following exposure to the 8K-
p27 conjugate as compared to the PTD-5-p27 conjugate. 
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Figure 9.  Internalization of C. perfringens-expressed SIV p27 conjugated to PTD sequences 
DC2.4 (A) or CaCo2 (B) cell line cells were exposed to C. perfringens expressing unconjugated SIV p27 (wt-p27), 
PTD-5-conjugated p27 (PTD-5-p27), or 8K-conjugated p27 (8K-p27).  Internalized protein was detected by 
quantitative Western blot and normalized to 106 cells.  Graphs are representative of at least 3 independent 
experiments per cell line.  Bars represent average internalized protein from 6 samples + standard error of the mean.  
Values of p were determined by Student’s t-test against wt-p27-treated cells.  *p<0.1. 
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Table 4.  Viable cells (in millions) remaining after treatment with vaccine constructs in wells seeded with 
equal numbers of CaCo2 cells 
 
vaccine construct used for treatment 
Cp-p27 Cp-PTD-5-p27 Cp-8K-p27 
trial 1 19.12 3.89 6.05 
trial 2 20.49 3.44 3.34 
trial 3 7.45 1.83 0.73 
 
 
It is important to note that the viability of cells was also assessed after treatment with 
bacteria.  Viability of DC2.4 cells was not altered.  However, massive killing of CaCo2 cells was 
observed following treatment with PTD conjugates, while cells treated with the unconjugated 
construct in the same experiment maintained high viability (Table 4). 
3.5.4 Functional Capacity of  BMDCs Exposed to C. perfringens Expressing PTD-
Conjugated p27 
It was next determined whether the p27-specific immune stimulatory capacity of DCs 
was enhanced following exposure to PTD conjugates using a p27-specific IFN-γ ELISpot assay.  
Similar to C. perfringens expressing wild-type p27, a strong p27-specific response was 
stimulated by both PTD conjugate vaccines (p<0.01 compared with empty vector vaccine) 
(Figure 10 A).  No significant difference in immune stimulation between wild-type and PTD-
conjugated vaccine strains was observed.  In addition, the percentage of p27 epitope presentation 
via MHC class I was not improved using C. perfringens expressing either PTD conjugate 
compared to C. perfringens expressing unconjugated p27 (Figure 10 B). 
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Figure 10.  Effect of PTD-conjugation to p27 on BMDC-mediated IFN-γ stimulation 
IFN-γ ELISpot assays were performed on p27-specific splenocytes with BMDCs exposed to C. perfringens carrying 
an empty expression plasmid (empty vector) or expressing unconjugated p27 (wt-p27), PTD-5-conjugated p27 
(PTD-5-p27), or 8K-conjugated p27 (8K-p27).  A, Averages of triplicate samples are shown with error bars 
indicating standard error of the mean.  *p<0.01 via Student’s t-test against empty vector.  B, The percentage of total 
IFN-γ due to MHC class I epitope presentation as determined by ELISpot with antibodies directed against MHC 
class I or II molecules.  +p<0.05 against both wt-p27 and PTD-5-p27 via Student’s t-test. 
 
3.5.5 Immunogenicity of C. perfringens Expressing PTD-Conjugated p27 
In vivo immunogenicity of the oral C. perfringens vaccine expressing 8K-conjugated p27 
was tested in small groups of mice.  Spleen cells were assayed for p27-specific IFN-γ T cell 
immune response in via ELISpot.  As a control, other groups of mice were fed with PBS or C. 
perfringens expressing unconjugated p27.  As shown in Figure 11, conjugation of p27 to 8K did 
not improve the splenic response to p27 induced by Cp-p27.  Both C. perfringens-based vaccines 
produced splenic p27-specific responses lower than the PBS control group and over 100 times 
lower than adenovirus carrying p27, a systemically delivered vaccine well-known to stimulate 
immunity in the spleen. 
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Figure 11.  Effect of PTD conjugation to p27 on systemic immunogenicity in vivo 
p27-specific IFN-γ ELISpots from spleen cells of mice inoculated intramuscularly with adenovirus expressing p27 
(Ad-p27) or orally gavaged with PBS, C. perfringens expressing p27 (Cp-p27), or C. perfringens expressing 8K-
conjugated p27 (Cp-8K-p27).  Averages of at least 2 mice per group are shown with error bars representing standard 
error of the mean. 
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3.6 DISCUSSION 
Since the dose of antigen delivered to intestinal immune tissue and the intracellular 
processing of antigen internalized by DCs have effects on the resultant immune response to the 
antigen, engineering antigen for ideal delivery and processing is important to achieve a maximal 
immune response.  It was hypothesized that including a PTD sequence conjugated to vaccine-
delivered p27 would both increase antigen delivery into DCs and enhance DC presentation of 
p27 antigens on MHC class I.  These improvements were anticipated to prime stronger cellular 
immune responses in vivo than using p27 without PTD peptide. 
The results presented here demonstrate that, when compared with C. perfringens 
expressing unconjugated p27, conjugation of PTD to p27 in the C. perfringens vaccine enhanced 
in vitro internalization of p27 by epithelial cells and DCs without enhancing or inhibiting the 
ability to induce maturation of DCs.  DCs exposed to vaccine containing PTD-p27 conjugate 
protein stimulated similar levels of p27-specific IFN-γ as the unconjugated vaccine strain.  This 
response appeared to be mediated by both MHC class I and MHC class II in the case of the PTD-
5 conjugate but primarily by MHC class II in the case of the 8K conjugate.  A pilot study of 
immunization using the 8K conjugate strain displayed no improved splenic cellular immunity 
when compared with the wild type Cp-p27 strain. 
Despite the trend towards higher levels of DC maturation and p27-specific IFN-γ 
production in samples exposed to PTD-conjugated vaccines, further evaluation of the in vivo 
response to PTD-conjugated Cp-p27 vaccine strains is not being pursued in light of several 
important implications from the literature and critical evaluation of the data.  
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First, in vivo responses that were improved by including PTD-conjugation in other 
reported systems have only been observed when in vitro studies showed a minimum of 4-fold 
enhanced internalization into cells [345, 346]. The current study shows significantly improved 
internalization, but the increase is only 1- to 2-fold in DCs, the major APC in the gut.   
Second, the overall percentage of response mediated by MHC class I antigen presentation 
was not enhanced by PTD-5-conjugation to p27.  While MHC class I- and MHC class II-
mediated IFN-γ ELISpot assays demonstrated a slightly stronger MHC-class I-restricted 
response with the PTD-5-conjugated vaccine construct, the increase was not statistically 
significant and was less than 2-fold higher when compared with the unconjugated construct (data 
not shown).  The differences observed in these experiments are not expected to overtly alter 
biological function in vivo.  Finally, the overall IFN-γ production in these assays was not 
enhanced in PTD-conjugated vaccine-treated cells when compared with the unconjugated 
vaccine. 
Third, in vivo testing of the 8K-p27 fusion construct against the unconjugated Cp-p27 
vaccine showed very low responses to p27 in the spleen of mice.  While other experiments in the 
Gupta lab have demonstrated that mice immunized with the vaccine construct maintained low 
IFN-γ p27-specific responses in spleen but showed a robust response in the Peyer’s patches, in 
light of the previous points the lack of enhanced splenic response may simply be due to the fact 
that the PTD-conjugate is not effective enough in vivo. 
Fourth, recent literature indicates that delivery of certain PTD-conjugated proteins may 
be cytotoxic to cells, particularly when used at high concentrations [347, 348].  In in vitro 
experiments in the current study, massive killing of CaCo2 cells treated with PTD-conjugated 
vaccine constructs was observed, while cells treated with the unconjugated construct in the same 
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experiment maintained viability.  Conjugation of β-galactosidase, antimicrobial peptides, and 
NEMO (NF-κB essential modulator)-binding domain to PTD-5 and 8K have not been reported to 
cause cytotoxic effects on other cell types, including epithelial cells from cervical (HeLa cells) 
and airway (A549 and HBE144 cells) mucosal sites [288, 291, 344, 349].  Several other PTD 
peptides attached to various cargoes have been observed to be safely delivered to CaCo2 cells 
without disrupting the integrity of the cells [350-352].  Therefore, it was unexpected that PTD 
conjugation to p27 would damage CaCo2 cells.  However, Szeto et al. have demonstrated that 
related protein cargoes delivered to CaCo2 cells via identical PTD sequences differentially target 
the mitochondria [353].  In their study, protein targeted to the mitochondrial matrix induced 
mitochondrial swelling which leads to apoptosis, whereas protein targeted to the inner 
mitochondrial membrane did not cause cytotoxicity.  Targeting of cationic peptides to the 
mitochondria may be mediated by their positive charge, but the reason why certain proteins 
delivered via PTD sequences enter the mitochondrial matrix is unclear. 
Furthermore, few studies have successfully demonstrated enhanced immunity using PTD 
conjugates, and conflicting results about immune response induction via PTD-conjugated 
vaccination have been reported [354-357].  The most effective in vivo uses of PTD conjugates 
are those that aim to selectively destroy cells in the context of diseases like cancer and 
autoimmunity [349, 358, 359].  This suggests that the toxic side effects of many PTDs, including 
PTD-5 and 8K, may be best used in applications other than vaccination. 
These findings raise concern that including a PTD sequence in the Cp-p27 vaccine would 
compromise the epithelial barrier of the mucosa, thus putting a vaccinee at risk for 
complications.  Indeed, it has recently been reported that the very breakdown of the gut mucosa 
contributes to HIV pathogensis [360].  Furthermore, since the in vitro findings have not 
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demonstrated sufficiently higher internalization or p27-specific IFN-γ stimulation rates with 
PTD-conjugated p27 expressed by C. perfringens compared with wild-type Cp-p27, it is unlikely 
that a significant enhancement of immunity would be achieved through vaccination with these 
PTD-conjugated constructs.  The observed benefits of slightly enhanced antigen internalization 
and maintenance of processing through the MHC class I pathway with the use of PTD 
conjugation to p27 in the C. perfringens vaccine are far outweighed by the harmful effects likely 
to be exerted upon gut epithelial cells upon oral inoculation.  Thus, further use of PTD-
conjugated C. perfringens expressing SIV p27 as an oral vaccine is not warranted. 
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4.0  MUCOSAL ADJUVANT OPTIMIZATION FOR USE WITH CP-P27 
4.1 PREFACE 
The study described in this chapter was performed in Dr. Phalguni Gupta’s laboratory.  
Ruth Helmus and Poonam Poonam conducted the first two animal experiments together with the 
assistance of Lori Caruso and Dr. Yue Chen in vaccine administration and sample collection and 
processing.  The final three experiments were conducted by Ruth Helmus with technical 
assistance by Poonam Poonam, Lori Caruso, Dr. Yue Chen, and Dr. Cheng-Li Shen.  Flow 
cytometry was performed with the assistance of Luann Borowski, Kim Stojka, and Edwin 
Molina from the laboratory of Dr. Charles R. Rinaldo, Jr.  LT(R192G) was graciously provided 
by Dr. John D. Clemens, and Dr. Ted M. Ross provided guidance for CpG ODN sequence 
selection.  Statistical advising was provided by Dr. Patrick Tarwater, and Dr. Marsha P. Cole 
provided instruction and the use of GraphPad.  Animals were cared for by the University of 
Pittsburgh Division of Laboratory Animal Resources.  Portions of this work were presented as a 
poster abstract at the 2007 Keystone Symposia on HIV Vaccines (Optimization of anti-SIV gut 
mucosal vaccine response using Clostridium perfringens, adenovirus, and synergistic mucosal 
adjuvants.  R. Helmus, P. Poonam, L. Caruso, Y. Chen, and P. Gupta.) 
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4.2 ABSTRACT 
The use of mucosal adjuvants can improve immunogenicity of a mucosally-delivered 
vaccine as well as direct immunity towards a Th1/cellular response or Th2/humoral response.  
Cp-p27 is a Clostridium perfringens-based vaccine designed to deliver intact simian 
immunodeficiency virus (SIV) p27 to the inductive immune tissue of the gut.  In this study, the 
three mucosal adjuvants (cholera toxin (CT), mutant E. coli heat-labile enterotoxin 
(LT(R192G)), and unmethylated cytosine-phosphate-guanine oligodinucleotides (CpG ODNs)) 
were evaluated for use with orally delivered Cp-p27 in mice to optimize gut cellular immunity.  
At optimal doses, all adjuvants improved IFN-γ ELISpot responses in small intestine Peyer’s 
patches (PPs) as compared to unadjuvanted Cp-p27.  The use of LT(R192G) or CpG ODNs 
generated better responses than CT.  A combination of LT(R192G) and CpG ODNs provided 
higher immunity than either used alone in both PPs and the lamina propria gut effector tissue.  
However, the functionality of CD8+ T cells was better when 25μg LT(R192G) was utilized 
alone.  Overall, the use of 25μg LT(R192G) provided the best quality of cellular immunity 
without significantly compromising the strength of immunity. 
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4.3 INTRODUCTION 
Two of the largest challenges in generating an effective vaccine against human 
immunodeficiency virus (HIV) are the development of mucosal immunity and inducing effective 
CD8+ and CD4+ T cell responses.  Since HIV is largely transmitted via mucosal tissue and 
immune tissue in the gut is a primary viral target in early infection and remains a reservoir in 
chronic infection [39, 64, 74, 75, 78, 79, 312-314], induction of mucosal immunity is important 
for effective prevention of HIV infection and propagation.  Stopping infection at the mucosa may 
ablate infection or lower the severity of resulting infection; indeed, once virus has established 
infection outside of mucosal tissue, it cannot be eliminated from the host [36].  Using the 
monkey model of mucosal exposure to simian immunodeficiency virus (SIV), Murphey-Corb et 
al. observed that monkeys who were SIV-negative following viral challenge displayed SIV-
specific CD8+ T cells in the small intestine [79].  Additional studies have shown that the 
presence of vaccine-induced SIV-specific gut CD8+ T cells can slow the appearance of SIV in 
the blood [120, 121].  This demonstrates the capacity for gut mucosal immunity to slow the 
establishment of productive SIV infection.  In addition, stimulation of immunity at one mucosal 
site can impart immunity in distal mucosal tissues [249-251].  Therefore, further improvements 
to vaccine strategies that induce gut immunity against SIV may be able to prevent persistent SIV 
infection. 
Since mucosal tissue possesses a natural propensity for immune tolerance via the 
generation of Th3 or T-regulatory cells [252], an effective mucosal vaccine must overcome this 
tolerance to induce a Th1 response that includes CD8+ T cells that produce multiple antiviral 
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cytokines and display cytotoxic capacity [40, 42, 136, 138-140].  An effective immune response 
would also include multifunctional CD4+ T cells that concurrently express interleukin-2 (IL-2), 
tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ) [136, 137, 142, 212].  These 
types of CD8+ and CD4+ T cell responses have been associated with viral control following 
infection [40, 42, 136-141]. 
In mucosal tissue, an immune response is generated only under inflammatory conditions, 
such as those generated by pathogenic organisms that damage cells of the gut wall.  Adjuvants 
are molecules which exert inflammatory effects by mimicking the presence of pathogenic 
threats.  When used in mucosal vaccination, adjuvants can both overcome tolerance and direct 
the immune response towards either Th1 or Th2.  The strength and type of immune response 
generated in response to mucosal vaccines is determined by the form and amount of adjuvant 
delivered with the vaccine antigen.  To date, few adjuvants have effectively displayed safety in 
humans while retaining adjuvanticity 
One classical mucosal adjuvant is cholera toxin (CT), which is derived from Vibrio 
cholerae and helps drive Th2 and possibly Th1 responses [265, 361].  This adjuvant is very adept 
at overcoming mucosal tolerance, leading to the generation of antigen-specific antibodies against 
numerous proteins when delivered orally.  Whole CT causes diarrhea in humans, but safe 
mutants are being developed [263, 265, 362-364].  LT(R192G), an inactive, nontoxic mutant of 
the Escherichia coli heat labile toxin, stimulates Th1 and Th2 responses when delivered orally 
with protein [365].  This adjuvant has been found to be safe for use in humans while still 
retaining adjuvant activity [263, 366]. Cytosine-phosphate-guanine oligodinucleotides (CpG 
ODNs) are synthetic oligonucleotides containing unmethylated CpG motifs reminiscent of 
bacterial DNA; they are recognized by toll-like receptor 9, and ensuing signal transduction leads 
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to Th1 responses [278, 367].  Whereas CT and LT(R192G) likely stimulate the immune system 
through downstream effects of cAMP, CpG ODNs trigger immune responses by activating signal 
transduction through Ras and MyD88 pathways.  Many studies have demonstrated that 
combining CpG ODNs with one of the bacterially-derived adjuvants can enhance resulting 
immune responses by stimulating immunity through both pathways [368-371]. 
Clostridium perfringens expressing SIV p27 (Cp-p27) can effectively deliver p27 to gut 
mucosal immune tissue when delivered orally.  Inclusion of adjuvants in the Cp-p27 vaccine 
formulation is expected to enhance the immune response induced following inoculation.  
Therefore, it is important to determine the optimal dose of mucosal adjuvants for use with the 
Cp-p27 vaccine.  It is hypothesized that combinations of optimal doses of strong mucosal 
adjuvants delivered with Cp-p27 would improve the strength of cellular immunity as determined 
by IFN-γ production via ELISpot and the quality of immune response by monitoring intracellular 
cytokine production and cytotoxicity via flow cytometric analysis. 
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4.4 MATERIALS AND METHODS 
Animals 
Female Balb/c mice were purchased from Charles Rivers Laboratories, Inc. and housed in 
a pathogen-free facility in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee and federal regulations.  Animals were used at 6 to 8 weeks of age. 
 
Clostridium perfringens vaccine strain Cp-p27 
Construction of the Clostridium perfringens vaccine expressing SIV p27 (Cp-p27) has 
been described previously [306].  Culture and isolation of sporulated Cp-p27 was performed as 
described in Chapter 2.  Isolated sporulating bacteria were sonicated, and the concentration of 
p27 was enumerated by desitometry of quantitative Western blots.  Vaccine was then stored at -
140°C until use. 
 
Oral adjuvants 
Whole, active cholera toxin was purchased from Sigma and stored at 4°C until use. 
HPLC-purified S-thiolated CpG oligodinucleotides (ODN) were purchased from Sigma-Genosys 
and stored at -20°C until use.  CpG ODN sequences were:  CpG-
A=TCCATGACGTTCCTGACGTT; CpG-B=TGACTGTGAACGTTCGAGATGA [372, 373]. 
The isolation of LT(R192G) has been described previously [258].  LT(R192G) was provided by 
Dr. John D. Clements and was reconstituted to 1mg/mL in sterile water and stored at 4°C until 
use.   
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Vaccination 
Animals were inoculated via gavage using an infant enteral feeding tube inserted down 
the esophagus into the stomach, where a total volume of 500μL containing Cp-p27 ± adjuvant(s) 
was delivered.  Each Cp-p27 dose contained approximately 250μg p27 as determined by 
quantitative Western blot.  Three inoculations per trial were conducted, with inoculations at 2 
week intervals. 
 
Serum sample collection and processing 
Pre-immune serum samples were acquired through venopuncture of the lateral saphenous 
vein, and blood was collected into heparinized capillary tubes.  At sacrifice, blood samples were 
collected via heart puncture, and blood was allowed to coagulate on ice for several hours before 
separation.  For all samples, serum was separated from blood by centrifugation at room 
temperature at 750xg for 20 minutes.  Serum samples were stored at -70°C. 
 
Fecal sample collection and processing 
Four to seven days before sacrifice, fecal matter was collected from each mouse and 
processed on ice.  Approximately 50-150mg of fecal material was obtained from each mouse.  
Samples were weighed and fully resuspended in Complete Mini protease inhibitor cocktail (1 
tablet/mL PBS containing 0.1% sodium azide; Roche) by adding 1mL per 100 or 200mg of fecal 
matter.  Resuspended samples were vortexed and then centrifuged at 13000rpm for 10 minutes in 
a tabletop centrifuge.  Supernatant was assayed immediately. 
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Tissue collection and cell isolation 
Mice were sacrificed about 10 to 15 days after the final inoculation.  The small intestine 
was aseptically removed and processed.  Before cell isolation, the intestine was rinsed with 1mL 
sterile PBS.  This intestinal wash was pelleted to remove solid matter using a tabletop centrifuge 
at 13000 rpm for 10 minutes, and the supernatant was stored at -70°C. 
Dissection of intestinal tissue was performed on ice, and when tissues and cells were not 
being treated enzymatically, they were kept on ice.  Fatty tissue was removed from small 
intestine tissue, and the lumen was thoroughly flushed with PBS.  Peyer’s patches (PPs) were 
carefully removed with fine scissors and then washed with agitation at 37°C for 20 minutes in 
30mL pre-warmed EDTA-DTE solution (PBS containing 10% bovine growth serum (HyClone), 
1mM EDTA, and 1mM dithioerythritol) in a 50mL conical tube placed lengthwise on an orbital 
shaker.  PPs were next rinsed repeatedly with Hank’s buffered saline solution and incubated at 
37°C in 6-well plate wells in 5mL pre-warmed collagenase solution (RPMI 1640 containing 10% 
fetal calf serum and 1mg/mL collagenase D (Roche)) without agitation.  PP tissues were then 
gently crushed, and released cells were passed through nylon mesh, pelleted for 5 minutes with 
centrifugation at 4°C at 1200 rpm, and washed. 
To isolate lamina propria (LP) cells, following PPs removal the remaining intestinal 
tissue was cut open longitudinally and cut into 0.5-1cm pieces, working on ice.  Pieces were 
placed in pre-warmed EDTA-DTE solution in a 125mL Erlenmeyer flask and stirred at 37°C for 
30 minutes.  The medium was poured off, and pieces were vortexed in fresh warm EDTA-DTE 
solution four times at room temperature to remove residual epithelial cells.  Pieces were then 
placed in fresh warm EDTA-DTE solution in the flask and stirred at 37°C for an additional 15 
minutes.  Typically the medium was clear after this step.  However, if medium was cloudy after 
 84 
this step, the vortexing step was repeated and tissue was again placed in fresh warm EDTA-DTE 
solution and stirred at 37°C for an additional 15 minutes.  This was repeated until medium was 
clear after the 15 minutes of stirring.  Tissue pieces were then rinsed repeatedly with RPMI 
containing 2% bovine growth serum to remove EDTA.  Pieces were then stirred at 37°C in 
prewarmed collagenase solution in the flask for 30 minutes, after which time samples were 
observed for cloudiness in the medium, indicating LP cell release.  If medium was not cloudy, 
sample was returned to 37°C for an additional 15 minutes of stirring.  If medium was cloudy, 
collagenase-treated tissue pieces were gently crushed, and released cells were passed through 
nylon mesh, pelleted with centrifugation at 4°C at 1200rpm for 5 minutes, and kept on ice in 
serum-containing medium.  Remaining tissue pieces were returned to fresh collagenase solution 
for additional treatment, repeating the stirring at 37°C and cell isolation steps just described.  
When all tissue was digested (typically after a total of 2 or 3 collagenase treatments), cells were 
washed, the cell pellet was resuspended in 12mL ice-cold 40% isotonic Percoll in 1xPBS, and 
the cell suspension was distributed equally into 3 15mL conical tubes (i.e. 4mL per tube).  Each 
4mL cell suspension was then underlayed with 2mL ice-cold isotonic Percoll (9 parts Percoll to 1 
part 10x HBSS (v/v)).  Tubes were then centrifuged at 1700rpm with no brake at 4°C for 20 
minutes.  The resulting interface was harvested and diluted ≥10-times into fresh RPMI 
containing serum, and these LP lymphocytes were pelleted for 10 minutes with centrifugation at 
4°C at 1500 rpm. 
 
IFN-γ ELISpot 
Detection of interferon-gamma (IFN-γ) from freshly isolated cells was performed using 
mouse IFN-γ ELISpot Kits from Mabtech activated and blocked as described in Chapter 2.  PPs 
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cells were plated with 2x105 cells per well in a volume of 200μL ELISpot media (RPMI-1640 
with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 0.1mM non-essential amino acids, 
2mM L-glutamine, 10mM HEPES, and 1mM sodium pyruvate) in ELISpot plates.  Because of 
lower yields, LP cells were generally plated at 5x104 or 1x105 cells per well in 200μL.  Samples 
were stimulated with two separate pools of SIVmac 239 gag 15-mer peptides overlapping by 11 
amino acids (NIH AIDS Research and Reference Reagent Program) covering the majority of 
SIV p27 with peptides 5265 through 5298 of SIV gag with each peptide at a concentration of 
5μg/mL.  Each sample also contained a background control where a concentration of DMSO 
equivalent to that in the peptide pools was added to the well.  As a positive control, each sample 
was also stimulated with 1mg/mL concanavalin A.  All treatments for all samples were plated in 
triplicate, except when low LP yields made this impossible, in which case at least two wells per 
treatment per sample were plated.  Cells were incubated at 37°C for 24h.  Detection of IFN-γ 
spot-forming cells (sfc) was performed as described in Chapter 2.  When dry, sfc on plates were 
counted on an automated ELISpot reader.  Background sfc values from background control wells 
were removed as appropriate, and sfc were normalized to 106 cells. 
 
SIV p27-specific ELISA 
EIA/RIA Plates were coated overnight at room temperature with recombinant SIV p27 
isolated from E. coli.  After blocking plates, serial dilutions of serum or undiluted samples of 
fecal extracts or intestinal washes were placed in wells and incubated at room temperature for 2h 
(serum) or at 4°C overnight (fecal extracts and intestinal washes).  Plates were washed, and 
AKP-conjugated α-mouse IgG1 or IgG2a antibody or biotin-conjugated α-mouse IgA (BD 
Biosciences) was incubated in appropriate wells for 1h at room temperature.  For IgA detection, 
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plates were washed and a secondary AKP-conjugated streptavidin (Sigma) was then incubated in 
appropriate wells for 30 minutes at room temperature.  Finally, 4-nitrophenyl phosphate 
disodium salt hexahydrate (Sigma) was used to detect p27-specific antibody, and optical density 
was read on a plate reader at 405nm.  Background values from negative control wells on each 
plate were subtracted. 
 
Surface, intracellular cytokine, and CD107a staining 
FITC-α-CD107a (clone 1D4B), R-PE-α-CD8 (53-6.7), APC-α-IL-2 (JES6-5H4), PE-
Cy7-α-IFN-γ (XMG1.2), Biotin-α-TNF-α (MP6-XT3), and APC-Cy7-streptavidin were 
purchased from BD Pharmingen.  PE-Cy5-α-CD3 (clone 145-2C11) was purchased from 
BioLegend.  Isotype control antibodies were purchased from the same manufacturers according 
to the fluorescent conjugate used. 
Freshly isolated cells (maximum 106 cells) were cultured for 5 hours at 37°C in 96-well 
plates in 200μL growth media (DMEM with 10% fetal calf serum,  1mM sodium pyruvate, 2mM 
L-glutamine, 0.025M 2-mercaptoethanol, and 1.25mM HEPES) containing 5μg/mL α-CD107a 
antibody, 3μM monensin, 5μg/mL brefeldin A, and 5μg/mL peptides spanning the entire p27 
protein.  As a background control, one well of cells of each sample was cultured without peptide.  
As a positive control, samples were cultured with 50ng/mL phorbol myristate acetate and 
1μg/mL ionomycin instead of peptide. 
After the culture period, plates were cooled to 4°C overnight.  Cells were surface stained 
for CD3 and CD8, washed with FACS buffer (PBS with 0.1% bovine serum albumin and 0.1% 
sodium azide), fixed in 4% paraformaldehyde, and permeabilized with FACS buffer containing 
0.2% saponin.  Following permeabilization, cells were intracellularly stained for IL-2, IFN-γ, 
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and TNF-α, washed, fixed, and stored in the dark at 4°C in FACS buffer.  All samples were fully 
analyzed by flow cytometry within 12 hours of staining. 
 
Flow cytometry and analysis 
Stained cells were analyzed using a BD Canto flow cytometer.  FCS files were analyzed 
using FlowJo version 7.2.2 (Tree Star, Inc.).  Cells in the lymphocyte gate were gated on 
CD3+CD8+ or CD3+CD8- cells, and gates for individual cytokines and CD107a were established 
with control cells stained only for CD3 and CD8.  Cells in the cytokine and CD107a gates were 
analyzed with Boolean gating to generate the percentage of cells expressing each combination of 
functional markers.  Background expression values were subtracted from peptide-stimulated 
values for each sample.  Graphical representation of functionality was achieved using SPICE 
software kindly provided by Dr. Mario Roederer of the NIH VRC.  For SPICE analysis, 
individuals with no p27-specific response were excluded.  A threshold value of the 75% 
confidence values of negative percentages for each T cell subset was used. 
 
Statistics 
Statistical analyses were performed using GraphPad Prism version 4.  Unless otherwise 
noted, values of p were determined assuming a nonparametric distribution and employing a 
Kruskal-Wallis test followed by the Dunn procedure to compare groups.  Antibody titer values 
were first transformed to log10 before analysis.  Results were considered significant if p<0.05. 
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4.5 RESULTS 
4.5.1 Single Adjuvant Screening 
Since adjuvants have been observed to stimulate immunity differently depending upon 
the vaccine with which they are delivered, the optimal adjuvant(s) and their doses needed to be 
established for their use with the Cp-p27 vaccine.  To screen a variety of adjuvants at different 
doses for their ability to aid in priming gut cellular immunity, small groups of mice (3 per group) 
were orally inoculated with equivalent doses of Cp-p27 and varying doses of cholera toxin (CT), 
mutant heat-labile toxin (LT(R192G)), or unmethylated cytosine-phosphate-guanine 
oligodinucleotides (CpG ODN).  Control groups consisted of mice vaccinated orally with Cp-
p27 without adjuvants or with PBS.  Cells from small intestinal PPs were assayed for p27-
specific IFN-γ production using an ELISpot assay.  As shown in Figure 12, the highest immune 
responses were observed in groups of mice that received 5μg CT, 1μg LT(R192G), or 50μg of 
each CpG ODN.  In contrast, the mice that received 1, 5, or 10μg CpG ODNs or 10 or 50μg CT 
did not induce any significant cellular responses compared to the PBS-only or Cp-p27-only 
control groups.  LT(R192G) at 1, 5, 25, or 50μg produced cellular responses higher than the 
control groups, although this was not statistically significant.  Serum (IgG1 and IgG2a) and fecal 
extract and intestinal wash IgA levels were low in all groups, with no difference observed 
between vaccinated mice and the PBS control group (data not shown). 
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Figure 12.  Adjuvant effects on p27-specific IFN-γ immune induction in Peyer’s patches via oral Cp-p27 
vaccination 
Mice were immunized orally with Cp-p27 and various doses of adjuvants.  Control animals received PBS or Cp-p27 
without adjuvant.  p27-specific IFN-γ ELISpot results from small intestinal PPs are shown.  Results from individuals 
animals are represented by diamonds (control), triangles (CpG ODNs), circles (LT(R192G)), or squares (CT), and 
horizontal bars indicate the average response for each group. 
 
4.5.2 Adjuvant Combinations 
Since both CpG ODN and LT(R192G) primed greater cellular responses than CT when 
used with Cp-p27, efforts were concentrated on further study on CpG ODNs and LT(R192G) as 
adjuvants with Cp-p27.  CpG ODNs and LT(R192G) in combination have been shown to 
stimulate stronger cellular immunity than when used alone [280, 368, 369].   In some of these 
studies, lower doses of adjuvants in combination were found to produce stronger cellular 
immune responses than higher doses of either adjuvant alone.  In other studies, higher doses of 
one or both adjuvants were required in combination to induce strong immune responses.  Thus, 
an experiment was initiated to determine the optimal dose of CpG ODNs for use with 1μg 
LT(R192G) to induce a cellular immune response following Cp-p27 vaccination. 
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Groups of mice were inoculated orally with Cp-p27 with various combinations of doses 
CpG ODNs with 1μg LT(R192G), and their cellular immune responses were compared with 
groups of mice that received each adjuvant dose alone or Cp-p27 alone.  IFN-γ ELISpot assays 
of cells from PPs showed that 25μg CpG ODN provided better average cellular responses than 
50 or 100μg CpG ODN (Figure 13).  However, 50μg CpG ODN combined with LT(R192G) 
generated a better but statistically insignificant response than 25 or 100μg CpG ODN combined 
with LT(R192G).  The highest response was in the group that received 1μg LT(R192G) and 
50μg CpG ODNs.  This was the only group that displayed a significantly higher cellular response 
compared with the group that received Cp-p27 without adjuvants.  SIV p27-specific serum (IgG1 
and IgG2a) and gut mucosal (IgA) antibody levels were also assessed, but antibody levels were 
low and no differences were observed between any of the groups (data not shown). 
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Figure 13.  Effects of combinations of LT(R192G) and CpG ODNs on p27-specific cellular immunity to Cp-
p27 in Peyer’s patches 
Mice were immunized orally with Cp-p27 with varying doses of CpG ODNs and/or 1μg LT(R192G) adjuvants.  
Control animals received Cp-p27 without adjuvant.  Average p27-specific IFN-γ ELISpot results from small 
intestinal PPs of 4 mice per group are shown with error bars representing standard error of the mean. 
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4.5.3 Optimal LT(R192G) Dose 
One unexpected result from the single adjuvant screening experiment was that the lowest 
dose of LT(R192G) produced stronger average responses than higher doses.  LT(R192G) has 
been extensively characterized and is recommended to be used at 25μg per dose (J. D. Clements, 
personal communication).  The single adjuvant screening experiment trial described currently 
(Figure 12) used a small number of mice in each group, and there was much variability within 
each group.  For example, in the 1μg LT(R192G) group, one mouse displayed a cellular response 
7-times that of the other two mice.  To more clearly define which dose was optimal for use with 
Cp-p27, larger groups of mice (10 per group) were vaccinated with either 1μg or 25μg 
LT(R192G) and equivalent doses of Cp-p27.  This experiment also included an assessment of 
both PPs and intestinal lamina propria (LP) cellular responses.  As the effector tissue of the gut 
associated lymphoid tissue, the LP is the site where cells primed in the PPs and other inductive 
sites migrate and exert their effects.  The response in the LP thus provides a more accurate 
representation of the level p27-specific cells that can act against an infection.  After vaccination 
with Cp-p27, more cellular response was detected in the 25μg dose group than the 1μg group in 
both PPs and LP (Figure 14).  This neared significance in PPs (p=0.0716 via Mann Whitney test) 
(Figure 14 A).  As in the previous experiment, p27-specific serum IgG1 and IgG2a and intestinal 
wash IgA levels were very low in all groups and no differences were observed between groups 
(data not shown). 
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Figure 14.  Optimal dose of LT(R192G) with Cp-p27 inducing p27-specific responses in gut inductive and 
effector tissues 
Mice were immunized orally with Cp-p27 and 1μg or 25μg LT(R192G).  Average p27-specific IFN-γ ELISpot 
results from small intestinal PPs of 10 animals (A) and lamina propria of 6 animals (B) are shown with error bars 
representing standard error of the mean.  Value of p determined by the 1-tailed Mann Whitney test. 
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4.5.4 Inductive and Effector Responses of Optimal Adjuvant Combinations 
An experiment was next conducted to confirm the enhanced response resulting from the 
use of both LT(R192G) and CpG ODNs using the 25μg dose of LT(R192G).  The combination 
of 25μg LT(R192G) and CpG ODNs did not show a significantly higher level of IFN-γ ELISpot 
response in PPs than either adjuvant alone (Figure 15 A).  In the LP, the average p27-specific 
IFN-γ ELISpot response was higher, although not significantly, in the LT(R192G) group than in 
the CpG ODN group, and the group that received both adjuvants displayed the strongest 
response (Figure 15 B). 
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Figure 15.  Effects of LT(R192G) and CpG ODNs on p27-specific cellular immunity to Cp-p27 in gut 
inductive and effector tissues 
Mice were immunized orally with Cp-p27 with CpG ODNs and/or 25μg LT(R192G) adjuvants.  Average p27-
specific IFN-γ ELISpot results from small intestinal PPs of 10 animals (A) and lamina propria of 6 animals (B) are 
shown with error bars representing standard error of the mean. 
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A final vaccination trial was conducted to confirm these results and to determine the 
quality of the cellular response induced by each vaccine/adjuvant combination.  The ability for 
CD4+ and CD8+ T cells to produce interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) in 
addition to IFN-γ has been associated with better ability of these T cells to combat viral 
infections [40, 42, 136, 138-140].  The production of these cytokines was examined through 
intracellular staining followed by single-cell analysis in a flow cytometer.  Therefore, PPs and 
LP cells from vaccinated mice were assayed with cell staining and flow cytometry in addition to 
IFN-γ ELISpot. 
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Figure 16.  Effects of adjuvant type and dose on p27-specific cellular immunity to Cp-p27 in gut inductive and 
effector tissues 
Mice were immunized orally with Cp-p27 with 1μg or 25μg LT(R192G) with our without CpG ODNs.  Control 
animals received Cp-p27 without adjuvant.  Average p27-specific IFN-γ ELISpot results from small intestinal PPs 
of 10 animals (A) and lamina propria of 6 animals (B) are shown with error bars representing standard error of the 
mean. 
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Like the data shown in Figure 15, the 25μg dose of LT(R192G) generated more p27-
specific IFN-γ ELISpot response than the 1μg dose in both PPs and LP (Figure 16).  The 
combination of CpG ODNs and 1μg LT(R192G) produced a greater average level of response in 
PPs than the LT(R192G) alone (Figure 16 A).  The same result held true in the LP with the 25μg 
LT(R192G) dose (Figure 16 B).  However, in PPs, CpG ODNs delivered with 25μg LT(R192G) 
resulted in a somewhat lower level of response than with just the LT(R192G) alone (Figure 16 
A). 
4.5.5 T Cell-Mediated Cytotoxicity Induced by Vaccination 
As determined by CD107a surface staining, in CD8+ T cells there was a trend towards 
recipients of LT(R192G) to have a larger percentage of cells displaying p27-specific cytotoxicity 
as compared with recipients of both LT(R192G) and CpG ODNs (Figure 17), though these 
differences were not statistically significant.  Both PPs and LP CD8+ T cells from the 25μg 
LT(R192G) group contained a much higher percentage of p27-specific CD107a-positive cells 
than all other vaccine groups (Figure 17). 
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Figure 17.  p27-specific degranulation in gut mucosal CD8+ T cells following immunization with Cp-p27 and 
combinations of adjuvants 
Cells from small intestinal Peyer’s patches (A) and lamina propria (B) were surface stained for CD3 and CD8.  SIV 
p27-specific surface expression of CD107a was detected on CD8+CD3+ cells via via flow cytometry.  Bars represent 
the average values from 5-10 animals per group plus standard error of the mean.  Light grey bars, no adjuvant; black 
bars, 1μg LT(R192G); black striped bars, 1μg LT(R192G) + CpG ODNs; dark grey bars, 25μg LT(R192G); dark 
grey striped bars, 25μg LT(R192G) + CpG ODNs. 
 
4.5.6 Multi-Cytokine Analysis:  Strength and Quality of Immune Responses 
The percentages of CD3+CD8+ and CD3+CD8- cells displaying any p27-specific cytokine 
response (IL-2, TNF-α and/or IFN-γ) were determined to evaluate the quality of response in each 
T cell subset.  The percentage of cells displaying response to any cytokine was calculated.  As 
the dose and number of adjuvants administered with Cp-p27 was increased, the response to any 
cytokine in LP CD8- T cells decreased (Figure 18).  This was also the case in PPs CD8- T cells, 
with the exception that mice immunized using 25μg LT(R192G) and CpG ODNs displayed the 
best response (Figure 18).  In PPs CD8+ T cells, little difference in p27-specific cytokine 
responsiveness was observed between animals who received only LT(R192G) at either dose 
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(Figure 18).  Use of CpG ODNs with either dose of LT(R192G) improved PPs CD8+ T cell 
responsiveness, with recipients of 25μg LT(R192G) and CpG ODNs showing the largest 
percentage of p27-specific cells of all groups (Figure 18).  CD8+ T cells in the LP demonstrated 
greater percentages of p27-specific cytokine responsiveness when mice received 25μg 
LT(R192G) than 1μg or no adjuvant, and use of CpG ODN with LT(R192G) improved cytokine 
responsiveness (Figure 18).  The highest CD8+ T cell response in the LP was observed in the 
group that received 25μg LT(R192G) and 50μg CpG ODNs (Figure 18). 
Percentages of p27-specific cells producing each cytokine varied depending on the dose 
and type of adjuvants administered.  Compared with the no adjuvant control group, CD8- T cells 
from PPs displayed a significantly lower percentage of IFN-γ in mice immunized using 1μg 
LT(R192G), while immunization using 25μg LT(R192G) and CpG ODNs generated a 
significantly higher IFN-γ response, and a similar but statistically insignificant trend was also 
observed in PPs CD8+ T cells (Figure 18).  With either LT(R192G) dose, addition of CpG ODN 
slightly improved IFN-γ response in PPs CD8- T cells, whereas the opposite was true in LP CD8- 
T cells and very little difference was observed in LP CD8+ T cells (Figure 18). 
TNF-α levels were somewhat lower in both T cell subsets in PPs and LP in recipients of 
adjuvant than in mice who only received Cp-p27 (Figure 18).  Use of CpG ODN with 
LT(R192G) improved the percentage of p27-specific TNF-α-producing cells compared with 
LT(R192G) only, although not significantly (Figure 18).  In all cells from both tissues, IL-2-
responsiveness was lower in adjuvant recipients than Cp-p27 only recipients, although slight 
improvements were observed in mice who received 25μg LT(R192G) in some cases (Figure 18).  
The combination of CpG ODN with LT(R192G) produced insignificantly lower percentages of 
IL-2 responsive cells in most cases (Figure 18). 
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Figure 18.  T cell p27-specific cytokine responsiveness in gut mucosal tissues following immunization with Cp-
p27 and combinations of adjuvants 
Cells from small intestinal Peyer’s patches (left) and lamina propria (right) were surface stained for CD3 and CD8.  
SIV p27-specific IL-2, TNF-α, and IFN-γ production from CD8- (A) and CD8+ (B) and CD3+ cells was detected via 
intracellular staining and analysis via flow cytometry.  Percentage of cells with any cytokine response was then 
determined (“any”).  Bars represent the average values from 5-10 animals per group plus standard error of the mean.  
Light grey bars, no adjuvant; black bars, 1μg LT(R192G); black striped bars, 1μg LT(R192G) + CpG ODNs; dark 
grey bars, 25μg LT(R192G); dark grey striped bars, 25μg LT(R192G) + CpG ODNs.  For “any” CD8- Peyer’s 
patches cells, p=0.0597 via the Kruskal-Wallis test.  *p<0.05 compared with 1μg LT(R192G) group. 
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The responses of each group were further evaluated for the percentage of cytokine 
response due to T cells with more than one function, as well as the level of multifunctionality 
(e.g. 2 or 3 functions), referred to as complexity.  Overall, the percentage and complexity of 
multifunctionality in both CD8+ and CD8- T cell subsets in PPs were not significantly affected 
by use of adjuvants with Cp-p27 inoculation.  In the LP, any addition of adjuvant increased the 
percentage and/or complexity of multifunctionality compared with Cp-p27 inoculation (Figure 
19).  The exceptions to these trends occurred in the CD8- subset in the 1μg LT(R192G) group, 
which demonstrated percentages of multifunctional cells that were much higher in PPs and lower 
in LP compared with the Cp-p27-only group (Figure 19).  The percentage of IL-2+TNF-α+ CD8- 
p27-specific PPs T cells in the 1μg LT(R192G) group was significantly higher than in the Cp-
p27-only group (Figure 19).  Although not significant, a similar trend was observed in the LP of 
mice who received 25μg LT(R192G), which displayed higher percentages of CD8- p27-specific 
response due to IL-2+TNF-α+ than mice who only received Cp-p27 (Figure 19).  Recipients of 
25μg LT(R192G) without CpG ODNs were the only group to display IL-2+TNF-α+IFN-γ+ cells 
as part of their LP CD8+ T cell response (Figure 19). 
Immune response comparison between tissues within vaccine groups is also of interest.  
Inoculation with Cp-p27 generated responses that were slightly more multifunctional and 
complex in PPs than LP in both T cell subsets (Figure 19).  In contrast, immunization using 25μg 
LT(R192G) with or without CpG ODNs stimulated higher percentages and complexity of 
multifunctionality in LP as compared to PPs in both T cell subsets (Figure 19). 
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Figure 19.  Multifunctional gut T cell cytokine responses in inductive and effector tissues resulting from 
vaccination 
Data generated from Boolean-gated CD8- and CD8+ CD3+ cells stained for IL-2, TNF-α, and IFN-γ were analyzed 
for concurrent functionality using SPICE software.  A, The average percentage of total response by Peyer’s patch 
and lamina propria cells at each level of multifunctionality is represented by slices in pie charts.  B, Bars 
representing average percent of total CD8- or CD8+ p27-specific CD3+ cell response in each tissue.  *p<0.05 per 
Wilcoxen signed-rank test compared with the no adjuvant group. 
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4.6 DISCUSSION 
Mucosal vaccination typically requires the use of adjuvant to overcome tolerance and 
drive the induction of an appropriate immune response.  Although Cp-p27 appears to possess 
inherent immunostimulatory capacity, likely due to the presence of its own unmethylated CpG 
DNA moieties and peptidoglycan, the coadministration of mucosal adjuvant with the bacteria 
was expected to alter the type of immunity induced by oral vaccination.  Given the varying 
capacities of CT, LT(R192G), and CpG ODNs to drive the induction of CD8+ and CD4+ T cell 
responses, it was expected that including one or more of these adjuvants in the Cp-p27 vaccine 
milieu would affect the resultant immunity.  Both 1μg and 25μg LT(R192G) was found to 
stimulate gut cellular responses in PPs and LP when delivered with Cp-p27.  Although inclusion 
of CpG ODNs with LT(R192G) improved the strength of the response, the resultant cells 
displayed poorer quality of responses.  The optimal adjuvant regimen to deliver with Cp-p27 to 
generate a strong, quality T cell response in gut effector tissue appears to be 25μg LT(R192G). 
CT and LT and their mutants are related bacterial proteins that share many 
characteristics.  However, their adjuvant capacities are not identical.  Mucosal delivery of CT 
consistently results in the production of Th2-type cells in mouse models, particularly when 
delivered orally [262, 263].  On the other hand, LT generally induces the production of Th1-type 
cells in addition to Th2-type cells [263, 264].  These differences have been suggested to be due 
to the induction of 5-hydroxytryptamine by CT but not LT [263].  Other studies have 
demonstrated further mechanisms such as preferential induction of apoptosis in different T cells 
subsets by CT or LT [374-376].  Undoubtedly the reasons for different adjuvant characteristics 
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between CT and LT are complex and remain to be fully explained.  The current study supports 
the concept that LT more potently stimulates cellular immunity (generally associated with Th1 
responses), since mice who received LT demonstrated better antigen-specific IFN-γ responses 
than those who received CT. 
Several mechanisms have been suggested for the adjuvant activity associated with orally 
administered CT and LT [263].  These include perturbation of the gut epithelial leading to 
increased permeabilization and therefore access of antigen to underlying cells; improved antigen 
presentation by cells such as dendritic cells (DCs); and altering B and T cell proliferation and 
immune maturation.  The A subunit of both toxin proteins naturally possesses ADP-ribosylating 
activity, leading to an increase in cAMP after the B subunit of the toxin binds GM1-ganglioside 
on the host cell membrane and the toxin gains entry into the cytosol.  The toxins prevent GTP 
hydrolysis by the α subunit of the GTP-binding protein family, thereby irreversibly activating 
adenylate cyclase and leading to watery diarrhea by activation of protein kinase A and the 
opening of membrane chloride channels.  Other downstream effects of cAMP include activation 
of Raf/Ras and PI3-kinase, which may collectively result in the activation of transcription factors 
that can help promote T cell growth, including NF-κB [263, 377]. 
Uncoupling of the ADP-ribosylating activity from immunostimulatory activity has been 
demonstrated by mutating the enzyme active site or by preventing the dissociation of the A and 
B subunits of each toxin [258, 263, 364, 378-385].  Of these alterations of LT, the mutation of 
arginine to glycine at position 192 (LT(R192G)) has arguably maintained the highest level of 
adjuvant activity while displaying the lowest level of toxicity [258, 263].  Thus, in addition to the 
improved cellular immunity induced with the use of LT(R192G), on an entirely practical level 
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the use of LT(R192G) with the Cp-p27 vaccine is preferable to CT because it is more likely to 
applicable in humans. 
A completely separate mechanism for immunostimulation is utilized by CpG ODNs [270, 
272].  CpG ODNs interact with DCs by binding to intracellular Toll-like receptor 9, which 
recognizes the unmethylated cytosine-phosphate-guanine pattern in the context of certain 
flanking nucleotides.  Signal transduction through MyD88-dependent and -independent pathways 
leads DC maturation and the production of cytokines that drive the formation of Th1-type 
responses.  This tendency to drive cellular immune response formation helps to explain why the 
use of CpG ODNs as adjuvant to Cp-p27 inoculation generated the greatest PPs cellular 
responses in the current study.  This response was observed with the high doses (≥25μg) of CpG 
ODNs but not low doses (<25μg).  This is likely due to the fact that naked DNA, such as the 
CpG ODNs, is easily destroyed in the gastrointestinal system.  Although the CpG ODNs utilized 
were generated with S-thiolation to ensure the highest level of stability, they remain targets for 
degradation.  This will be important to consider for future development of this and other oral 
vaccines, since larger amounts of adjuvant involves greater overall price for the vaccine. 
Because of the two distinct pathways through which CT/LT and CpG ODNs exert their 
adjuvant effects, it stands to reason that combining the adjuvants for simultaneous delivery could 
increase the strength of the resulting immune responses through additive effects.   However, in 
practice this is not always the case.  The results of the current study also demonstrated that only 
certain combinations of doses of LT(R192G) and CpG ODNs produced stronger responses than 
either adjuvant alone.  It was observed that LT(R192G) can stimulate immunity that can be 
detected in LP, whereas the response formed in the presence of CpG ODNs was mainly 
detectable in PPs and seemed to lower the LP response when 1μg LT(R192G) was used. 
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Characterization of the nature of the immune response induced in mice using LT(R192G) 
with CpG ODNs as adjuvants has been examined using a variety of antigens delivered via many 
routes.  McCluskie et al. observed that oral administration of LT(R192G) provided Th2-biased 
antibody response to antigen whereas administration of LT(R192G) and CpG ODNs displayed a 
more balanced Th1/Th2 response [368].  A similar trend was observed by Gerber et al. after oral 
inoculation of mice with virus-like particles:  immunogen delivered with CpG ODNs led to a 
predominantly Th1-type humoral response, while immunogen delivered with LT(R192G) 
provided more similar levels of Th1- and Th2-type antibodies [283].  Other studies have shown 
that this balanced LT-induced response is dependent upon the site of inoculation.  Delivery of LT 
provided a Th1-bias when inoculation occurred intracolonically but not intragastrically [386].  
Intranasal inoculation using LT or LT derivatives resulted in primarily Th2-type responses [282, 
368, 369].  In addition, the dose of each adjuvant played a role in the type of immunity, with 
lower doses tending to bias responses more towards Th2-type responses and higher doses 
providing more Th1-type response, including more CTL activity.  Furthermore, the Th1/Th2 
response bias differed depending upon the protein antigen delivered with the adjuvant. 
These studies exemplify the importance of determining the appropriate dose and 
adjuvants for use with each unique immunogen or vaccine.  In the current study, the lower dose 
of LT(R192G) produced lower cellular responses than the higher dose in both PPs and LP.  The 
quality of these responses differed as determined by intracellular cytokine staining, with both 
doses of LT(R192G) generating a more multifunctional response in CD8- cells than CD8+ cells 
in PPs.  The low dose (1μg) produced a more multifunctional response in CD8+ cells than CD8- 
cells in LP, and the higher dose (25μg) displayed a more balanced CD8+/CD8- response.  This 
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suggests that LT(R192G) may stimulate both Th1- and Th2-type responses in PPs and LP, 
although further analysis beyond the scope of this project would be required to confirm this. 
When either LT(R192G) dose was utilized with CpG ODNs or if no adjuvant was 
included, multifunctionality was reduced but T cells demonstrated more similar levels of 
multifunctionality in CD8- and CD8+ populations in both gut tissues.  IL-2 production of antigen-
specific cells has been a hallmark of effective T cell activity [132], and it is interesting to note 
that more IL-2 production is observed in the LP CD8+ cells of mice inoculated with only 
LT(R192G) than with both LT(R192G) and CpG ODNs.  That the CD107a expression on CD8+ 
T cells is also decreased in both PPs and LP when CpG ODNs are combined with LT(R192G) 
adds credence to the possibility that CpG ODNs are in fact negatively influencing the effector T 
cell immune response formation with this vaccine.  Clearly, the strength and quality of cellular 
immune responses are affected by the dose and type of adjuvant used with Cp-p27, and overall 
the use of 25μg LT(R192G) provides the best quality T cell response without compromising the 
strength of response. 
In conclusion, use of mucosal adjuvants at optimal doses improved gut cellular immune 
responses to Cp-p27 vaccination.  The use of both LT(R192G) and CpG ODNs produced the 
strongest responses, but the best quality of response was generated by using only LT(R192G).  
For future studies directed at generating effective gut CD8+ T cells using Cp-p27, vaccination 
should include 25μg LT(R192G) as an oral adjuvant. 
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5.0  MUCOSAL IMMUNE RESPONSE OF CP-P27 USING A PRIME-BOOST 
STRATEGY WITH ADENOVIRUS EXPRESSING P27 
5.1 PREFACE 
The study described in this chapter constitutes a manuscript in preparation.  The 
experiments were performed in the laboratory of Dr. Phalguni Gupta by Ruth Helmus with the 
technical assistance of Poonam Poonam, Lori Caruso, Dr. Yue Chen, and Dr. Cheng-Li Shen in 
vaccine administration and sample collection and processing.  Flow cytometry was performed 
with the assistance of Luann Borowski, Kim Stojka, and Edwin Molina from the laboratory of 
Dr. Charles R. Rinaldo, Jr.  The adenovirus vaccine used in these experiments was generated in 
the University of Pittsburgh Vector Core by the laboratory of Dr. Andrea Gambotto in 
collaboration with Dr. Simon Barratt-Boyes [387].  LT(R192G) was graciously provided by Dr. 
John Clemens, and Dr. Ted M. Ross provided guidance for CpG ODN sequence selection.  
Statistical advising was provided by Dr. Patrick Tarwater, and Dr. Marsha P. Cole provided 
instruction and the use of GraphPad.  Animals were cared for by the University of Pittsburgh 
Division of Laboratory Animal Resources.  Portions of this work were presented as poster 
abstracts at AIDS Vaccine 2006 (A novel Clostridium perfringens-based SIV vaccine with 
adenovirus boosting induces strong systemic and gut mucosal immune responses.  R. Helmus, P. 
Poonam, L. Caruso, Y. Chen and P. Gupta.) and the 2007 Keystone Symposia on HIV Vaccines 
(Optimization of anti-SIV gut mucosal vaccine response using Clostridium perfringens, 
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adenovirus, and synergistic mucosal adjuvants.  R. Helmus, P. Poonam, L. Caruso, Y. Chen, and 
P. Gupta.) 
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5.2 ABSTRACT 
Two major goals of HIV/SIV vaccination are to induce multifunctional cellular immunity 
and immunity in mucosal tissues such as the gut.  An oral Clostridium perfringens-based vaccine 
(Cp-p27) that delivers SIV p27 to gut inductive immune tissue was evaluated for its ability to 
prime cellular immunity in the gut.  Priming via oral vaccination with the Cp-p27 vaccine 
followed by boosting with a systemically delivered adenovirus expressing SIV p27 (Ad-p27) was 
performed to create a multifunctional gut immune response in the gut as well as systemic 
immune responses.  Immunization with Cp-p27 alone generated multifunctional p27-specific 
cellular responses in small intestinal lamina propria (LP) but very little systemic response.  In 
contrast, systemic inoculation with Ad-p27 generated systemic responses but a low cellular 
response with little multifunctionality in the LP.  Priming with Cp-p27 and boosting with Ad-p27 
resulted in the highest systemic and gut mucosal responses, as well as the highest degrees of p27-
specific multifunctional CD8+ T cells in the gut.  These results indicate that priming of intestinal 
tissue with Cp-p27 can enhance the otherwise limited gut mucosal cellular response generated 
via systemic inoculation with Ad-p27. 
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5.3 INTRODUCTION 
Growing evidence emphasizes the importance of the gut mucosa in HIV and SIV 
infection:  CD4+ T cells in the gut are rapidly infected and depleted soon after infection [64, 74, 
75, 312-314]; CD4+ T cell repopulation of the gut is prevented throughout infection [75-77]; 
cellular loss in the gut may promote bacterial translocation that contributes to generalized 
systemic immune activation [360]; and gut cells harbor virus throughout infection, thus serving 
as viral reservoirs [39, 78, 79].  In light of these findings, it is imperative to concentrate vaccine 
efforts on stimulating immune responses that prevent or curtail infection of the gut.  Other 
mucosal tissues are important in the early steps of HIV infection, such as the rectum and vagina 
where the majority of HIV transmission occurs.  Immunity induced in the gut-associated 
lymphoid tissue (GALT) may be able to afford immunity at these distal mucosal sites, also [250]. 
While inducing cellular immunity at mucosal sites is important in HIV/SIV vaccinology, 
the functionality of immune responses induced against HIV/SIV also affects the outcome of 
infection [40, 42, 136-140].  Functionality refers to a cell’s ability to proliferate and carry out 
effector functions against a pathogen.  For example, a correlation exists between control of HIV 
or SIV infection and the presence of CD8+ T cells from peripheral blood mononuclear cells 
(PBMC) concurrently expressing surface CD107a as a marker of antigen-specific cytotoxicity 
and producing IFN-γ, TNF-α, IL-2, and/or MIP-1β [40, 42].  HIV-infected patients who slowly 
progress to AIDS disease display significantly higher percentages of HIV-specific PBMC CD8+ 
T cells that demonstrate four or more of these functions than rapidly progressing patients [40].  
PBMC-derived antigen-specific CD8+ T cells concurrently producing IL-2 and IFN-γ are known 
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to be superior in their proliferative capacity and ability to eliminate antigen [132, 142-144, 148, 
149].  While information about the functionality of gut cells during HIV/SIV infection is limited 
[80, 139, 140], it is expected that not just the level of response but also the quality of immunity, 
including multifunctional CD8+ T cells, in this tissue will relate directly to the outcome of 
infection or effectiveness of vaccine-induced immune responses [388].  Thus, examining the 
functional cellular responses in mucosal tissues such as the gut may provide correlations between 
control of HIV/SIV infection and immunity, either natural or vaccine-induced. 
To address the need for gut mucosal priming of multifunctional cellular responses, a 
recombinant Clostridium perfringens bacterial strain expressing SIV p27 (Cp-p27) is used for the 
development of an oral vaccine that induces cellular immunity in the gut.  This orally delivered 
vaccine can deliver large amounts SIV p27 antigen to the terminal ileum of the small intestine, 
where gut inductive immune tissues known as Peyer’s patches (PPs) are concentrated.  Whereas 
strictly systemic administration of leading HIV/SIV vaccine candidates, such as adenovirus-
vectored vaccines, can produce systemic immunity but have failed to produce strong mucosal 
immunity [216, 230], a number of studies have demonstrated that mucosal priming followed by 
systemic boosting is an effective vaccination strategy for producing immunity in both systemic 
and mucosal tissues [228, 241-246].  Thus, it is hypothesized that priming the gut mucosa with 
the oral Cp-p27 vaccine would enable the inductive (PPs) and effector (lamina propria) tissues of 
the gut to better respond to intramuscular immunization using adenovirus (Ad) serotype 5 
carrying SIV p27 (Ad-p27).  This report evaluates the strength and functionality of immune 
responses generated by these two vaccines using a prime-boost strategy in mice. 
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5.4 MATERIALS AND METHODS 
Animals 
Female Balb/c mice were purchased from Charles Rivers Laboratories, Inc. and housed in 
a pathogen-free facility in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee and federal regulations.  Animals were used at 6 to 8 weeks of age. 
 
Clostridium perfringens vaccine strain Cp-p27 
Construction of the Clostridium perfringens vaccine expressing SIV p27 (Cp-p27) has 
been described previously [306].  Culturing of Cp-p27 was performed in the presence of 
10μg/mL chloramphenicol at 37°C.  Fresh 8h cultures of Cp-p27 grown in fluid thioglycolate 
broth (Difco) were used to inoculate modified Duncan-Strong medium [299] which was grown 
for 18h to induce sporulation.  Sporulation of at least 90% of all bacteria in cultures was 
confirmed by phase-contrast light microscopy.  Sporulated bacteria were isolated and washed 
with phosphate buffered saline (PBS) using centrifugation.  Isolated sporulating bacteria were 
sonicated, and the concentration of p27 was enumerated by desitometry of quantitative Western 
blots.  Vaccine was then stored at -140°C until use.  
 
Adenovirus vaccine strain Ad-p27 
E1/E3-deleted adenovirus serotype 5 expressing codon-optimized SIV gag p45 was 
constructed by the University of Pittsburgh Vector Core as described in Gao, et al. [387]. 
Determination of adenovirus particle concentration was performed by spectrophotometer 
analysis using a validated assay based on Adenovirus Reference Material obtained from the 
ATCC.  Virus was stored at -70°C until thawing on ice for use. 
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Oral adjuvants 
Whole, active cholera toxin (CT) was purchased from Sigma and stored at 4°C until use.  
5μg CT was used for each vaccine dose. HPLC-purified S-thiolated cytosine-phosphate-guanine 
oligodinucleotides (CpG ODN) were purchased from Sigma-Genosys and stored at -20°C until 
use.  CpG ODN sequences were:  CpG-A=TCCATGACGTTCCTGACGTT; CpG-
B=TGACTGTGAACGTTCGAGATGA [372, 373].  50μg of each CpG ODN was used for each 
vaccine dose. The isolation of LT(R192G) has been described previously [258].  LT(R192G) 
was provided by Dr. John D. Clements and was reconstituted to 1mg/mL in sterile water and 
stored at 4°C until use.  1μg LT(R192G) was used for each vaccine dose. 
 
Vaccination 
Mice were inoculated with Cp-p27 via gavage and/or Ad-p27 intramuscularly.  To 
gavage mice, an infant enteral feeding tube was inserted down the esophagus into the stomach.  
Here the Cp-p27 vaccine dose, consisting of bacteria expressing 250μg p27 plus adjuvants, was 
delivered in a total volume of 500μL in PBS.  Control mice received 500μL PBS via gavage.  109 
pfu of Ad-p27 were delivered in 50μL into the quadriceps muscle using a 26G needle.  As a 
control, mice received 50μL PBS intramuscularly.  Vaccines were administered at 3 week 
intervals. 
 
Fecal sample collection and processing 
Two to four days before sacrifice, fecal matter was collected from each mouse and 
processed on ice.  Approximately 50-150mg of fecal material was obtained from each mouse.  
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Samples were weighed and fully resuspended in Complete Mini protease inhibitor cocktail (1 
tablet/mL PBS containing 0.1% sodium azide; Roche) by adding 1mL per 100 or 200mg of fecal 
matter.  Resuspended samples were vortexed and then centrifuged at 13000rpm for 10 minutes in 
a tabletop centrifuge.  Supernatant was assayed immediately. 
 
Tissue collection and cell isolation 
Mice were sacrificed, and spleen, mesenteric lymph node (MLN), and small intestine 
were aseptically removed and processed.  Spleens were gently crushed with glass stoppers to 
release splenocytes, which were passed through nylon mesh, pelleted with centrifugation at 4°C 
at 1200 rpm for 5 minutes, treated with 3-5mL red blood cell lysis buffer (Sigma) for 5 minutes 
with a gentle shake after 3 minutes, and washed with RPMI containing serum.  Some cells were 
used fresh in subsequent assays, while others were stored in 1mL aliquots in 10% DMSO in FCS 
at -140°C until use.  Fatty tissue on MLNs was carefully removed, and MLN tissues were gently 
crushed using glass stoppers to release cells, which were passed through nylon mesh and pelleted 
with centrifugation at 4°C at 1200 rpm for 5 minutes.  Isolation of spleen and MLN cells was 
performed at room temperature with centrifugation using a centrifuge cooled to 4°C to preserve 
the integrity of isolated cells. 
Dissection of intestinal tissue was performed on ice, and when tissue and cells were not 
being treated enzymatically, they were kept on ice.  Before cell isolation, the intestine was rinsed 
with 1mL sterile PBS.  This intestinal wash was pelleted to remove solid matter using a tabletop 
centrifuge at 13000 rpm for 10 minutes, and the supernatant was stored at -70°C.  Fatty tissue 
was removed from small intestine tissue, and the lumen was thoroughly flushed with PBS.  
Peyer’s patches and lamina propria cells were then isolated as described in Chapter 4. 
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Serum sample collection and processing 
Pre-immune serum samples were acquired through venopuncture of the lateral saphenous 
vein, and blood was collected into heparinized capillary tubes.  At sacrifice, blood samples were 
collected via heart puncture, and blood was allowed to coagulate on ice for several hours before 
separation.  For all samples, serum was separated from blood by centrifugation at room 
temperature at 750xg for 20 minutes.  Serum samples were stored at -70°C. 
 
Thawing of splenocytes 
Vials of cells were removed from -140°C storage, placed in a 37°C water bath for 2 
minutes, and resuspended by dropwise addition of 1mL room temperature RPMI containing 
serum followed by addition of 8mL RPMI containing serum in 1mL aliquots, with mixing of 
cells after addition of each drop or aliquot.  Cells were then pelleted for 5 minutes with 
centrifugation at 4°C at 1200 rpm.   
 
IFN-γ ELISpot 
Detection of interferon-gamma (IFN-γ) was performed using mouse IFN-γ ELISpot Kits 
from Mabtech.  Plates were prepared as described in Chapter 2.  Most cells assayed via ELISpot 
were freshly isolated.  However, frozen-thawed spleen cells were used in the second experiment.  
Spleen, MLN, and PPs cells were plated with 2x105 cells per well of the activated ELISpot plate 
in a volume of 200μL ELISpot media (RPMI-1640 with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, 0.1mM non-essential amino acids, 2mM L-glutamine, 10mM HEPES, 
and 1mM sodium pyruvate).  Because of lower yields, LP cells were generally plated at 5x104 or 
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1x105 cells per well in 200μL.  Samples were stimulated as with two separate pools of SIVmac 
239 gag 15-mer peptides overlapping by 11 amino acids (NIH AIDS Research and Reference 
Reagent Program) covering the majority of SIV p27 with peptides 5265 through 5298 of SIV gag 
with each peptide at a concentration of 5μg/mL.  Each sample also contained a background 
control where a concentration of DMSO equivalent to that in the peptide pools was added to the 
well.  As a positive control, each sample was also stimulated with 1mg/mL concanavalin A.  All 
treatments for all samples were plated in triplicate, except when low LP yields made this 
impossible, in which case at least two wells per treatment per sample were plated.  Cells were 
incubated at 37°C for 24h.  Detection of IFN-γ spot-forming cells (sfc) was performed as 
described in Chapter 2.  When dry, sfc on plates were counted on an automated ELISpot reader.  
Background sfc values from background control wells were removed as appropriate, and sfc 
were normalized to 106 cells. 
 
SIV p27-specific ELISA 
EIA/RIA Plates were coated overnight at room temperature with recombinant SIV p27 
isolated from E. coli.  After blocking plates, serial dilutions of serum or undiluted samples of 
fecal extracts or intestinal washes were placed in wells and incubated at room temperature for 2h 
(serum) or at 4°C overnight (fecal extracts and intestinal washes).  Plates were washed, and 
AKP-conjugated α-mouse IgG, IgG1 or IgG2a antibody or biotin-conjugated α-mouse IgA 
antibody (BD Biosciences) was incubated in appropriate wells for 1h at room temperature.  For 
IgA detection, plates were washed and a secondary AKP-conjugated streptavidin (Sigma) was 
then incubated in appropriate wells for 30 minutes at room temperature.  Finally, 4-nitrophenyl 
phosphate disodium salt hexahydrate (Sigma) was used to detect p27-specific antibody, and 
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optical density was read on a plate reader at 405nm.  Background values from negative control 
wells on each plate were subtracted. 
 
Surface, intracellular cytokine, and CD107a staining 
FITC-α-CD107a (clone 1D4B), R-PE-α-CD8 (53-6.7), APC-α-IL-2 (JES6-5H4), PE-
Cy7-α-IFN-γ (XMG1.2), Biotin-α-TNF-α (MP6-XT3), and APC-Cy7-streptavidin were 
purchased from BD Pharmingen.  PE-Cy5-α-CD3 (clone 145-2C11) was purchased from 
BioLegend. Isotype control antibodies were purchased from the same manufacturers according to 
the fluorescent conjugate used. 
Freshly isolated cells (maximum 106 cells) were cultured for 5 hours at 37°C in 96-well 
plates in 200μL growth media (DMEM with 10% fetal calf serum,  1mM sodium pyruvate, 2mM 
L-glutamine, 0.025M 2-mercaptoethanol, and 1.25mM HEPES) containing 5μg/mL α-CD107a 
antibody, 3μM monensin, 5μg/mL brefeldin A, and 5μg/mL peptides spanning the entire p27 
protein.  As a background control, one well of cells of each sample was cultured without peptide.  
As a positive control, samples were cultured with 50ng/mL phorbol myristate acetate and 
1μg/mL ionomycin. 
After the culture period, plates were cooled to 4°C overnight.  Cells were surface stained 
for CD3 and CD8, washed with FACS buffer (PBS with 0.1% bovine serum albumin and 0.1% 
sodium azide), fixed in 4% paraformaldehyde, and permeabilized with FACS buffer containing 
0.2% saponin.  Following permeabilization, cells were intracellularly stained for IL-2, IFN-γ, 
and TNF-α, washed, fixed, and stored in the dark at 4°C in FACS buffer.  All samples were fully 
analyzed by flow cytometry within 12 hours of staining. 
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Flow cytometry and analysis 
Stained cells were analyzed using a BD Canto flow cytometer.  FCS files were analyzed 
using FlowJo version 7.2.2 (Tree Star, Inc.).  Cells in the lymphocyte gate were gated on 
CD3+CD8+ or CD3+CD8- cells, and gates for individual cytokines and CD107a were established 
with control cells stained only for CD3 and CD8.  Cells in the cytokine and CD107a gates were 
analyzed with Boolean gating to generate the percentage of cells expressing each combination of 
functional markers.  Background expression values were subtracted from peptide-stimulated 
values for each sample.  Graphical representation of functionality was achieved using SPICE 
software kindly provided by Dr. Mario Roederer of the NIH VRC.  For SPICE analysis, 
individuals with no p27-specific immune response were excluded.  Threshold values were 
determined by calculating confidence values of negative percentages for each T cell subset.  For 
PPs, the 90% value was used; for LP, the 75% value was used. 
 
Statistics 
Statistical analyses were performed using GraphPad Prism version 4.  Values of p were 
determined assuming a nonparametric distribution and employing a Kruskal-Wallis test followed 
by the Dunn procedure to compare groups.  Antibody titer values were first transformed to log10 
before analysis.  Results were considered significant if p<0.05. 
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5.5 RESULTS 
5.5.1 Optimal Order of Mucosal and Systemic Inoculation in a Prime-Boost 
Vaccine Model 
To determine whether the oral C. perfringens vaccine carrying SIV p27 (Cp-p27) 
performed better as a prime or a boost to a systemically delivered adenovirus serotype 5 
encoding SIV gag vaccine (Ad-p27), groups of five mice were vaccinated three times with 
different regimens as described in schedule 1 in Figure 20 A, and resulting systemic and mucosal 
immunity was investigated.  Group A was a control group, and the mice received PBS at each 
inoculation.  Mice in group B received three oral doses of Cp-p27 at days 0, 21, and 42.  Mice in 
groups C and D received one dose of Ad-p27 intramuscularly at day 0, and those in group D also 
received two subsequent oral Cp-p27 inoculations as a boost at days 21 and 42.  Mice in group E 
received two oral inoculations of Cp-p27 at days 0 and 21 followed by an intramuscular boost 
with Ad-p27 at day 42.  All Cp-p27 doses included CT and CpG ODNs as adjuvants.  Eight to 
ten days after the final vaccination, mice were sacrificed.  Peripheral blood serum, intestinal 
washes, and fecal samples were collected and examined for humoral immune responses.  Cells 
isolated isolated from spleen, mesenteric lymph node (MLN), and small intestinal Peyer’s 
patches (PPs) were examined for cellular immune responses. 
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Figure 20.  Vaccination schedules implementing Cp-p27 and Ad-p27 
Female Balb/c mice 6 weeks of age were inoculated with orally delivered Clostridium perfringens carrying SIV p27 
gene (Cp-p27) and/or intramuscularly delivered adenovirus serotype 5 carrying SIV gag gene (Ad-p27) at the 
indicated timepoints.  Control inoculation with oral or intramuscularly delivered phosphate buffered saline was 
delivered as appropriate. 
 
5.5.1.1 Systemic Cellular Responses 
Animals in groups C, D, and E, who received Ad-p27, displayed cellular p27-specific 
IFN-γ production in spleen, while those from group B displayed a low response similar to the 
control group A.  The strongest cellular response was observed in group E, which had received 
Cp-p27 followed by Ad-p27 boosting (Figure 21 A).  The response in group E was statistically 
higher than group B and control group A (p<0.001 and p<0.01, respectively). 
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5.5.1.2 Systemic Humoral Responses 
Serum antibodies specific for p27 were detected by ELISA (Figure 21 B).  Mice from 
groups A and B displayed low antibody titers for both Th1-type (IgG2a) and Th2-type (IgG1) 
antibodies.  The highest titers were observed in groups C and D.  The titers in groups A and B 
were statistically lower than in group C (IgG1) or groups C and D (IgG2a) (p<0.05).  Group E 
also displayed a higher IgG2a titer than groups A or B, although this was not statistically 
significant.   Antibody titers were probably lower in group E than in groups C and D because the 
mice in group E were sacrificed before antibody responses were matured, a process that normally 
takes approximately three weeks. 
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Figure 21.  Immune responses stimulated by Cp-p27 and Ad-p27 
Mice were immunized against SIV p27 with Cp-p27 and Ad-p27 vaccines as described in Figure 1.  A, p27-specific 
IFN-γ ELISpot results from spleen, mesenteric lymph node (MLN), and small intestinal Peyer’s patches (PPs).  Grey 
bar, group A; black bar, group B; white bar, group C; speckled bar, group D; slashed bar, group E.  Kruskal-Wallis 
test p-values:  for spleen, p=0.0003; for MLN, p=0.0005.  *p<0.01, **p<0.001 compared with group 5.  Error bars 
represent standard error of the mean.  B, Serum antibody titers detected by p27-specific ELISA.  White bar, IgG1; 
black bar, IgG2a.  For both isotypes, via the Kruskal-Wallis test of log10 transformed endpoint titer values, p≤0.001.  
#p<0.05 compared with group D, +p<0.05 compared with both groups C and D.  Error bars represent standard error 
of the mean.  C, Intestinal wash OD405 values detected by p27-specific ELISA.  Via Kruskal-Wallis test, p=0.0107.  
#p<0.05. 
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5.5.1.3 Gut Mucosal Cellular Responses 
Mucosal tissues were also assayed for p27-specific IFN-γ production (Figure 21 A).  
Animals in group C group displayed minimal IFN-γ in PPs.  This response was slightly 
heightened in group D.  A p27-specific cellular immune response was observed in PPs from 
group B, and the highest response was in group E.  These data indicate that priming with Cp-p27 
stimulates a gut mucosal immune response that is improved by systemic Ad-p27 boosting. 
Although a p27-specific IFN-γ was expected in the MLN, which drains the GALT 
(reviewed in [252] and [389]), no cellular response was detected in the MLN of mice in group B 
(Figure 21 A).  Animals in group E, which received Cp-p27 followed by an Ad-p27 boost, 
displayed cellular responses in the MLN that were statistically higher than the PBS-only control 
group A as well as group B (p<0.01).  Responses in MLN of group E were also higher than those 
in groups C and D, although not significantly. 
5.5.1.4 Gut Mucosal Humoral Responses 
SIV p27-specific IgA was detected in intestinal washes from groups B and E at higher 
levels than control group A.  As shown in Figure 21 C, the highest response was observed in 
group E, which was statistically higher than group D (p<0.05) but not control group A.  Low 
antibody responses were observed in groups C and D.  Fecal samples did not contain detectable 
IgA in any group (data not shown). 
5.5.2 Investigation of Vaccines’ Contributions to Gut Immunity  
These data suggest that orally delivered Cp-p27 is able to prime a gut mucosal immune 
response but not a systemic response.  Furthermore, priming with Cp-p27 before Ad-p27 
administration provided a stronger immune response than Cp-p27 boosting after Ad-p27 
inoculation.  In order to further explore the potential of Cp-p27 as a mucosal priming vaccine, 
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the strength and functional quality of cellular responses were measured in both the gut effector 
tissue, the lamina propria (LP), and the inductive PPs tissue after vaccination.  In this second 
study, LT(R192G) and CpG ODN adjuvants designed for oral use [258, 372, 373] were 
employed with Cp-p27.  This experiment was performed twice, with similar results. 
In this experiment (see Figure 20 B, schedule 2), group 1 consisted of 5-6 control mice 
who received PBS only.  Groups of ten mice were inoculated with oral Cp-p27 and/or 
intramuscular Ad-p27.  Mice in group 2 received three inoculations of Cp-p27 at days 0, 21, and 
42; mice in group 3 received one inoculation of Ad-p27 at day 42 (group 3); and mice in group 4 
received two inoculations of Cp-p27 at days 0 and 21 followed by a boost of Ad-p27 at day 42.  
Mice were sacrificed 10 to 14 days after the last inoculation, which is the timepoint at which 
peak cellular responses to Ad-based vaccines are detected. 
5.5.2.1 Systemic Cellular Responses 
Spleen cells assayed by ELISpot for p27-specific IFN-γ production displayed no p27-
specific response in mice immunized with Cp-p27 alone (group 2) or with PBS (group 1) (Figure 
22 A).  Mice who received Ad-p27 (group 3) displayed p27-specific splenic IFN-γ responses, 
significantly higher than group 2 (p<0.05).  The cellular response was even was higher in group 
4, with p<0.01 compared with group 2. 
5.5.2.2 Systemic Humoral Responses 
Group 2 displayed low titers of p27-specific IgG1 and IgG2a antibodies in the serum, 
similar to control group 1 (Figure 22 B).  Groups 3 and 4 both had high titers of p27-specific 
IgG1 and IgG2a, which were statistically higher than groups 1 and 2 (p<0.001).  Within each 
group, the titers of Th1-type and Th2-type antibodies were similar, indicating no bias towards 
any one antibody isotype. 
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Figure 22.  Systemic and gut mucosal immune responses generated from Cp-p27 and Ad-p27 vaccination 
Mice were immunized against SIV p27 with Cp-p27 and Ad-p27 vaccines as described in Figure 1.  A, p27-specific 
IFN-γ ELISpot results from spleen, small intestinal Peyer’s patches (PPs) and small intestinal lamina propria (LP).  
Grey bar, group 1; black bar, group 2; white bar, group 3; slashed bar, group 4.  Kruskal-Wallis test p-values:  for 
spleen, p=0.0011; for PPs, p=0.0056; for LP, p<0.0001.  #p<0.05, *p<0.01, **p<0.001.  Error bars represent 
standard error of the mean.  B, Serum antibody titers detected by p27-specific ELISA.  White bar, IgG1; black bar, 
IgG2a.  For both isotypes, via the Kruskal-Wallis test of log10 transformed endpoint titer values, p<0.0001.  
**p<0.001 compared with both group 1 and group 2.  Error bars represent standard error of the mean. 
 
5.5.2.3 Gut Mucosal Cellular Responses 
Unlike the previous experiment using cholera toxin as an adjuvant with Cp-p27 (Figure 
21), responses to Cp-p27 using LT(R192G) and CpG ODNs in animals of group 2 did not 
generate p27-specific IFN-γ ELISpot responses higher than then PBS control group 1 in PPs 
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(Figure 22 A).  Cellular responses were observed in groups 3 and 4, with group 4 again showing 
the strongest p27-specific cellular response.  As in the spleen, the cellular response in PPs was 
not significantly different between groups 3 and 4, but the response in group 4 was statistically 
higher than group 2 (p<0.01). 
The LP showed a different hierarchy of p27-specific cellular response (Figure 22 A).  In 
this effector tissue, all vaccinees displayed stronger responses than the control group 1.  In the 
LP, group 2 demonstrated a slightly higher cellular response than group 3.  The p27-specific 
IFN-γ response in group 4 was higher than any other group and very significantly higher than 
control group 1 (p<0.001).  Whereas the magnitude of p27-specific IFN-γ production by 
splenocytes and LP lymphocytes was similar in group 3, in group 4 the LP response was nearly 
twice that in the spleen (Figure 22 A). 
5.5.2.4 Gut Mucosal Humoral Responses 
Intestinal p27-specific IgA and IgG was evaluated by ELISA, and all groups 
demonstrated low levels of antibody for both isotypes.  There was no difference in OD levels in 
any vaccinated group compared with the PBS control group 1 (data not shown). 
5.5.3 Function of p27-Specific T Cells 
To evaluate other functions of the p27-specific gut mucosal cells, cells were stained for 
the cytotoxic degranulation marker CD107a, and intracellular cytokine staining was performed to 
detect IFN-γ, TNF-α, and IL-2 production.  These four immune functions were then detected by 
flow cytometry.  Cells were surface stained for CD3 and CD8 to differentiate CD8+ and CD8- T 
cells.  In PPs, CD3+CD8- cells are 95-96% CD4+; in LP, they are 88-90% CD4+ (data not 
shown). 
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Figure 23.  T cell p27-specific cytokine responsiveness in gut mucosal tissues following immunization with Cp-
p27 and/or Ad-p27 
Cells from small intestinal Peyer’s patches (left) and lamina propria (right) were surface stained for CD3 and CD8.  
SIV p27-specific IL-2, TNF-α, and IFN-γ production from CD8+ (A) and CD8- (B) CD3+ cells was detected via 
intracellular staining and analysis via flow cytometry.  Percentages of cells with each cytokine and any cytokine 
response were then determined.  Grey bars, group 1; black bars, group 2; white bars, group 3; slashed bars, group 4.  
Error bars represent standard error of the mean.  In all cases of statistical significance between groups, p≤0.03 via 
the Kruskal-Wallis test.  #p<0.05, *p<0.01, **p<0.001. 
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5.5.3.1 Individual Cytokine Levels Vary with Delivered Vaccine 
The percentage of cells producing each cytokine in the two gut tissues was calculated 
from flow cytometry results (Figure 23).  Group 2 displayed slightly more production of each of 
IL-2, TNF-α, and IFN-γ in PPs CD8+ and CD8- T cells compared with group 1.  Group 3 
demonstrated very little production of any cytokine except in PPs CD8+ T cells, which had 
higher but statistically insignificant percentages of TNF-α and of IFN-γ producing cells than 
control group 1.  IL-2 and TNF-α production in PPs CD8- T cells from group 3 were statistically 
lower than in group 2.  The IL-2 production of PPs CD8+ T cell in group 4 was statistically 
higher than in group 3.  Group 4 demonstrated insignificantly higher percentages of IL-2, TNF-α, 
and IFN-γ producing PPs CD8+ T cells compared with control group 1.  In PPs CD8- T cells, 
group 4 had low levels of all cytokines except for IL-2.  There was a slightly higher level of 
production of each cytokine by LP CD8+ and CD8- T cells in group 4 compared with all other 
groups.  Group 2 also showed a higher percentage of IL-2 producing cells than group 1, but this 
was not statistically significant.  
5.5.3.2 Multifunctional T Cells in Peyer’s Patches 
All mice displayed production of at least one of the assayed cytokines in response to p27 
in PPs T cells.  The percentage of CD8+ T cells showing any cytokine responsiveness to p27 was 
highest in groups 2 and 3 (Figure 23).  The percentage of p27-specific cytokine-producing CD8- 
T cells was highest in groups 2 and 4, although no vaccine groups displayed significantly higher 
CD8- PPs T cell responses than the PBS control group.  Group 2 displayed a statistically higher 
CD8- T cell response in PPs than group 3 (p<0.001). 
The cells from each vaccinated group were then evaluated for multifunctionality (at least 
2 different functions in the same cell) of cytokine production and degranulation.  Within the 
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CD8+ PPs T cell response, multifunctionality was observed significantly more often in group 4 
compared with group 2 or group 3 (p=0.026 and p=0.013, respectively) (Figure 24).  CD8- PPs T 
cells were also most multifunctional in group 4; mice from group 2 displayed some 
multifunctionality, and mice in group 3 demonstrated no multifunctionality within the CD8- T 
cell subset in PPs (Figure 24).  The lack of multifunctional PPs CD8- cells in group 3 mice 
created statistically significant differences in complexity (i.e. 2- vs. 3- vs. 4-functions) of 
multifunctionality profiles when comparing group 3 with either group 2 or group 4 (p<0.001).  
These results demonstrate a difference in CD8- (CD4+) and CD8+ T cell responses in PPs 
dependent upon the vaccine vector used to deliver p27 antigen. 
5.5.3.3 Multifunctional T Cells in Gut Lamina Propria 
Most mice in all groups demonstrated a positive p27-specific response to at least one 
cytokine in the LP:  10/10 group 1 (100%); 13/13 group 2 (100%); 11/12 group 3 (92%); and 
11/11 group 4 (100%).  However, the percentage of p27-specific cells producing any cytokine in 
mice from group 3 was lower than that in PBS control group 1 mice in both CD8- and CD8+ LP 
T cells (Figure 23).   Of the p27 responsive mice, higher percentages of CD8- and CD8+ T cells 
demonstrated a p27-specific cytokine response in animals vaccinated with Cp-p27 (groups 2 and 
4) compared with only Ad-p27 (group 3) (Figure 23).  The highest percentages were observed in 
group 4. 
Although not statistically significant, a larger portion of the p27-specific response was 
due to multifunctional cells (cytokines and/or degranulation) in group 4 than in groups 2 and 3, 
particularly in the CD8+ T cell subset (Figure 24).  Of particular interest, the level of 
multifunctionality of LP CD8+ T cells was greater in mice from group 4 (2-, 3-, and 4-function 
responses) than in group 3 mice (2-function responses only). 
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Figure 24.  Multifunctional gut T cell responses in inductive and effector tissues resulting from vaccination 
Data generated from Boolean-gated CD8+ and CD8- cells from Peyer’s patches and lamina propria stained for 
CD107a, IL-2, TNF-α, and IFN-γ were analyzed for concurrent functionality using SPICE software.  A, The average 
percentage of total response at each level of multifunctionality is represented by slices in pie charts.  Values of p 
were determined with SPICE software comparing distribution between pies grouped by slice color using 10000 
permutations.  B, The average percentage of total response for each combination of functions is shown with error 
bars representing standard error of the mean. 
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(Figure 24 continued) 
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5.6 DISCUSSION 
Newly acquired HIV and SIV infections quickly target gut mucosal tissue, and the 
inability to restore the gut mucosal immune system following initial depletion of its CD4+ T cells 
contributes to the pathology and persistence of HIV and SIV [64, 74, 75, 78, 79, 312-314].  
Nevertheless, vaccine-induced gut CD8+ T cell immunity has been shown to impede the 
dissemination of SIV in rhesus macaques following challenge [121], providing evidence in 
support of the hypothesis that containment of infection at mucosal sites can reduce the severity 
of HIV/SIV infection [34, 36].  The systemic and mucosal presence of both CD8+ and CD4+ 
multifunctional cellular responses against lentiviruses has also been associated with protection 
from or control of HIV and SIV infections [40, 42, 136-140]. 
One of the challenges of HIV/SIV vaccine design is the complexity of inducing immune 
responses in the gut.  It is often difficult to deliver sufficient amounts of vaccine antigen to the 
relevant GALT inductive tissues, namely PPs.  Both oral and rectal inoculation strategies are 
under investigation for this purpose, with varying levels of resultant mucosal and systemic 
responses [49, 121, 247, 248, 332, 390-397].  Some systemically delivered vaccines can induce a 
degree of mucosal response.  Intramuscular immunization with recombinant Ad carrying 
HIV/SIV antigens has been shown to induce strong systemic cellular immunity, as well as 
limited cellular immunity in PPs [216, 230].  Under these circumstances, the gut mucosal 
immune response was several degrees of magnitude lower than the systemic immune responses.  
Data from a recent clinical trial using an Ad serotype 5-based vaccine demonstrated a lower than 
anticipated protective ability despite inducing strong systemic immunity against HIV (reviewed 
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in [207]); gut mucosal responses were not defined.  In light of these findings and the importance 
of gut mucosal immunity against HIV and SIV, a strategy to improve the gut mucosal immunity 
generated from leading HIV/SIV vaccine candidates is desirable. 
The current study attempted to generate multifunctional mucosal immune responses in 
the gut through immunization of mice with an oral C. perfringens-based vaccine against SIV 
p27.  Despite low systemic humoral and cellular responses with this vaccine strategy, strong 
cellular responses in the inductive (PPs) and effector (LP) gut tissues were observed.  CD8+ T 
cells from the LP of Cp-p27-vaccinated mice contained cells concurrently displaying two, three, 
and four of the cytokine and cytotoxic immune functions associated with effective cellular 
immunity.  Additionally, this study investigated whether the oral Cp-p27 vaccine used as a prime 
could improve gut mucosal responses to subsequent intramuscular inoculation of Ad-5 carrying 
SIV p27.  These results indicate that mice that were first primed with Cp-p27 and then boosted 
with Ad-p27 generated stronger systemic and gut cellular responses to SIV p27 compared with 
unprimed Ad-p27 recipients.  Multifunctionality of PPs and LP CD8+ and CD8- T cell subsets 
was also increased in Cp-p27-primed mice that were then boosted with Ad-p27.  Compared with 
mice who only received Cp-p27, the multifunctionality of CD8+ T cells in LP was strikingly 
improved in mice boosted with Ad-p27. 
Together, these observations suggest that different functional profiles are stimulated in 
inductive and effector gut lymphoid tissue depending on which vaccines mice receive.  The 
observation that the percentage of responsive LP CD8+ T cells in recipients of Ad-p27 only is 
much lower compared with mice who received Cp-p27 only and Cp-p27 boosted with Ad-p27 
suggests that intramuscular Ad-p27 vaccination provides limited stimulation of LP CD8+ T cell 
responses.  Finally, the current study suggests that immunization with Cp-p27 stimulates 
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multiple cytokine and degranulation events in the lamina propria, enabling a subsequent 
inoculation of Ad-p27 to boost the memory T cell response in this effector tissue while also 
improving the functionality of T cells in inductive PPs tissue. 
The ability of vaccine-induced multifunctional CD8+ T cell immunity to predictably 
prevent HIV or SIV infection is not wholly understood.  In rhesus macaques immunized with 
live-attenuated SHIV, animals who controlled viral replication against SIV challenge were found 
to have more multifunctional responses in PBMC-derived CD8+ T cells than macaques who 
displayed high viral loads [42].  However, study of PBMC T cell immunity in an individual who 
acquired HIV after vaccination against HIV has suggested that infection can occur even in the 
face of multifunctional vaccine-induced responses similar to those seen in long-term non-
progressor HIV patients [398].  Clearly there remains much to be learned regarding the 
relationship between immune responses and protection from and/or control of HIV/SIV 
infection.  In light of the many reports that anti-HIV/SIV immunity in PBMC does not accurately 
reflect that in the gut tissues [74, 77, 399], it will be important to include these mucosal sites in 
future evaluations.  Tasca et al. observed that uninfected SHIV-exposed rhesus macaques 
demonstrating resistance to infection following vaginal challenge displayed more jejunal gut 
lamina propria CD8+ T cells with concurrent expression of IFN-γ and TNF-α than susceptible 
macaques [140].  Further studies into the quality of immune response, i.e. multifunctional CD8+ 
T cells, in various gut tissues will provide insight into an understanding of the true definition of 
protective immunity. 
In conclusion, oral vaccination of mice with Cp-p27 induces multifunctional cellular 
immunity in the LP, and boosting with intramuscular Ad-p27 enhances both LP and systemic 
immunity.  Future studies with Cp-p27 will focus on the memory phenotype of induced T cells, 
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long-term immunity induced by vaccination, and the level of protection against challenge 
infection generated by Cp-p27 immunization.  Cp-p27 should be considered as a mucosal prime 
for other vaccination strategies.  Oral administration of vaccines is often preferable in the field to 
inoculation strategies requiring sterile needles, so including Cp-p27 in a vaccination regimen 
involving Ad or another injected vaccine would have the added benefit of reducing the number 
of needle-based inoculations.  Inclusion of Cp-p27 could also lower the cost since culture of Cp-
p27 does not require expensive techniques and reagents associated with vaccines generated 
through cell culture and other common vaccine production methods. 
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6.0  FINAL DISCUSSION AND CONCLUSIONS 
6.1 EXPERIMENTAL FINDINGS OF CURRENT STUDY WITH CP-P27 
6.1.1 Overview of Results 
The experiments described in the preceding four chapters were aimed at addressing the 
hypothesis that the Cp-p27 vaccine, consisting of Clostridium perfringens expressing SIV p27 
from the sporulation-induced cpe promoter, can deliver p27 to gut DCs and thereby prime 
mucosal and systemic humoral and cellular immunity against SIV.  Since cellular immunity is 
important in control of SIV and HIV infection, the bulk of the experiments addressed the 
induction of T cell immune responses following exposure to Cp-p27 under in vitro and in vivo 
conditions.  DCs of systemic and gut origin were observed to mature and stimulate p27-specific 
T cell responses following exposure to Cp-p27.  Inclusion of PTD sequences conjugated to the 
p27 increased the uptake of antigen by DCs, but such conjugation did not improve p27-specific 
cellular immune responses.  Cp-p27 delivered orally produced gut cellular immunity, which was 
improved by the coadministration of mucosal adjuvants.  This response was greatest in strength 
with 25μg LT(R192G) plus 50μg CpG ODNs and optimal in functional quality with 25μg 
LT(R192G) alone.  Systemic immune responses were not induced by Cp-p27 vaccination alone, 
but oral priming using Cp-p27 followed by an intramuscular Ad-p27 boost improved systemic 
cellular immune responses.  Such a prime-boost strategy also improved cellular immunity in the 
gut effector lamina propria tissue compared with Ad-p27 or Cp-p27 alone.  Altogether, this work 
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demonstrates that Cp-p27 can stimulate cellular immunity in the gut mucosal tissue after delivery 
to gut DCs, and that Cp-p27 can prime systemic immunity for an improved response to 
subsequent booster vaccination with Ad-p27. 
6.1.2 Significance of Results 
This is the first study demonstrating that the use of a non-invasive bacterial-based protein 
delivery system directed at the gut can induce strong, multifunctional cellular immunity in the 
gut.  The safety, ease, and cost-effectiveness of such a delivery system make the Cp-p27 vaccine 
an attractive vector for further evaluation.  This study did not evaluate Cp-p27-induced mucosal 
immunity generated in distal mucosal tissues.  Studies in many mammals indicate that 
stimulation of immunity at gut mucosal can also generate immunity in vaginal and rectal tissue 
[48, 49, 238, 249-251, 311, 400-405].  Some evidence for this phenomenon exists in humans, 
although other findings suggest that primates do not readily display transfer of gut immunity to 
vaginal or rectal tissues [250, 400-404].  Regardless, the presence of cellular immunity at these 
sites of initial HIV transmission may not completely block early HIV infection, and cellular 
immunity at secondary infection sites, such as the gut, may be required to lower the severity of 
infection by controlling viral replication [36, 119].  Studies in the macaque model suggest that a 
vaccine-induced gut cellular response to SIV can slow the establishment of mucosally-acquired 
SIV infection and results in a lower viral set-point [120, 121], which often correlates with a 
longer period before developing AIDS as well as less transmission of virus [55, 56, 213, 214]. 
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6.2 COMPARISON OF CP-P27 WITH OTHER VACCINE VECTORS AGAINST SIV 
AND HIV 
6.2.1 Systemic Immunity 
A number of other approaches to oral vaccination have been described in the literature.  
Oral inoculation using viral vectors including adenovirus, vaccinia virus, papilloma virus, and 
adeno-associated virus have all been studied in mice [228, 392, 406-408].  Orally delivered 
virus-based vaccines have been observed to result in between 80 and 600 antigen-specific 
ELISpot sfc/106 in spleen.  In comparison, systemically delivered viral-based vaccines tend to 
provide IFN-γ ELISpot counts ranging from 500 to 1500 sfc/106 in mouse splenocytes. 
Bacterial vectors such as Lactococcus lactis, Salmonella enterica serovar Typhimurium 
and Listeria monocytogenes are also under investigation as oral vaccine vectors and have been 
shown to induce systemic immunity in mice [236, 248, 331, 332, 334, 393, 395].  Shigella 
flexneri may also be useful as an oral vaccine vector but has thus far only been examined in the 
context of intranasal inoculation [237, 409, 410].  When delivered mucosally, many of the 
bacteria-based vaccines also result in respectable levels of antigen-specific systemic cellular 
immunity, detectable in the spleen at levels around 200-300 IFN-γ ELISpot sfc/106 cells or with 
high levels of T cell proliferation or cytotoxicity rates.  The exception to these common 
observations comes from studies using Listeria monocytogenes engineered to express HIV gag, 
wherein mice immunized orally with a L. monocytogenes-based HIV vaccine demonstrated few 
or no HIV-specific CD8+ T cells in the spleen [228, 332, 411].  Similarly, vaccination with Cp-
p27 in the current study generated a low p27-specific cellular immune response in the spleen. 
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6.2.2 Gut Mucosal Immunity:  Peyer’s Patches and Mesenteric Lymph Nodes 
In other studies [228, 332], cellular immune responses in the PPs were observed but not 
strong after oral inoculation using L. monocytogenes, similar to observations with Cp-p27 alone 
in the current study.  Salmonella-based oral vaccination appears capable of stimulating antigen-
specific PPs cellular immunity on the order of 250-400 sfc/106 cells, although these results are 
not conclusive since one report observed nearly identical antigen-specific response levels 
following inoculation with an empty vector Salmonella and another utilized a 6-day 
restimulation protocol before the assay in order to enhance the detectable response [409, 412].  
Intramuscularly delivered Ad has been observed to generate 50 to 100 antigen-specific sfc/106 
cells detected in an IFN-γ ELISpot assay of PPs cells, similar to the results obtained in the 
current study [216, 230]. 
The response generated by Cp-p27 was confined to gut tissue local to the site of p27 
delivery and was not observed in the draining lymph node (MLN) or systemic tissue.  Two 
possibilities may explain the lack of immunity detected in the MLN.  First, the timepoints used 
for analysis may not represent timepoints when draining lymph nodes contain antigen-specific 
IFN-γ producing cells.  This is supported by findings from Zhu et al. who observed that, 
following intrarectal administration of an adenovirus, the cellular response of the iliac lymph 
node draining the rectal mucosa was detectable at days 4 and 6 following inoculation but not at 
day 14, indicating that detectable response waned in the inductive tissue within two weeks [413].  
Rayevskaya and Frankel [332] observed a similar phenomenon in which cellular PPs responses 
following oral inoculation with a L. monocytogenes-based HIV vaccine were highest at day 7 
after the final inoculation, and the response was much lower by day 14.  It is likely that the 
transient Cp-p27-induced response in the PPs represents the priming of cells in this inductive 
 139 
tissue which then migrate and establish themselves in the LP effector site.  Further 
characterization of the kinetics and memory phenotype of the responses observed following Cp-
p27 immunization will make this clear. 
An alternative explanation for the lack of Cp-p27-induced MLN cellular immune 
response takes into account the difference in trafficking of PPs and LP APCs, specifically DCs.  
LPDCs primarily travel to the MLN to present antigen, whereas PPDCs can relocate from the 
SED to T and B cell areas of the PP and may not frequently migrate to MLN [252, 266, 268].  
Thus, even if the PPDCs exposed to Cp-p27-delivered p27 efficiently acquire antigen, the 
responses they stimulate may not be detectable in the MLN.  Responses in the MLN and 
systemic tissue have been observed following oral vaccination with other bacterial-based vectors, 
and this may be because these other vectors deliver protein to cells in the LP through direct 
infection and subsequent active replication [247, 331-333].  For example, a Salmonella-based 
vaccine delivers vaccine antigen by entering macrophages in the gut LP [247, 331]. 
This explanation would also reconcile the differences in systemic immunity stimulatory 
capacity observed using different oral vectors noted above since the vectors use different 
methods of antigen delivery to gut tissue.  L. monocytogenes infects both monocytes and DCs, 
the latter being most prevalent in the gut in PPs [229, 334, 389].  Likewise, Cp-p27-expressed 
protein is thought to be primarily taken up by DCs in PPs since protein is delivered to the ileum 
in particulate inclusion bodies which are preferentially transcytosed by the M cells that allow 
protein to access PPs.  On the other hand, bacterial vectors such as Shigella and Salmonella can 
infect macrophages, which in the gut reside predominantly in the LP.  Viral-based vectors also 
deliver protein by infecting cells in the LP.  The handling of antigen by PPDCs and by 
macrophages or DCs from LP differs in both the pathways for epitope presentation on MHCs 
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and trafficking of cells to immune inductive sites [229].  The latter difference may play a major 
role in determining the systemic or mucosal homing of immune cells induced by these various 
vaccines.  PPDCs are apt to prime immunity in PPs but do not necessarily travel to the MLN, and 
immune cells primed in PPs home to gut LP [414].  Gut LP macrophages may induce immunity 
when they travel to inductive sites in the MLN; cells primed in the MLN can seed the systemic 
immune system [229, 389]. 
In reports describing mouse cellular immune responses against HIV gag following oral 
inoculation, mice with cellular responses in PPs and MLN displayed protection from challenge 
with HIV gag-expressing vaccinia virus [332, 391-394].  Stronger responses were consistently 
observed in gut compared with spleen in these previously reported oral inoculation studies.  In 
the current study, oral Cp-p27 vaccination followed by a systemic Ad-p27 boost also produced 
stronger immunity in the gut than in the spleen, whereas oral inoculation with the Cp-p27 
vaccine alone induced almost no detectable response in the spleen.  Although the previously 
described L. monocytogenes-based vaccine also did not induce strong systemic cellular 
immunity, upon boosting with an intramuscularly delivered Ad-vectored vaccine, the percentage 
of antigen-specific CD8+ T cells in the spleen increased by at least 20-fold, a level at least 10-
times that induced by the Ad vaccine alone [228, 332].  The strength of this response increased 
incrementally as more primes of the oral L. monocytogenes vaccine was administered before the 
Ad boost.  A similar trend was observed in PPs, where low levels of HIV-specific CD8+ T cells 
were detectable following L. monocytogenes vaccination, but response to an Ad boost was 
improved in a Listeria dose-number dependent manner.  These L. monocytogenes studies and the 
current Cp-p27 study demonstrate that even when immunity induced by an oral vaccine is at 
undetectable levels, immunity exists that can be boosted with a separate vector. 
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Furthermore, the low levels of spleen, PPs, and MLN cellular immunity induced by the L. 
monocytogenes vaccine did not hamper its ability to effectively control a viral challenge [228, 
332].  Although these CTL responses were rather low (approximately 20-25 lytic units/106 cells 
in each tissue) and did not persist at high levels in spleen, MLN, or PPs, the immunized mice 
were protected from challenge with gag-expressing vaccinia virus via either intraperitoneal or 
oral inoculation [332].  This may indicate that low levels of immunity in the gut mucosa are 
sufficient to prevent infection by a mucosally targeted pathogen and/or that stronger gut 
immunity may exist in other compartments, such as effector LP tissue, even when responses in 
inductive tissues (PPs and MLN) are low.  These studies also raise the possibility that the prime-
boost strategy with Cp-p27 and Ad-p27 could provide protection from challenge with p27-
expressing vaccinia virus in mice. 
6.2.3 Gut Mucosal Immunity:  Lamina Propria 
A few studies have reported the antigen-specific IFN-γ ELISpot response of gut LP cells 
following immunization.  In one such study, an intrarectally delivered modified vaccinia Ankara-
based vaccine provided similar levels of antigen-specific IFN-γ sfc (800-900 sfc/106 cells) in the 
small intestine LP as did Cp-p27 vaccine in the current study [396].  Other vaccine strategies 
have induced varying levels of cytolytic cellular responses in the LP.  For example, Belyakov et 
al. generated about 20% specific lysis at a 12.5:1 effector:target ratio in LP lymphocytes via 
intrarectal inoculation of HIV peptides with CT; this response provided control of a subsequent 
intrarectal HIV envelope-expressing vaccinina virus challenge [49]. 
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6.2.4 Functional Quality of Vaccine-Induced Gut Cellular Responses 
Cellular immune responses in gut mucosal tissues of mice have also been assayed via 
intracellular cytokine staining for IFN-γ in a few reports [216, 396].  The data from these reports 
suggest that oral immunization stimulates stronger cellular immunity in the gut than the spleen, 
whereas intramuscular immunization creates the opposite result.  Lin et al. reported that a high 
dose (5x1011) of intramuscularly delivered Ad induced antigen-specific IFN-γ production in 
about 2% of PPs CD8+ T cells [230].  In the current study, a lower dose (1x109) of Ad-p27 
generated IFN-γ production in 0.95% CD8+ T cells from PPs, and Cp-p27 induced an antigen-
specific IFN-γ response in 0.75% of PPs CD8+ T cells.  The antigen-specific IFN-γ response of 
small intestinal LP CD8+ T cell following Cp-p27 and/or Ad-p27 vaccination in the current study 
were also similar to responses observed in gut-associated tissue in other studies, including in the 
jejunal lamina propria of monkeys inoculated through various routes with a vaccine vectored by 
the poxvirus NYVAC [140, 391].  The current finding of about 1% of CD8+ or CD4+ T cells 
expressing IFN-γ in an antigen-specific manner following immunization with Cp-p27 or Ad-p27 
is consistent with many other studies in animals and humans, including individuals who control 
HIV viral replication [138, 141, 147, 215, 415-417].   
The combination of IFN-γ with other functions of CD8+ T cells appears to associate with 
effective CD8+ CTL responses and control of SIV/HIV infection [40, 132].  Higher percentages 
of vaccine-induced antigen-specific cells that express both IFN-γ and TNF-α have been observed 
in gut-associate tissue of monkeys who resisted infection than in susceptible vaccinated animals, 
similar to the current findings [140].  All published studies detailing vaccine-induced expression 
of more than two functions have been performed with systemic and not mucosal cells (examples 
in [215, 398, 415, 418]).  In these studies the vector that was used affected the quality of the 
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cellular response.  For example, heterologous prime-boost immunization of mice using a herpes 
simplex virus amplicon followed by an Ad-vectored vaccine provided more multifunctional 
CD4+ and CD8+ cells than homologous prime-boosting [215].  In the same study, multifunctional 
CD8+ T cells expressing IFN-γ, IL-2 and/or TNF-α made up about 15% of the total antigen-
specific response.  Similar trends were observed in the current study in which multifunctionality 
was greater in mice primed with Cp-p27 and boosted with Ad-p27 than mice who were 
vaccinated with only one vector, with a maximum of about 15% (IFN-γ, TNF-α , IL-2) or 25% 
(CD107a, IFN-γ, TNF-α , IL-2) of the gut mucosal cellular response due to multifunctional cells. 
6.3 CRITICAL EVALUATION OF CP-P27 AND SUGGESTIONS FOR FUTURE 
STUDY 
6.3.1 Benefits and Drawbacks of Cp-p27 
Oral vaccination with Cp-p27 is superior to many other vaccines in its ability to induce 
cellular immunity in the gut LP.  However, one of the benefits many of these other vaccines have 
over Cp-p27 is the ability to induce systemic immunity.  Both systemic and mucosal immunity 
are thought to be necessary for effective protection against HIV disease.  As described above, 
there are different methods of protein delivery by Cp-p27 and systemic-inducing vaccines which 
likely determine the ability of these vaccines to induce systemic or mucosal immunity.  Although 
the delivery mechanism of vectors such as attenuated Salmonella, Shigella and various viruses 
promotes both mucosal and systemic immunity, their ability to infect or colonize the gut may not 
be ideal for use in humans.  Regions with the greatest threat of HIV tend to also have high rates 
of gastrointestinal (GI) disease, such as diarrhea, rendering the gut mucosa less resistant to 
control of attenuated bacteria.  Complications might easily occur if a vaccine vectored by an 
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invasive or colonizing bacteria or virus were delivered to the gut of individuals already fighting 
gastrointestinal disease.  The C. perfringens vectoring the Cp-p27 vaccine enters a non-
replicative, dormant state in the small intestine and delivers vaccine protein to inductive sites 
without infecting or colonizing the mucosa.  Cp-p27 thus has the advantage of not contributing to 
GI disease. 
An additional benefit of the C. perfringens vaccine vector system is the ease with which 
different genes can be inserted into the expression plasmid and placed under control of the strong 
C. perfringens cpe gene.  For example, a C. perfringens vaccine expressing HIV p24 has been 
constructed and is currently under investigation in animal studies.  Also, p27 under control of the 
cpe promoter has  been inserted into the chromosome of C. perfringens, eliminating the need for 
an expression plasmid [305].  The safety and adaptability of the C. perfringens vector would be 
of further value if the vector could also induce systemic immunity.  Therefore, future study of the 
C. perfringens vaccine vector system should concentrate on achieving systemic immune 
responses through oral vaccination, increasing the safety of the C. perfringens vector, and 
broadening immunity by inducing responses against additional viral proteins and stimulating 
antibodies. 
6.3.2 Systemic Immunity Via C. perfringens-Based Oral Vaccination 
The BMDCs used in this study represent systemic DCs that are able to mediate systemic 
immune response formation [419, 420].  In addition, these DCs can stimulate gut immunity 
insomuch as BMDCs delivered intraperitoneally have been observed to travel to MLN where 
they stimulate T cells that home to the gut [420].  Perhaps this is how systemic antigen can gain 
access to the gut.  That systemic Ad-p27 vaccination induced responses in MLN suggests that 
this may be the case in the current study.  Thus, in order for Cp-p27 to generate systemic as well 
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as mucosal immunity, the vaccine vector may need to more efficiently deliver p27 to cells that 
can travel to the MLN, such as LP antigen presenting cells including epithelial cells.  The 
attempt to improve p27 uptake by epithelial cells by incorporation of PTD sequences on the N-
terminal of p27 proved to be an ineffective solution to this challenge, since PTD incorporation 
caused death of epithelial cells in vitro; therefore, alternative strategies should be pursued.  
While PTD-based improvement of the antigen appears to be less than ideal, other methods for 
enhancing and directing immunity can be explored.  Some of these options include directly 
conjugating adjuvant to the antigen expressed by C. perfringens, or fusing an ubiquitination tag 
on the antigen to direct it for ubiquitination and proteasomal cleavage into MHC class I epitopes. 
6.3.3 Safety of Cp-p27 
Despite the fact that most C. perfringens rapidly undergoes sporulation in the intestine, 
rendering it nonreplicative and dormant, one of the safety concerns of utilizing C. perfringens as 
an oral vaccine vector is that C. perfringens carries a variety of toxin-encoding genes which can 
lead to disease.  The C. perfringens type A from whence Cp-p27 was engineered encodes two 
major exotoxins, α-toxin (also known as phospholipase C) and θ-toxin (also known as 
perfringolysin O).  Oral consumption of C. perfringens carrying these two genes is considered 
safe in normal humans, and it is only when such bacteria enter deep wounds that they are 
associated with disease, namely gas gangrene.  However, there is the potential for C. perfringens 
delivered to the gut to enter tissue if the normal GI mucosal tissue is compromised.   Given that 
preexisting GI diseases are often found in the regions in most desperate need of HIV vaccines, it 
is prudent to take as many precautions as possible.  Because of this, C. perfringens strains with 
inactivation of both α-toxin and θ-toxin have been developed and have been shown to express 
SIV p27 and deliver antigen to the terminal ileum [304, 305]. 
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Although there is no evidence for recombination of genetic material between food-
acquired C. perfringens and gut resident C. perfringens or other bacteria in the gut, there is the 
potential for a resistance gene to be transferred if it were included in a vaccine.  In the course of 
the development of the α- and θ-toxin-double knockout mutant, a C. perfringens strain 
expressing SIV p27 from a chromosomally-encoded gene [305].  This expression strategy has 
improved safety for human use in that it circumvents the need for an antibiotic resistance gene as 
is required in the plasmid expression strategy.  To maintain the plasmid in recombinant Cp-p27, 
continuous culture with antibiotic is necessary, which is an added cost and may introduce traces 
of antibiotic into the final vaccine preparation.  Unnecessary use of antibiotics in the absence of 
infection has fueled the emergence of mutli-drug resistance strains of many bacteria over the past 
several decades.  In addition, genetic material encoded on the chromosome is less likely to 
transfer from a vaccine strain to naturally occuring strains of C. perfringens compared with 
plasmid-encoded genetic material.  The plasmid-encoded version of Cp-p27 would be more 
likely to inadvertently introduce further antibiotic resistance genes or vaccine antigen genes into 
the human population.  Thus, future research with C. perfringens expressing SIV p27 can be 
performed utilizing the new generation of C. perfringens with multiple safety mutations and 
lacking antibiotic resistance genes. 
6.3.4 Broadening Immunity Using Additional Viral Protein Genes 
The production of an immune response that is reactive against a variety of viral proteins 
is thought to aid in protection from disease progression.  As virus mutates its proteins in an 
attempt to evade immunity, a broad immune response increases the likelihood of the immune 
system to successfully recognize viral protein epitopes and control virus.  The incorporation of 
various viral proteins into a vaccine would thus be beneficial.  Many different viral proteins 
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could be placed under control of the cpe protmoter in the C. perfringens vector, creating C. 
perfringens strains expressing other viral enzymes such as reverse transcriptase, accessory 
proteins required for replication such as tat, and structural proteins such as envelope.  The 
inclusion of these and other proteins in vaccines have been useful in generating protective 
responses in the SIV macaque model [421-426]. 
The contribution of cellular responses against envelope proteins in providing protection 
against SIV or HIV disease progression is unclear.  Some evidence suggests that envelope-
specific CD8+ T cell responses may not play a large role in protection of SIV-infected macaques 
from disease progression [114, 427].  Thus, vaccination that can also induce antibody responses 
against envelope proteins would likely be more beneficial.  The incorporation of an envelope 
protein would be a special case for expression by C. perfringens as the bacterium lacks the 
capacity to correctly glycosylate this protein in a manner useful for successful antibody response 
formation against most portions of gp120.  However, certain portions of the gp41 molecule do 
not require glycosylation-controlled structural constraints for production of neutralizing 
antibodies and are also quite conserved among all HIV types, thus making them attractive for use 
in C. perfringens.  The membrane proximal region of gp41 contains targets for three broadly 
neutralizing antibodies [428-430].  The ELDKWA sequence comprising amino acids 662 
through 667 of gp41 is the target of the broadly neutralizing antibody 2F5, which has been 
shown to effectively neutralize about 90% of all tested HIV isolates from around the world [428, 
431].  Inoculation of peptides encoding the ELDKWA sequence and derivatives of it have been 
able to induce some HIV-neutralizing antibodies in animal models [432-434], and the expression 
of this sequence from the cpe promoter in C. perfringens would be a feasible approach for 
utilizing the bacterial vector to induce protective antibody production via vaccination. 
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6.3.5 Humoral Immunity Via Cp-p27 Vaccination 
The Cp-p27 vaccine was detected to stimulate only very low levels of intestinal p27-
specific IgA and IgG.  Antibodies against p27 or the HIV capsid protein p24 are not known to 
neutralize SIV or HIV, respectively; however, it would be useful for C. perfringens expressing 
an envelope protein to induce a mucosal neutralizing antibody response to prevent infection.  
The expression from the cpe promoter encourages the expressed protein to accumulate in 
particulate inclusion bodies, which are more likely to be internalized and processed through 
pathways promoting Th1-type immune responses.  If protein were expressed in a soluble form 
instead of in particulate inclusion bodies, a Th2-type immune response promoting antibody 
formation would be more likely to be induced.  It may be possible to produce soluble protein in 
C. perfringens from the cpe promoter if sequences encoding secretion pathway-targeting motifs 
were included in the antigen gene placed under control of the cpe promoter. 
Another way to induce a humoral response creating antibodies is through the use of 
adjuvants that promote Th2-type response formation.  The adjuvants utilized in the majority of 
the current study, CpG ODNs and LT(R192G), are known to promote Th1-type immunity more 
than Th2-type responses.  The use of CT has been recognized as promoting Th2-type immunity, 
particularly when the CT or CTB subunit is conjugated directly to the antigen being delivered.  
The results in Chapter 4 of the current study demonstrated lower cellular gut immunity induction 
through the use of CT versus CpG ODNs or LT(R192G).  Although not tested in this study, the 
literature supports that this may be due to a preferential induction of Th2-type immunity that 
prevents cellular immune response formation and promotes antibody responses.  This is 
consistent with the results of the current study in that cellular immunity decreased as the dose of 
CT increased.  Thus, it seems possible that the inclusion of Th2-promoting adjuvants may aid in 
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the formation of antibody responses as a result of oral vaccination with a C. perfringens-based 
vaccine. 
6.3.6 Additional Studies Suggested for Cp-p27 
In addition to pursuing strategies to spread Cp-p27-induced immunity to tissues other 
than the gut, future studies should include investigations of the vaccine to induce long-term 
immunity and protection from challenge.  The responses described in this study were determined 
about two weeks after the final vaccination.  A vaccine trial not described in this study examined 
the response four weeks after two Cp-p27 vaccinations and determined that cellular immunity 
remained detectable in LP, although to a lower level than at two weeks.  This is somewhat 
expected since IFN-γ production by T cells generally subsides as antigen is cleared.  Future 
studies assessing long-term immunity should include evaluation of memory cell surface 
molecules and IL-2 production of antigen-specific cells [132, 206].  Testing the protective 
capacity of Cp-p27 against virus establishment and disease progression may involve utilizing the 
SIV monkey model of immunization and infection.  In addition, challenge of mice with p27-
encoding vaccinia virus can provide data about the protective effectiveness of Cp-p27 vaccine-
induced immunity. 
6.4 CONCLUDING REMARKS 
Previous to the initiation of the study described in this manuscript, it was known that p27 
could be delivered to the locale of terminal ileum PPs after oral administration of Cp-p27 and 
that Cp-p27-delivered p27 could enter DCs of gut and systemic origin [306].  The current study 
has shown that these DCs can mature and stimulate cellular responses.  This was not 
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significantly improved by the incorporation of N-terminus PTD sequence fusion to p27.  It is 
evident from this study that Cp-p27 can induce multifunctional cellular immunity in the gut at 
levels similar to those observed through other oral vaccination strategies; humoral immunity in 
the gut following Cp-p27 vaccination is evident but limited.  The Cp-p27-induced response 
shows the ability to be improved with inclusion of adjuvants, which could be used to sway the 
quality of cellular immunity.  Although the cellular response was limited to gut tissue and not 
draining LN and systemic tissues, Cp-p27 vaccination did not generate tolerance since 
subsequent systemic antigen delivery via intramuscular Ad-p27 vaccination resulted in cellular 
responses in the spleen.  Additionally, there was a slight increase in systemic response when Cp-
p27 was given before Ad-p27.  Cp-p27 can thus prime gut immunity that can be enhanced by a 
systemic boost.  Vaccination using the oral Cp-p27 and systemic Ad-p27 prime-boost strategy 
holds promise for showing effectiveness against p27-expressing vaccinia virus challenge since 
the level and functional quality of gut cellular immunity observed after this vaccination regimen 
was similar to that induced by other vaccine strategies that have provided protection against viral 
challenge.  This evaluation of Cp-p27 contributes to the fields of HIV/SIV vaccine development 
and mucosal vaccinology by demonstrating an example of a mucosally delivered vaccine 
providing a prime for a systemic vaccine boost and by characterizing Cp-p27 as a novel vector to 
continue exploring for mucosal vaccine use. 
In conclusion, Cp-p27 represents a novel vaccine vector that can stimulate gut mucosal 
cellular immunity displaying characteristics currently thought to correlate with protection from 
SIV disease progression.  More study is required with C. perfringens-vectored vaccines to make 
them viable for use as vaccines that induce systemic and mucosal immunity through the 
production of both antigen-specific cellular responses and neutralizing antibodies.  Many 
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questions still remain regarding basic immunology and the interplay between HIV/SIV and host 
cells.  A continued focus on defining the mechanisms of immune response formation and the role 
of innate and mucosal immunity on protection from disease may provide a more accurate 
understanding of the rational goals for HIV prophylaxis.  As correlates of protection are further 
defined, Cp-p27 may prove to be a basis for an inexpensive, easily administered vaccine for 
priming mucosal tissue and stimulating protective immunity. 
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